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The rising prevalence, mortality and high economic burden of asthma require a better 
understand the pathophysiology of this chronic respiratory disorder and the need to 
explore for more potentially effective therapies to treat this disease. Increasing 
numbers of patients who respond poorly to available standard therapies also implicate 
the necessity to develop and uncover alternative and complementary strategies and 
drug compounds. Our recent investigations of an anti-malarial drug, artesunate, have 
revealed promising anti-inflammatory potential in an experimental model of allergic 
asthma, notably suppressing various hallmarks of asthma, airway inflammation, 
mucus hypersecretion and airway hyperresponsiveness. Key allergic cytokines, such 
as IL-4, IL-5 and IL-13 were dose-dependently suppressed by artesunate and we were 
able to isolate the inhibition of the PI3K/Akt signaling cascade by artesunate as a 
molecular drug mechanism. From this study, we were able to optimize a safe and 
effective dosage regime of artesunate treatment for allergic asthma and propose the 
research project of developing artesunate as an anti-inflammatory agent for treating 
allergic asthma.  
Current evidences have highlighted oxidative stress as a major upcoming pathogenic 
factor in promoting patients’ resistance to standard therapies. Compounds which 
ameliorate oxidative stress, neutrophil recruitment and promote nuclear Nrf2 
activations have also been singled out as promising alternative drug candidates to 
control allergic asthma. As part of the drug development process, we investigated if 
artesunate was capable to suppress aeroallergen-induced airway inflammation and 
related oxidative stress and subsequent oxidative lung damage. A potent 
corticosteroid, dexamethasone, was included as a positive drug control and for the 
purpose of comparing artesunate to standard corticosteroids therapy. Our results 
xiv 
reveal promising anti-oxidative effects by artesunate in allergic asthma, with robust 
and consistent suppression of airway eosinophilia, neutrophilia, major oxidative 
markers, namely 3-nitrotyrosine (product of protein nitration), 8-OHdG (product of 
oxidative DNA damage) and 8-Isoprostane (product of lipid peroxidation). In addition, 
artesunate and dexamethasone were found to possess no direct radical scavenging 
effects and their anti-inflammatory effects were largely mediated via alteration of 
various pro-inflammatory and anti-inflammatory genes. Suppression of the oxidative 
damage markers were attributed to the modulation in gene expressions of major 
pulmonary antioxidants (catalase and SODs) and robust suppressions of pro-oxidants 
(iNOS, NADPH oxidases and related subunits).  
In both human bronchial epithelial cells and inflamed murine lung tissues, we noted 
for the first time consistent promotion of nuclear Nrf2, a major anti-inflammatory 
transcription factor, which regulates the expressions of many major antioxidants and 
pro-oxidants in the airways. Our collective results indicate that artesunate possess 
promising anti-inflammatory effects in experimental allergic asthma, which includes 
potent suppression of oxidative damage markers, pro-oxidants and modulation of 
pulmonary antioxidants, which are likely to be mediated via the promotion of the 
nuclear Nrf2. The effects of artesunate were consistently comparable and 
complementary to potent corticosteroid and these results suggest that artesunate may 
be a promising alternative drug compound for treating allergic asthma.   
Metabolomics is an promising investigative platform for studying biochemical and 
metabolic changes in biological systems and can offer new opportunities to 
understand novel disease-relevant molecular changes in allergic asthma, as well as to 
discover new metabolic markers characteristic of this respiratory disease. In addition, 
metabolomics may equally be useful to uncover both positive and potentially adverse 
xv 
drug-induced metabolism changes, which may help to reveal unique drug mechanisms 
of artesunate in allergic asthma. Recent applications of metabolomics to explore non-
invasive metabolic markers in allergic asthma have demonstrated possible metabolite 
profile changes detected in the urine and exhaled breath condensate of experimental 
and clinical asthma. However, it is presently unestablished if there are relevant 
changes in allergic-inflamed lungs which can be potentially detected in the BALF. In 
this study, we employed an integrated approach of parallel liquid-chromatography 
(LC-) and gas chromatography (GC-) mass spectrometry (MS) analysis to investigate 
for novel BALF metabolic changes in experimental asthma. A potent corticosteroid, 
Dexamethasone, was also studied to investigate if the BALF metabolic changes we 
observed were reversible by current standard corticosteroid therapy.  
Our results revealed distinctive BALF metabolic profile changes between asthmatic 
animals versus aerosolised saline controls. Multivariate statistical analysis further 
implicated novel energy, lipids, sterols and carbohydrate metabolite changes in the 
BALF. Elevations of energy metabolites, lactate, malate and creatinine were observed 
with consistent losses in pulmonary carbohydrates, arabinose, galactose and mannose. 
Reductions in phosphatidylcholines were accompanied by corresponding increases in 
choline, while reductions in sterols, cholic acid, cholesterol and cortol suggest 
possible suppression in cortisol metabolism. Pearson correlation analysis further 
revealed for the first time that these metabolite changes shared statistically significant 
moderate-strong correlations with BALF inflammatory cells changes, implicating that 
our uncovered metabolites may be disease-associated metabolite changes. Metabolic 
pathways analysis has also suggested potential metabolic links between the various 
groups of altered metabolites.  
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Dexamethasone treatment effectively reversed many key metabolite changes, but was 
ineffective in repressing lactate, malate and creatinine and induced additional 
metabolite changes. This study demonstrates that metabolomic analysis of BALF can 
provide an in-depth understanding of altered lung metabolism in asthma and elucidate 
unique disease-relevant metabolite profiles. Metabolomic analysis of BALF offers a 
promising approach to investigate allergic asthma. Corticosteroids can help restore 
certain lung metabolism, but also induce additional metabolite changes. Our overall 
findings revealed considerable pathway changes in lung metabolism in asthmatic 
lungs, including energy, amino acids and lipid metabolism.  
 
With our established understanding of BALF metabolite changes in allergic airways, 
we were interested to understand the metabolic effects of artesunate in allergic asthma 
and whether this anti-inflammatory drug would induce similar or differential 
metabolic effects as compared to dexamethasone. Using the same metabolomics 
platform, we proceeded to investigate the metabolic effects induced by artesunate in 
the same experimental asthma model. Complementing metabolomics, we employed a 
comprehensive systems pharmacology approach to study the effects of artesunate, 
which included pharmacokinetic investigations of artesunate in the serum and lung 
tissues, multiplex inflammatory cytokine profiling of the BALF, murine peripheral 
blood and human epithelial cell toxicological tests.  
 
Our results have demonstrated that artesunate was consistently able to suppress 
airway inflammation and related inflammatory cytokines, IL-4, IL-5, IL-13 (allergic 
cytokines), IL-17, G-CSF, MCP-1 and IL-12p40 (pro-inflammatory cytokines). 
Pharmacokinetic analysis uncovered that serum levels of artesunate is rapidly 
xvii 
metabolised into active metabolite, Dihydroartemisinin (DHA) upon intra-peritoneal 
administration and only DHA levels are detected in the lungs. Peripheral blood 
toxicological tests indicate no significant changes in blood leukocyte numbers. WST-
1 assay also showed that artesunate did not induce any significant cell death in human 
bronchial epithelial cells (Beas-2B). Metabolomics analysis revealed artesunate 
exerted promising restorative metabolic effects in allergic asthma. While inducing no 
observable metabolic profile changes in naïve animals, artesunate was able to 
specifically modulate the allergic inflamed BALF and serum metabolic profiles and 
related metabolite changes. These metabolic effects were distinctly different from 
drug effects induced by dexamethasone and suggest that these two anti-inflammatory 
drugs may mediate their protective metabolic effects differently in allergic asthma. 
Using Pearson correlation analyses, we uncovered substantial associations between 
specific BALF metabolites and inflammatory cytokines, as well as potential links 
between BALF and serum metabolite changes.  
 
Our overall findings demonstrate that artesunate is a safe and effective anti-
inflammatory agent, which exhibits specific and differential protective metabolic 
effects in allergic asthma, as compared to clinically-used corticosteroid.  
Metabolomics may be an effective analytical technology to reveal and differentiate 
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A consensus clinical definition for asthma recognizes this disorder to be a chronic 
inflammatory condition of the airways, characterized by airway inflammation, 
pathophysiological lung and epithelial damage and remodeling, mucus hypersecretion, 
and airway hyperresponsiveness (AHR) (Table 1A, Figure 1.01). This chronic 
inflammatory respiratory disorder of the airways is importantly a complex interplay of 
immune and allergic responses, in which many cells and cellular elements play 
different pathophysiological roles. The chronic inflammation of the airways causes a 
characteristic increase in AHR that leads to recurrent episodes of wheezing, 
breathlessness, chest tightness, coughing (Masoli, Fabian, Holt, Beasley, & Program, 
2004) and failure to use appropriate medications or to adhere to treatments and 
development of resistance to standard therapeutics can eventually lead to death. 
Current research of asthma encompasses several major directions which involve 
improving current molecular understanding of the disease, uncovering better disease-
relevant biomarkers and developing novel therapeutics to complement available 
therapies. Rising numbers of asthmatics who respond poorly to current therapeutics 




Table 1A: The clinical “A-E” components of asthma. Table adapted from (Blakey, 
et al., 2013) 
 
 






1.02 Prevalence and Morbidity of Asthma 
There has been a sharp increase in the global prevalence, morbidity, mortality, and 
economic burden associated with asthma over the last few decades; Asthma is 
estimated to affect over 300 million people worldwide with an estimated additional 
100 million persons with asthma by 2025 (Masoli, et al., 2004; S. P. Peters, Ferguson, 
Deniz, & Reisner, 2006) (Figure 1.02). The prevalence of asthma is found to increase 
by 50% every decade (Braman, 2006). Although most asthmatic patients are 
considerably well-controlled by available therapies, such as corticosteroids and 
bronchodilators, deaths due to uncontrolled asthma still accounts for over 250,000 
deaths annually worldwide.  
Internationally, there is an increasing trend in the number of hospital admissions for 
asthma, reflecting an increase in severe asthma, poor disease management and 
poverty (Beasley, 2002). The associated economic cost of asthma is considerable both 
in terms of direct medical costs (such as hospital admissions and pharmaceutical costs) 
and indirect medical costs (such as time lost from work and premature death). A 
recent report has revealed that the annual direct health care cost of asthma, for just the 
United States of America alone, is approximately $50.1 billion; indirect costs (e.g. 
lost productivity) add another $5.9 billion, for a total of $56.0 billion dollars (Barnett 
& Nurmagambetov, 2011).  
In Singapore, a notable local population of over 5% of adults and 20% children are 
affected by asthma (Singapore_Health_Promotion_Board, 2013). The total cost of 
asthma in Singapore is projected to exceed US$33.93 million per annum (Chew, Goh, 
& Lee, 1999). This was made up of US$17.22 million in direct costs and US$16.71 
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million in indirect costs. Inpatient hospitalisation accounted for the largest proportion 
of direct medical expenditure, approximately US$8.55 million. The loss of 
productivity from acute asthma accounted for the largest proportion of the indirect 
costs at US$12.70 million. The escalating worldwide concerns regarding the 
increasing prevalence, morbidity, mortality and economic burden of asthma prompts 
the need to study asthma and its disease mechanism better so as to explore for more 
innovative therapeutic agents. 
 
 
Figure 1.02: The global burden of asthma: Prevalence of Asthma. Figure adapted 





1.03 Development of Asthma 
Asthma has many causes, including inhaled exposure to allergens and isocyantes, and 
often the inciting agents are not known. Inhaled allergens are identified as important 
environmental factors in the pathogenesis of asthma and most likely its persistence 
(Busse & Rosenwasser, 2003). Extensive reviews on the genetics of asthma can only 
agree upon that there is a major hereditary contribution to the underlying causes of 
asthma and the inheritance pattern of asthma demonstrates that it is a “complex 
genetic disorder” such as that seen in arthritis and diabetes mellitus (Lemanske & 
Busse, 2003). The interaction between host factors (genetics) and environmental 
stimuli can result in the development of airway inflammation, altered pulmonary 
physiology, and asthmatic symptoms in the susceptible host. For the most part, 
independent of the cause, the pathology is identical and the course of disease similar, 
indicating that the inflammatory response and the airway pathology are common 
responses of the respiratory tract to allergens and injury (Cohn, Elias, & Chupp, 2004). 
For at least the past 15 years, asthma research has almost exclusively focused on 
inflammation as a cause of disease.  
 
1.04 Pathophysiology of Asthma 
Asthma is often initiated by the exposure and inhalation of allergens. Inhaled 
allergens first encounter dendritic cells (DCs), antigen presenting cells, which form a 
network lining the basement membrane of the airway epithelium. Dendritic cells will 
process the allergens, mature and migrate to draining lymph nodes, where they 
present the processed antigen to naïve CD4+ T cells (TH0 cells) (Busse et al., 2001). 
In the presence of various cytokines such as IL-4, the naïve T cells will differentiate 
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into TH2 cells, which contribute to the inflammatory response by generating an array 
of cytokines such as IL-4, IL-5, IL-9 and IL-13. These various cytokines have distinct 
functional effects in both the induction and development of the disease. 
Clinical management of asthma relies heavily on the monitoring of lung function and 
symptoms. Airway remodeling and inflammation eventually result in airway 
hyperresponsiveness (AHR) and airway obstruction, causing breathlessness and 
wheezing. AHR is defined as an increased bronchoconstrictor response to a 
nonspecific stimulus and is sometimes referred to as “twitchy” airways. With AHR 
being the clinical manifestation of the underlying cellular and molecular immunologic 
changes in the asthma and it is equally important to suppress the degree of AHR in 
asthma patients as well as the suppression of the various inflammatory mediators and 
cells involved in the disease. Although the precise mechanisms that control AHR are 
poorly understood but the magnitude of AHR has been found to correlate with the 
level of airway inflammation  (Jeffery, Wardlaw, Nelson, Collins, & Kay, 1989).  
Furthermore, the allergen-induced pathogenesis of airway inflammation and asthmatic 
phenotypes are resultant from a complex interplay of inflammatory cells, such as 
eosinophils, neutrophils, lymphocytes and macrophages, pulmonary bronchial 
epithelial cells and a variety of inflammatory and anti-inflammatory cytokines (Figure 
1.03). 
 
Amongst many inflammatory cytokines, IL-13 is found to be most associated with 
AHR, where blockade of IL-13 in animal models of allergic asthma, markedly inhibits 
allergen-induced AHR and delivery of IL-13 to the airways is able to cause AHR 
(Kuperman, et al., 2002). Eosinophils are also identified to be a primary inflammatory 
cell type responsible for causing AHR, mediated through the release of eosinophil 
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granule major basic protein (MBP), inducing AHR (Gleich, 2000). This suggests that 
the suppression of airway inflammation, such as eosinophilia, will contribute greatly 
towards the reduction in AHR experienced in asthmatic patients. In addition, many 
other factors, including the reduced airway diameter, an increase in smooth muscle 
contractility, the degree of epithelial injury, dysfunctional neuronal regulation, an 
increase in microvascular permeability, and many inflammatory mediators, have been 
associated with AHR. 
 
Another characteristic feature of severe asthma is overproduction of mucus. Mucus 
can mechanically narrow the airway lumen and, in severe asthma, form tenacious 
plugs that will obliterate the airway (Lemanske & Busse, 2003). Airway mucus 
protects the epithelial surface from injury and facilitates the removal of bacterial, 
cellular, and particulate debris from the lung. Mucus production is also an important 
feature of asthma and contributes substantially to morbidity and mortality, especially 
in more severe conditions of the disease (Tagaya & Tamaoki, 2007). Goblet cells and 
mucus glands are the sources of mucin glycoproteins (MUCs) and, to date, 13 MUC 
genes (MUC1-4, MUC5AC, MUC5B, MUC6-9, MUC11-13) have been identified in 
human airways. IL-13 has been suggested to independently induce cell hyperplasia 
independent of IL-4 and IL-5 (Wills-Karp & Chiaramonte, 2003). 
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Figure 1.03: Causative roles and relationships of pro-inflammatory cytokines in 
allergic asthma. Figure adapted from (Catley, Coote, Bari, & Tomlinson, 2011) 
 
1.04.1 Eosinophils 
Eosinophilia, or eosinophil-rich inflammation, is normally observed in parasitic 
inflammation or various allergic inflammations. Eosinophils are a unique class of 
inflammatory leukocytes (Figure 1.04) and are the major effector cells driving allergic 
airway inflammation and related hallmarks of the disease in allergic asthma (Figure 
1.05). The significance of eosinophils in pathogenesis of allergic asthma is 
highlighted by studies which demonstrated that mice that are deficient in the 
eosinophil lineage are protected from the major features of the disease (Humbles, et 
al., 2004; Lee, et al., 2004). Clinical studies employing specific monoclonal antibody 
therapy targeting eosinphils in asthmatic patients provided corroborating  evidences of 
eosinophils are key effector cells, driving respiratory exacerbations in allergic asthma 
(M. Castro, et al., 2011; Haldar, et al., 2009).  
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In asthma, eotaxin (a chemokine) binds to CC chemokine receptor 3 (CCR3), a 
receptor found abundantly on eosinophils, initiates the migration, accumulation and 
degranulation of eosinophils into the inflamed airways. Degranulation of eosinophils 
in the inflamed tissues results in massive release of secretory vesicles, containing 
disease-driving molecular factors, such as major basic cationic protein, eosinophil 
peroxidase, cytokines, chemokines, growth factors and enzymes (Figure 1.04C).  
These factors also comprise of reactive oxygen species (ROS) which leads to pro-
inflammatory signaling, epithelial and lung damage, as well as promoting 
inflammatory functions in other pro-inflammatory cells (Figure 1.06). 
 
Major allergic cytokines, IL-4, IL-5 and IL-13, also broadly promote the recruitment, 
survival and functions of eosinophils in allergic asthma. Knockout of the IL-5 or IL-5 
receptor prevents the development of eosinophilia (Kopf, et al., 1996; Yoshida, et al., 
1996), while overexpression of IL-5 results in massive systemic eosinophilia (Dent, 
Strath, Mellor, & Sanderson, 1990). While IL-4 and IL-13 can similarly drive the 
recruitment of eosinophils (Pope, et al., 2001; Schleimer, et al., 1992), monoclonal 
antibody therapy against either allergic cytokines have shown limited clinical efficacy 
(Busse, Ring, Huss-Marp, & Kahn, 2010; Catley, et al., 2011), probably due to the 
multifaceted nature of the disease and that these cytokines share many common over-
lapping non-redundant effects. These findings imply that broad inhibition of multiple 
pro-inflammatory factors, such as using corticosteroids, may potentially be a better 
therapeutic strategy to treat asthma.  
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Figure 1.04: The Eosinophil. (a) Human eosinophils isolated from peripheral blood, 
stained with modified giemsa at magnification x100. (b) Murine eosinophils stained 
with modified giemsa at magnification x100. (c) Transmission electron micrograph of 
murine eosinophil at magnification x 6000. Cytoplasmic secretory granules contain 
cationic major basic proteins, other cationic proteins, cytokines, chemokines, growth 
factors and enzymes. Figure adapted from (Rosenberg, Dyer, & Foster, 2013) 
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Figure 1.05: Extensive Effector functions of eosinophils in asthma and other 
allergic diseases. Figure adapted from (Fulkerson & Rothenberg, 2013) 
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Figure 1.06: Eosinophils possess diverse capabilities to promote pro-
inflammatory functions in other inflammatory leukocytes. Figure adapted from 
(Rosenberg, et al., 2013) 
 
1.04.2 Neutrophils 
Apart from eosinophils, neutrophils are also notable secondary effector cells driving 
the progression of airway inflammation in allergic asthma (Fahy, Kim, Liu, & 
Boushey, 1995). Under normal physiological conditions, neutrophils are not 
abundantly found in healthy lungs. Upon allergic stimuli, neutrophils are recruited to 
the lungs, alongside other inflammatory cells, where they exert a similar magnitude of 
inflammatory responses as eosinophils. It has been uncovered high levels of 
neutrophils are present in the sputum of severe asthmatics (Group, 2003), as 
compared to milder cases of the disease. Furthermore, other clinical studies have 
similarly provided additional evidences that severe asthma can be divided into two 
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characteristic phenotypes: (1) consisting of high eosinophilia and neutrophilia and (2) 
comprising of low eosinophilia with high neutrophilia (Sally E Wenzel, et al., 1999), 
suggesting neutrophils are a common inflammatory cellular response amongst 
different asthmatic phenotypes. Neutrophils possess many granular secretory vesicles, 
which contain similar pro-inflammatory arsenals, such as myeloperoxidase (MPO), 
cathepsins and serine proteases and are equally capable effector cells in generating 
multiple inflammatory responses and oxidative stress, resulting in the progression of 
the disease.  
 
Despite their established clinical efficacy at suppressing eosinophils, it has been 
consistently shown that current corticosteroids are poorly effective against neutrophils 
(P. J. Barnes, Maneechotesuwan, Essilfie-Quaye, Kharitonov, & Adcock, 2007; Ito, et 
al., 2008). Increasing awareness of the clinical relevance of neutrophilia has been 
noted with the corresponding elevated usage of corticosteroids. It has been 
hypothesized that potent neutrophilia in severe asthmatics may be attributed to the 
selective recruitment of these leukocytes by chronic exposures to corticosteroids 
which broadly suppress the recruitment of other inflammatory cells, other than 
neutrophils. Indeed, prolonged usage of corticosteroids in chronic asthmatics does 
lead to an uncontrolled neutrophil-rich airway inflammation which eventually 
develops into of the most severe or even fatal form of asthma, known as steroid-
resistant asthma (Sur, et al., 1993).  Similarly, cigarette smoke has been highlighted as 
a key promoting risk factor in human asthmatics as cigarette smoke is able to promote 
oxidative stress and enhanced neutrophilia, which further increases severity of the 
disease (Ahmad, Barnes, & Adcock, 2008; Nakamura, et al., 2008). Current 
therapeutic strategies against asthma also propose to discover potential anti-
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inflammatory agents which are capable of suppressing neutrophils, so as to 
complement corticosteroid therapy.  
 
1.05  Oxidative and Nitrosative stress in Asthma 
The classical hallmark of allergic asthma is airway inflammation. Airway 
inflammation results in the up-regulation of pro-oxidants in epithelial cells, airway 
smooth muscles and various inflammatory leukocytes. Promotion of various 
pulmonary pro-oxidants, such as NADPH oxidases (NOXs) and inducible nitric oxide 
synthase (iNOS) (Figure 1.07), generate reactive oxygen and nitrogen species 
(RONS), which results in oxidative damage of DNA, proteins and lipids in asthmatic 
lungs, inflammatory pathway signaling and related downstream inflammatory 
mediators expressions. Cumulative evidences summarized in several reviews have 
revealed that oxidative stress may initiate and augment inflammation, and may also 
result from inflammation, highlighting the importance and involvement of oxidative 
stress in the pathogenesis of the disease (Hoshino, et al., 2008; Sugiura & Ichinose, 
2008b). Increased levels of oxidative stress markers, including nitric oxide, 3-
nitrotyrosine, carbon monoxide, and 8-isoprostane had been measured in the sputum 
or exhaled breath condensate of asthmatics (Do, Bartlett, Dilmich-Ward, Chu, & 
Kennedy, 2008; Romieu, et al., 2008; Wood, et al., 2005), further supporting the 
clinical significance of oxidative stress.   
 
The lung is especially susceptible to oxidative stress and oxidant-induced damage 
from environmental exposures of ozone, carbon dioxide and various particulate matter 
(Dick, Brown, Donaldson, & Stone, 2003; N. Li, Hao, Phalen, Hinds, & Nel, 2003). 
Therefore, the lung, especially the epithelial cell barrier, is correspondingly endowed 
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with a rich assortment of defensive antioxidant enzymes to neutralize various RONS 
(Dunstan, et al., 2006; Ochs-Balcom, et al., 2006; Rahman, Biswas, & Kode, 2006). 
In asthma, expressions endogenous pulmonary antioxidants are also altered differently, 
with the reduction of catalase, glutathione-peroxidase (GPx) and elevation of 
superoxide dismutases (SODs) (Gumral, et al., 2009; Nadeem, Chhabra, Masood, & 
Raj, 2003a).  Superoxide dismutase is primarily responsible for the dismutation of 
superoxide anion (O2•-) into hydrogen peroxide (H2O2) and molecular oxygen (O2). 
Importantly, the impairment of key lung antioxidants, catalase and GPx will lead to 
the accumulation of reactive and damaging H2O2 and O2•
- 
radical species, as these 




The importance of oxidative stress in asthma is further exemplified by antioxidant 
therapies which have shown promising protective effects in experimental asthma 
models, suppressing both airway inflammation and airway hyperresponsiveness (S. M. 
Castro, et al., 2006; Y. S. Cho, et al., 2004). Furthermore, oxidative stress has also 
been found to be an important cause to other hallmark symptoms in asthma, such as 
mucus hypersecretion (P. J. Barnes, 2009a, 2009b). Recent studies have also 
implicated oxidative stress to play a major role in promoting corticosteroid-resistance 
in asthmatic patients (Adcock, Chou, Durham, & Ford, 2009; P. J. Barnes, 2004). 
Current strategies for reversing steroid resistance can be achieved primarily using 
antioxidants and Nrf2 activators, as well as theophylline, nortriptyline and PI3K-δ 
inhibitors, HDAC2 activators (Figure 1.09). Therefore, it will be invaluable to 
uncover novel potent anti-inflammatory agents which may complement existing 
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therapies to reduce oxidative stress and potentially reduce the development of steroid 












Figure 1.07: Overview of Pulmonary Antioxidants and Pro-oxidants in the Lung.  
Epithelial cells and various inflammatory cells possess a broad assortment  of RONS-
generating pro-oxidant enzymes, such as NOXs and iNOS, as well as various RONS-
neutralizing antioxidants, as SODs, catalase and GPx. Figure adapted from (Bowler & 
Crapo, 2002). 
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Oxidative Lung Damage to 
Proteins, Lipids and DNA.
 
Figure 1.08: Overview of Interplay between Inflammation, Oxidative Stress, 
Nitrosative Stress, Pro-oxidants and Antioxidants in Allergic Asthma. Figure 
adapted from (Nadeem, Masood, & Siddiqui, 2008). 
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Figure 1.09: Major pathways involving oxidative stress, PI3K/Akt and Nrf2 
promoting steroid resistance. Reversal of steroid resistance can be achieved 
primarily using antioxidants and Nrf2 activators, as well as theophylline, nortriptyline 
and PI3K-δ inhibitors, HDAC2 activators. Figure adapted from (P. J. Barnes, 2012) 
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1.06 Oxidative Damage Markers 
As reactive oxygen species (ROS) and reactive nitrogen species (RNS) are highly 
reactive and unstable for quantification, it is typically more feasible to quantify the 
chemical molecules, such as lipids, DNA or protein residues, which these RONS react 
with as a surrogate measure of RONS levels in the lungs (Figure 1.10). These reacted 
chemical molecules will often possess altered chemical or biological activities and are 
commonly known also oxidative damage markers. Oxidative damage markers are 
generally more stable than their RONS precursors and may be stored in -80°C for 
months for subsequent quantifications. In asthma and related lung diseases, these 
oxidative lung damage markers have been found to contribute directly to the 
inflammatory disease outcome and progression, thus becoming invaluable targets to 
understand the effects and extent of oxidative and nitrosative stress in inflammatory 
diseases.   
 
3-Nitrotyrosine, 3-NT, is a product of protein nitration, formed from NO and ONOO· 
damage on tyrosine residues (Dedon & Tannenbaum, 2004). Prior to this study, 3-NT 
has been identified to be an indicative biomarker for RNS-related lung damage in 
allergic asthma, especially under inactivated catalase conditions (Ghosh, et al., 2006; 
Hanazawa, Kharitonov, & Barnes, 2000). Studies have also shown that 3-NT levels 
are strongly linked to the eosinophils via eosinophil peroxidase in promoting nitric 
oxide and related down-stream oxidants production in severe asthma (Duguet, Iijima, 
Eum, Hamid, & Eidelman, 2001a; MacPherson, et al., 2001).  Importantly, nitration 
of tyrosine residues have been reported to promote loss or gain of functions in lung 
antioxidants (Radi, 2004), suggesting the pathophysiological role of 3-NT and 
nitrosative stress in allergic airways. 
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8-hydroxy-2-deoxyguanosine, 8-OHdG, is a product formed by H2O2, O2·
- and OH· 
free radical damage at the C-8 position of guanine, which is increasingly used as a 
marker of oxidative damage to DNA (Park & Floyd, 1992). Although, 8-OHdG is not 
commonly measured in asthma, a recent study has detected elevated levels of 8-
OHdG in allergic asthma (Proklou, et al., 2013), implicating the involvement of 
oxidative DNA damage in allergic asthma. This study also revealed that smoking can 
further increase levels of 8-OHdG, suggesting that this biomarker could be associated 
with increasing severity of airway inflammation and oxidative stress.  
 
8-isoprostane, 8-isoP, is a prostaglandin F2-like lipid product indicative of lipid 
peroxidation formed by H2O2, O2·
- and OH· free radical-catalyzed peroxidation of 
arachidonic acid (Morrow, Awad, Boss, Blair, & Roberts, 1992).  The relevance of 8-
isoP as a non-invasive in vivo biomarker in asthma and related inflammatory 
respiratory diseases was uncovered first in the exhaled breath condensate of asthmatic 
patients (Montuschi, et al., 1999; Montuschi, et al., 2000).  Importantly, it was also 
revealed that levels of 8-isoP were not inhibited in asthmatic patients under 
corticosteroids therapy, suggesting that current anti-inflammatory may be ineffective 
to regulate lipid peroxidation in allergic inflamed airways (Montuschi, et al., 1999). 
Studies have also shown that 8-isoP levels are directly linked to the progression of 
asthma, as levels of this oxidative damage marker correlated strongly to the increasing 
severity of the disease (Baraldi, Ghiro, et al., 2003; Zanconato, et al., 2004). 
Furthermore, 8-IsoP is also a reactive lipid product and can propagate further 
oxidative damage by modifying important biomolecules (Roberts, Montuschi, & 
Barnes, 2004). Amongst various lipid damage markers, 8-IsoP is considered one of 
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the most representative inflammatory biomarker which reflect the involvement of 
oxidative stress and subsequent oxidative lipid damage in allergic airways.  
 
Figure 1.10: Chemical structures of common oxidative and nitrosative damage 
markers. Original thesis figure by WE Ho et al. 2013. 
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1.07  The Protective Role of Nrf2 in Allergic Asthma 
Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is a redox sensitive basic leucine 
zipper transcription factor which is found to possess multiple protective functions 
against neurodegenerative diseases, inflammation and infections (J. Kim, Y. N. Cha, 
& Y. J. Surh, 2010) (Figure 1.11). Observed from the figure, Nrf2 is a major 
regulatory protective transcription factor which can be activated by a broad variety of 
harmful external stmuli, such as oxidative stress, UV, chemical damage and 
inflammatory mediators. As oxidative stress is revealed to play major 
pathophysiological roles in inflammation and allergic diseases, the importance of 
regulation of pro-inflammatory pro-oxidants and defensive antioxidants has become 
the focal point of therapeutic strategies against RONS-mediated disorders. Nrf2, a 
transcription factor normally found in the cytoplasm restricted by Kelch like-ECH-
associated protein 1 (Keap1). Upon activation by RONS or inflammatory stimuli, 
Keap1 is disrupted and Nrf2 will translocate into the nucleus, binding to Antioxidant 
Response Elements (ARE) regions on gene promoter regions encoding for 
antioxidants and other related genes with ARE regions (J. Kim, et al., 2010) (Figure 
1.12).  As Nrf2 is a relative newly-discovered transcription factor, the comprehensive 
profile of genes regulated by Nrf2 is not fully elucidated. Presently, many major 
antioxidants, such as CAT, SODs, GPx and HO-1 have been found to be regulated by 
Nrf2 (N. Li & Nel, 2006; Rangasamy, et al., 2005).  
 
The overall anti-inflammatory effects induced by Nrf2 activation can be profound and 
potent, as the induction of multiple protective antioxidants and anti-inflammatory 
genes is further compounded by the overall reduction of RONS-induced inflammatory 
signaling.   Indeed, allergic asthma mice models, featuring genetically Nrf2 knockout 
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mice have shown enhanced susceptibility to aeroallergen-induced airway 
inflammation (Figure 1.13), especially eosinophilia, pronounced inflammatory and 
allergic cytokine responses (IL-4, IL-13) and exaggerated mucus hypersecretion 
(Figure 1.14) and AHR (Rangasamy, et al., 2005). Broad reductions in the expression 
of various antioxidants promoting enhanced susceptibility to allergic airway 
inflammation, observed in these Nrf2 deficient mice, demonstrate that Nrf2 play 
critical protective functions against allergic asthma and related disease hallmarks 
(Williams, et al., 2008).  A recent study have also provided suggestive evidences that 
aeroallergens can lead to early and prolonged generation of RONS, which eventually 
limits Nrf2 activation and promote insensitivity to Nrf2-induced responses (Dworski, 
Han, Blackwell, Hoskins, & Freeman, 2011).  RONS-induced inactivation of Nrf2 
signaling and blockage of downstream antioxidant transcription will in turn form a 
vicious cycle involving excessive RONS formation and progressive loss of 
antioxidants defences, resulting in  the progression and pathogenesis of asthma and 
related respiratory diseases. 
 
With these evidences, there is a current drive in respiratory research to develop 
therapeutic compounds which limit or neutralise RONS formation (vitamins or 
antioxidants enzymes) or promote Nrf2 activation to control airway inflammation 
(Dworski, et al., 2011; Wood, Wark, & Garg, 2010). Furthermore, experts in the field 
have also repeatedly highlighted that the reduction of oxidative stress and/or 
promotion of Nrf2 are potentially useful therapeutic strategies to reverse 
corticosteroid insensitivity in severe asthmatics and patients with chronic obstructive 
pulmonary disease (COPD) (Adcock & Barnes, 2008; P. J. Barnes, 2010, 2012).  It is 
thus believed that the next prospective drug candidate for treating allergic asthma and 
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chronic respiratory diseases should possess pharmacological activities, such as 











Figure 1.11: Activation of Nrf2 Induced Cellular Responses. Figure adapted from 
(Kaspar, Niture, & Jaiswal, 2009) 
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Figure 1.12: Current Proposed Mechanism of Nrf2-regulated Gene Expressions. 
Figure adapted from (J. Kim, et al., 2010) 
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Figure 1.13: Nrf2 Deficiency Leads to Enhanced Airway Inflammation & 
Inflammatory Cell Infiltration. (A) Histological examinations (H&E) and (B) IHC 
staining of eosinophils reveal consistent results that lack of Nrf2 leads to increased 
airway inflammation and inflammatory cell infiltration, especially eosinophilia into 
the lungs. Figure adapted from (Rangasamy, et al., 2005) 
 
Figure 1.14: Knockout of Nrf2 Results in Exaggerated Mucus Hypersecretion in 
Allergic Asthma. Periodic acid Schiff (PAS) staining of histological sections of lungs 
from normal mice and Nrf2 deficient mice exposed to saline aerosol or OVA aerosol. 
Figure adapted from (Rangasamy, et al., 2005). 
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1.08  Current Treatments and Future Directions for Asthma 
With asthma being a major and increasing global chronic health problem, current 
therapies and treatments serve primarily to control the disease but not cure it (Figure 
1.15). Furthermore, despite the availability of effective and relatively cheap 
treatments, approximately 10% of asthmatic patients remain poorly controlled by 
available therapeutics. Therefore, treatments for asthma are constantly being 
developed, targeting at the inflammatory and physiological remodeling responses in 
asthma. Current available clinical interventions for allergic asthma involve two major 
therapeutic strategies, namely, control of allergic airway inflammation, as well as 
prevention of bronchoconstriction and AHR (Blakey, et al., 2013).  Corticosteroids 
are frequently used immunosuppressants for asthmatic patients and are regarded as 
the gold standard for treating asthma with good efficacy of disease control and 
reduction of risk for disease progression. However, these immune-based therapies are 
typically slower-acting and inadequate in providing timely relief against aeroallergen-
triggered respiratory exacerbations. Furthermore, corticosteroids are also ineffective 
with controlling neutrophilic-based inflammation which is also a major observed 
phenotype in asthmatics using steroid therapy. Long-term usage of corticosteroids is 
also discouraged as extensive usage of these sterols can lead to a broad range of 
adverse effects ranging from increased risk of cataracts, osteoporosis, deregulation of 
energy, lipids and cortisol metabolism as well as increased risks of other opportunistic 
fungal and bacterial infections (Cooper, van Staa, & Leufkens, 2002; Hanania, 
Chapman, & Kesten, 1995; Whitmore, 1997).  
 
A distinctive different approach for controlling asthma includes the use of long-term 
acting β-agonists (LABAs) and anticholinergics which focus on controlling the AHR 
29 
and related airway constriction. Despite their potent capabilities to rapidly relax 
airway smooth muscles, bronchodilators are exceptionally poor at suppressing on-
going airway inflammation which results in proliferation of oxidative damage and 
worsening of the disease condition. Such a therapeutic strategy has also been shown 
to exceptionally dangerous as the reduction of AHR without appropriate suppression 
of continual airway inflammation, leads to the false perception of controlling the 
disease and can lead to rapid and uncontrolled progression of the inflammatory 
process. In addition, prolonged use of β-agonists may also lead to the development of 
β2-adrenergic receptor densensitization and reduced expressions, resulting in 
dampened responses to β-agonists and insensitivity to bronchodilators (Nishikawa, 
Mak, Shirasaki, Harding, & Barnes, 1994).  
 
Although bronchodilators and/or moderate doses of regular inhaled steroids provide 
good control for most individuals with asthma, a significant proportion of asthmatic 
patients (~10%) can develop severe exacerbations that are difficult to prevent, leading 
to time lost from work, admission to hospital and the occurrence of life-threatening 
attacks. This group of severe asthmatics, although only a small percentage of the 
asthma population, utilizes a highly disproportionate amount of health care time and 
dollars (Weiss, Gergen, & Hodgson, 1992). They respond poorly to standard care for 
asthma, including inhaled and systemic corticosteroids. Despite extensive studies to 
understand this clinically severe state, little is known regarding the pathology of the 
process. Pathological studies have reported the possible existence of two distinct 
groups of severe asthmatics, with distinct physiological and clinical characteristics 
(Sally E Wenzel, et al., 1999), with prominent neutrophilia as a mutual phenotype in 
both groups.  
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Current mainstream therapies against asthma advocate the synergistic combination of 
corticosteroids with LABAs, so as to control both airway inflammation and 
respiratory distress (P. J. Barnes, 2002). In addition, multiple synergistic mechanisms 
have been uncovered with the use of corticosteroids and β-agonists, such as 
corticosteroid-induced expressions of β2-adrenergic receptors (Baraniuk, et al., 1997) 
and amplified corticosteroid actions with co-administration of LABAs (Oddera, 
Silvestri, Testi, & Rossi, 1998). Despite these exciting advances in current clinical 
strategies, there still exist strong clinical needs for an alternative class of anti-
inflammatory agents which function differently than corticosteroids, with 
pharmacological actions such as inhibition of neutrophilia, limiting RONS formation, 
reduced adverse effects and be complementary to existing therapies.  
 
 
Table 1B: Current available clinical interventions for asthma and indication of 
capability to control disease and to reduce risks of disease progression. Figure 












Figure 1.15: Current Clinical Therapies for Asthma. Original thesis figure by W.E. 
Ho 2013. 
 
1.08.1 Mechanisms of Corticosteroids: Dexamethasone 
Corticosteroids, or glucocorticoids, are a class of endogenously-produced or synthetic 
steroidal hormones which regulate a wide variety of anti-inflammatory metabolic 
functions in the body. Amongst the various clinically-used glucocorticoids, 
dexamethasone is the most potent synthetic anti-inflammatory derivative available for 
therapeutic use for asthma (Figure 1.16) (Cross, Paul, & Goldman, 2011). Currently, a 
less potent glucocorticoid, prednisolone, is more commonly used to treat most 
asthmatics, due to the considerations of balancing efficacy to control the disease and 
adverse effects profile (Bentley, et al., 1996).  In terms of anti-inflammatory potency, 
prednisolone is five times more potent than endogenous cortisol, while 
dexamethasone is twenty-five times more potent than cortisol (National Institute of 
Health, http://livertox.nih.gov/Corticosteroids.htm). Currently, dexamethasone is 
primarily reserved for use against severe asthmatics and asthmatic exacerbations and 
is one of the remaining anti-inflammatory arsenal against chronic severe asthma 
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(Cross, et al., 2011). There exists a need for an alternative broad-based anti-
inflammatory compounds which can induce comparable and anti-inflammatory effects 
as dexamethasone, but yet possess a more favorable adverse effects profile.  
 
Corticosteroids exert their anti-inflammatory functions by promoting transcription of 
various anti-inflammatory mediators, as well as the trans-repression of various NF-
κB-induced pro-inflammatory genes. Corticosteroids bind to cytoplasmic 
glucocorticoid receptors (GRs), which translocate to the nucleus where they bind to 
glucocorticoid response elements (GREs) in the promoter region of steroid-sensitive 
genes (Figure 1.17). Corticosteroids also directly or indirectly bind to coactivator 
molecules, such as CREB (cyclic adenosine monophosphate response element–
binding protein)-binding protein (CBP), p300/CBP-associated factor (PCAF), or 
steroid receptor coactivator-1 (SRC-1), which have intrinsic histone acetyltransferase 
(HAT) activity. This binding causes acetylation of lysines on histone-4, which leads 
to activation of genes encoding anti-inflammatory proteins, such as secretory 
leukoprotease inhibitor (SLPI) (Peter J. Barnes & Adcock, 2003).  Similarly, 
deactivation of pro-inflammatory mediator transcription is promoted by GRs, after 
activation by corticosteroids, translocate to the nucleus and bind to coactivators to 
inhibit HAT activity directly. They also recruit histone deacetylases (HDACs), which 
reverses histone acetylation leading in suppression of inflammatory genes.  These 
mechanisms which corticosteroids alter transcription of a wide profile of pro-
inflammatory and anti-inflammatory genes enable corticosteroids to be one of the 
most effective clinically-used broad-based anti-inflammatory drug (Figure 1.18). 
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Although corticosteroids are effective suppressors of airway inflammation, especially 
eosinophilia (Figure 1.19) and other related inflammatory cells and processes in 
allergic asthma (Figure 1.20), the use of these potent anti-inflammatory agents is not 
completely infallible. Prominent neutrophilic inflammation has been demonstrated 
during asthmatic exacerbations (Fahy, et al., 1995) and in cases of sudden-onset fatal 
asthma (Sur, et al., 1993). Other studies have attributed neutrophilic inflammation in 
severe asthmatics to the proliferated use of high dose of corticosteroids treatment, as 
corticosteroids have been found to increase neutrophil survival by reducing apoptosis 
of these cells (Cox, 1995; Meagher, Cousin, Seckl, & Haslett, 1996), while increasing 
apoptosis of eosinophils (Meagher, et al., 1996). Therefore, neutrophilic inflammation 
may explain for the poor response of severe, refractory asthmatics to corticosteroids 
and also that there is a need for the discovery of alternative complementary 
therapeutic agents for treating asthma other than using corticosteroids. 
 




Figure 1.17: How corticosteroids promote transcription of anti-inflammatory 
genes and inhibit transcription of pro-inflammatory genes. Figure adapted from 
(Peter J. Barnes & Adcock, 2003). 
 
Figure 1.18: Corticosteroids alter the transcription of various pro-inflammatory 






Figure 1.19: Direct and indirect molecular mechanisms of how corticosteroids 
inhibit eosinophilia. Figure adapted from (Fulkerson & Rothenberg, 2013) 
 
Figure 1.20: Cellular functions of corticosteroids in asthma. Figure adapted from 
(Peter J. Barnes & Adcock, 2003). 
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1.09 Artemisinins: The family of anti-malarial agents 
Artemisinins are a family of sesquiterpene trioxane lactone anti-malarial agents 
(Figure 1.21), derived from the sweet woodworm, Artemisia annua, a medicinal herb 
which has long been used in traditional Chinese medicine to treat fevers. This series 
of potent anti-malarial derivatives were chemically developed from artemisinin 
(Figure 1.22), which is the parent compound isolated in a Chinese drug discovery 
screen for traditional herbal extracts against malaria in the 1970s (van Agtmael, 
Eggelte, & van Boxtel, 1999).  Although artemisinins are the current mainstream 
medication against malaria, the World Health Organisation has strong 
recommendations to administer them in combination therapies with other anti-
malarial compounds, such as chloroquine and related quinines, to avert the 
development of drug resistance in the Plasmodium parasite species. There are 
numerous comprehensive reviews which have discussed the anti-parasitic 
mechanisms of artemisinins in malaria (Krishna, Bustamante, Haynes, & Staines, 
2008; Krishna, Pulcini, Fatih, & Staines, 2010; van Agtmael, et al., 1999).  
 
The strengths of artemisinins in anti-malarial therapy lie in their unique chemical 
structures which differ much from the standard quinoline (Kremsner & Krishna, 2004) 
and significantly rapid clearance of malaria parasites from the blood than other 
available anti-malarial agents. In addition, artemisinins are have been recognized for 
their established record of safety (Efferth & Kaina, 2010), especially in humans, as 
well as their permissive cost to be widely used. Artesunate, artemether and arteether 
are the more widely used derivatives of artemisinin for malaria (Figure 1.22) and are 
universally converted to the active metabolite, dihydroartemisinin (DHA), rapidly 
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upon administration into the body (White, 1994). Amongst the family of artemisinins, 
artesunate is the most commonly investigated analogue due to the addition of a 
hemisuccinate group which confers substantial water-solubility and high oral 
bioavailability, resulting in a more favourable pharmacological profile.  Artemisinins 
have also been readily formulated in a variety of different administrations, including 
oral, intravenous, intramuscular as well as rectal administration, to complement 
clinical applications.  
 
There are consistent interests in current research on artemisinins in malaria, which 
includes developing newer derivatives with safer and better efficacy for malaria 
treatment, exploring new combination therapies to overcome resistance, as well as 
understanding unknown mechanisms of artemisinins’ effects on the parasite. Despite 
worldwide concerns of emerging drug resistance to artemisinins as well as 
artemisinins-based combination therapies (Wongsrichanalai, 2013), there exists 
manifold of opportunities in employing artemisinins beyond malaria infections. The 
desirable properties of artemisinins and their wide spectrum of potent biological 
activities have spawned growing interests of investigating artemisinins in a wide 
variety of diseases, ranging from cancers, inflammatory diseases, autoimmune 
disorders, to viral and protozoan-related infections (Figure 1.24). Indeed, there is an 
upward trend of investigating artemisinins in many diseases outside of malaria, 
reflected by the consistent increases of publications of non-malaria artemisinin-related 
research over these years (Figure 1.23). Furthermore, artemisinins have been shown to 
possess broad and robust effects on multiple inflammatory signaling pathways, such 
as PI3K/Akt, NF-κB, MAPK and more (Figure 1.25), suggesting that this family of 
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anti-malarial compound may be suitable potential candidates suited for treating 




Figure 1.21: Chemical Structures of Current Key Artemisinins. Figure adapted 




















Figure 1.22: Overview of relationships of Artemisinin drug and Artemisia plant 
to key artemisinin members. Original thesis figure (W.E. Ho 2013). 
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Figure 1.23: Discovery and Impact of Artemisinin Pharmacological Actions 
Beyond Malaria. Figure adapted from W.E. Ho et. al. (2013) Artemisinins: 


































































































Figure 1.24: Bubble Map Outlining Various Biological Activities of Artemsinins 
and their Potential Clinical Applications in Different Diseases. Yellow circles with 
solid lines indicate different biological activities; Blue circles with dotted lines 
indicate potential applications of respective biological activity in various human 
diseases. Figure adapted from W.E. Ho et. al. (2013) Artemisinins: pharmacological 




Figure 1.25: Overview of the proposed modes of action of artemisinins on major 
signaling pathways that may contribute to its anti-inflammatory, anti-allergic 
and anti-cancer activities. + indicates activation and - indicates inhibition. 
*Promotion of Nrf2 is derived from the findings of this thesis. Adapted from W.E. Ho 
et. al. (2013) Artemisinins: pharmacological actions beyond anti-malarial (Accepted 
– in publication). 
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1.09.1 Artemisinins and Allergic Diseases 
Artemisinins were first shown to possess potent anti-allergic properties in vivo, in an 
experimental guinea pig model of allergic contact dermatitis, where topical 
applications of artesunate (0.85 – 5%) was capable of producing substantial inhibition 
of allergic inflammatory skin reactions (Chen & Maibach, 1994).  Interestingly, the 
study also uncover that the anti-inflammatory effects of artesunate in allergic contact 
dermatitis were specific inhibitory effects against allergic reactions and was 
ineffective against toxic (irritant)-induced contact dermatitis. A recent investigation of 
artesunate in experimental allergic contact dermatitis also described similar 
immunosuppressive effects using topical artesunate, resulting in pronounced 
reduction of swelling, spleen index and inflammatory cell infiltration, by inhibition of 
NF-κB p65, T-bet and IFN-γ expressions (T. Li, Chen, Liu, Zhou, & Bai, 2012). A 
Chinese hospital trial investigating artemisinins in a variety of allergic skin reactions 
have reported promising therapeutic outcomes by application of topical artesunate in 
ninety cases of allergic skin disorder patients, with potent efficacy against eczema, 
erythema multiforme, polymorphous sunlight eruption, hydroa aestivale and 
moderately effectiveness against atopic dermatitis, psoriasis vulgaris, 
dermatomyositis (Qibin & Huiling, 1997). 
 
Anti-allergic mechanisms of artemisinins have been further explained by a related 
study from our lab featuring a series of experimental models of allergic anaphylaxis 
(Cheng, et al., 2013). In a model of passive cutaneous anaphylaxis, artesunate (3 – 30 
mg/kg/d, i.p) could dose-dependently prevent IgE-mediated vascular permeability. 
Further shown in a murine model of passive systemic anaphylaxis, artesunate (3 – 30 
mg/kg/d, i.p) was dose-dependently effective against IgE-induced mast cell 
44 
degranulation, effectively preventing plasma histamine increases, subsequent 
hypothermia and even promoted rapid recovery of body temperature. These anti-
allergic actions of artesunate were further explored showing that upstream inhibition 
of IgE-mediated bronchial contractions by artesunate are due to upstream blockage of 
IgE-induced mast cell degranulation and not against direct receptor antagonism 
against histamine and leukotrienes (Cheng, et al., 2013). These potent anti-allergic 
mechanisms were demonstrated to be attributed to upstream inhibition of Syk tyrosine 
kinase and phospholipase-Cγ (PLCγ) activation, subsequently preventing downstream 
production of inositol trisphosphate (IP3) and cytosolic calcium influx. These 
collective results have suggested that artemisinins possess potential to be developed 
as a mast-cell stabilising agent, especially for treating hypersensitivity disorders. 
 
Although artemisinins have been recognised as a family of exceptionally safe drug 
and have being administered to millions of malaria patients worldwide, it is important 
to highlight that there have been four cases of IgE-mediated anaphylactic reactions to 
oral and intravenous artesunate (Dube, Panda, Agrawal, & Singh, 2012; Leonardi, 
Gilvary, White, & Nosten, 2001; Mohapatra, Srinivas, Kar, & Murmu, 2009).  These 
allergic reactions to artemisinins are considerably rare and somewhat paradoxical to 
the potent anti-allergic effects of artemisinins reported in various allergic diseases. 
However, these allergic reactions to artemisinins have not been well understood and 
further investigations are required to identify the mechanisms involved and 
susceptible populations. Together, these studies have suggested robust and broad-




1.09.2 Investigation of Artesunate in Allergic Asthma 
Our group initiated the first investigations of artesunate in allergic asthma and 
demonstrated that artesunate was dose-dependently effective against the major 
hallmarks of allergic asthma, namely, airway inflammation (Figure 1.26), mucus 
hypersecretion (Figure 1.27) and airway hyperresponsiveness (Cheng, et al., 2011). 
The study further established that similar protective effects of artesunate can also be 
observed in a house-dust mite-induced asthma model and as well as on human 
bronchial epithelial cells. Importantly, the study also concluded that these protective 
anti-inflammatory effects are largely mediated via inhibition of the PI3K-Akt and 
related downstream NF-κB signaling pathways. Notably, this study identified that the 
intraperitoneal dosage of 30 mg/kg of artesunate was most efficacious at suppressing 
various inflammatory symptoms as compared to dosages of 3 mg/kg and 10 mg/kg. 
The drug dosage regime uncovered from this study formed the key fundamental drug 
administration knowledge which facilitated the research in this PhD thesis.   
 
Artemisinins have also demonstrated novel and robust anti-inflammatory properties in 
experimental allergic asthma (Cheng, et al., 2011). Dose-dependent inhibition of 
airway inflammation, especially eosinophilia, was observed with intra- peritoneal 
injections of artesunate (3 – 30 mg/kg/d) (Cheng, et al., 2011), with comparable 
suppression of inflammatory cell counts to a potent glucocorticoid, dexamethasone .  
Interestingly, artesunate (30 mg/kg) was also found to inhibit the neutrophilic cell 
counts, which clinically-used glucocorticoids are consistently shown to be ineffective 
against (Ito, et al., 2008; Maneechotesuwan, Essilfie-Quaye, Kharitonov, Adcock, & 
Barnes, 2007). Indeed, earlier clinical trials of artemisinins in malaria have similarly 
reported slight depression of neutrophils in malaria patients receiving a five-day 
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regime of artemisinins, such as artesunate (600-1200 mg, oral) and artemether (480 
mg, i.m.) (Bunnag, Viravan, Looareesuwan, Karbwang, & Harinasuta, 1991). 
Importantly, artesunate (30 mg/kg/d) also demonstrated marked suppression on 
various hallmarks of allergic asthma, namely airway inflammation and infilitration, 
mucus hypersecretion and airway hyperresponsiveness. The study also revealed 
artesunate could induce dose-dependent inhibition of allergic cytokines and 
chemokines, IL-4, IL-5, IL13 and eotaxin in the inflamed lungs, with parallel 
suppressive effects on pulmonary expressions of major pro-inflammatory and 
adhesion molecules, IL-17, IL-33, TSLP, MUC5AC, ICAM-1, VCAM-1 and E-
selectin (Cheng, et al., 2011). These protective effects of artemisinins in allergic 
asthma have been attributed to pronounced inhibition along the PI3K/Akt signalling 
cascade and NF-κB activation, with significant blockage of Akt, tuberin, p70S6K and 
4E-BP1 activation.  
 
Despites discoveries of the anti-inflammatory potency of artesunate in allergic asthma, 
several limitations and knowledge gaps exists before artesunate can be successfully 
used as a clinical anti-inflammatory agent to treat asthma. It is presently unclear if 
oxidative and nitrosative stress, as well as the downstream oxidative lung damage, can 
be ameliorated by artesunate. Furthermore, it is also uncertain if artesunate could also 
influence other inflammatory signaling molecules which may contribute to the 
positive disease outcome. Furthermore, the efficacy of artesunate has not been 
compared to a standard therapeutic agent, such as corticosteroids. Lastly, molecular 
anti-inflammatory effects of artesunate in allergic asthma can be better explored using 
an advanced analytical platform, such as a mass-spectrometry based metabolomics.  
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Figure 1.26: Artesunate Reduces Hallmarks of Asthma – Airway Inflammation. 
Hematoxylin and Eosin (H&E) staining of histological lung sections for inflammatory 
cell infiltration. Artesunate (30 mg/kg, i.p.) could substantially reduce aeroallergen-
induced eosinophil-rich inflammatory cell influx in the allergic airways. Figure 
adapted from Cheng et al., 2011.  
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Figure 1.27: Artesunate Reduces Hallmarks of Asthma – Mucus Hypersecretion. 
Periodic acid-Schiff (PAS) staining of histological lung sections for mucus 
hypersecretion. Artesunate (30 mg/kg, i.p.) could dramatically reduce aeroallergen-
induced mucus hypersecretion in the allergic airways. Figure adapted from Cheng et 
al., 2011.  
 
1.10 Metabolomics 
Metabolomics refers to the comprehensive analysis of small molecule metabolites 
from cells, tissues, organs or organisms, being influenced by genetic modifications, 
pathological stimuli or environment (Nicholson, Lindon, & Holmes, 1999). There 
have been increasing uses of metabolomics as an investigative tool for both 
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experimental investigations and clinical disease diagnosis. Comparable to other 
‘omics’ techniques, metabolomics has been proven to be an acceptable and 
reproducible platform technology, capable of reflecting key signature processes that 
are occurring in a biological system as well as different disease states and progression 
(Figure 1.28) (W. B. Dunn, Bailey, & Johnson, 2005; Ng, et al., 2012; F. Xu, et al., 
2013).  
Currently, metabolomics is a core scientific discipline in the field of systems biology 
that specialises to study changes in the metabolome, which refers to the collection of 
both endogenous and exogenous metabolites present in the biological system 
(Warwick B. Dunn, Broadhurst, Atherton, Goodacre, & Griffin, 2011). Presently, 
there is a yearly average of over 1500 publications on various applications of 
metabolomics, indicating the increasing importance and utility of metabolomics to 
understand signature metabolic processes (Figure 1.29). There is an apparent 
awareness to study alterations of metabolites, as metabolites are in a unique position 
in biological processes, being the building blocks for all other biochemical species 
and structures including proteins (amino acids), genes and transcripts (nucleotides), 
and cell walls. 
Metabolomics, especially mass spectrometry (MS)-based metabolomics, has been 
described to be an emerging analytical tool in respiratory research, due to its high 
sensitivity and capability to simultaneously measure many biomarkers in a single 
biological sample (Adamko, Sykes, & Rowe, 2012). Indeed, there are corresponding 
rapid increasing proportions of MS-based metabolomics studies, alongside the 
increasing growth in metabolomics publications yearly (Figure 1.29).  Currently, gas-
chromatography (GC-) and liquid chromatography (LC-) based MS metabolomics are 
frequently-used analytical tools being used for various metabolomics analyses in 
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different diseases and applications (Ng, et al., 2012; F. Xu, et al., 2013; F. G. Xu, Zou, 
& Ong, 2009; Yang, et al., 2004).  The combinatory use of GC-MS and LC-MS for 
metabolomics investigations enables the determination and analysis of a larger profile 
of chemical molecules, which will potentially help uncover a unique and more 





Figure 1.28: Current Applications of Systems Biology Tools: Interlinked 
Relationships between the genome, transcriptome, proteome and the 
metabolome. Various specialised ‘omics’ tools can be employed to understand 
various molecular features of the biological system. Metabolomics is used to study 
changes in the metabolome – the collection of both endogenous and exogenous 
metabolites present in the biological system. Figure adapted from (Warwick B. Dunn, 
et al., 2011). 
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Other analytics – related metabolomics studies  
MS – related metabolomics studies
NMR – related metabolomics studies
Growing Trends in Mass Spectrometry-based Metabolomics Studies 
 
Figure 1.29: Emergent Trends in Metabolomics Studies and Mass Spectrometry-
based Metabolomics Studies. Figure adapted from (Warwick B. Dunn, et al., 2011) 
Liquid Chromatography – Mass Spectrometry
Strengths
High sensitivity 
Ability to quantify and identify a wide 
profile of metabolites
Limitations
Limited for  detecting relatively non-
polar metabolites, including lipids.
Gas Chromatography – Mass Spectrometry
Strengths
High Sensitivity
Able to detect gases or volatile compounds
Well-established metabolite ID libraries
Limitations
Chemical derivatization step required. 








Require larger volumes of sample
Poorer Sensitivity versus MS
LC/MS GC-MS
NMR
Current Major Analytical Tools for Metabolomics
 
Figure 1.30: Current Analytical Tools for Metabolomics Studies. Original Thesis 
figure by W.E. Ho 2013.  
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1.11 Metabolomics for Biomarker Discovery and Applications of Systems 
Pharmacology in Asthma 
In the field of respiratory research, there is a constant drive to better understand 
asthma and relevant novel molecular disease markers, so as to develop new 
pharmacological measures to ease the rapidly increasing morbidity and mortality 
associated with the disease. In asthma research, metabolomics is a relatively new 
technique which potentially offers novel and unique insights to widen our 
understanding of this pulmonary disease. To our knowledge, there have been only five 
existing studies which employed metabolomics as a diagnosis tool to differentiate 
asthmatic populations using their serum, urine or exhaled breath condensate samples 
(Figure 1.31) (Carraro, et al., 2007; Jung, et al., 2013; Mattarucchi, Baraldi, & Guillou, 
2011; Saude, et al., 2009a; Saude, et al., 2011). Using metabolomics, these studies 
were able to discriminate asthmatic subjects from healthy populations and have 
uncovered some potential disease-relevant urinary biomarkers (Figure 1.32). 
Importantly, these earlier studies have been focused on isolating biomarkers in the 
urine or breath largely for non-invasive diagnosis purposes. Therefore, there is an 
apparent lack of studies which validated these metabolic changes directly in the 
respiratory system, as well as to investigate for other potential metabolic changes 
from the site of inflammation, potentially providing a unique perspective to better 
understand metabolic mechanisms of the disease.  
 
Bronchoalveolar lavage fluid (BALF), obtained by flushing the lungs with fixed 
volumes of physiologic solutions, is a physiologically relevant sample to study 
respiratory diseases, as compared to urine. The use of BALF also offers a viable 
approach to evaluate inflammatory status in asthmatic lungs. Currently, the use of 
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BALF has been well-established to study many inflammatory components of asthma, 
such as inflammatory cells profile, cytokine profile and even oxidative biomarkers 
(Bao, et al., 2009; Cheng, et al., 2011; Wanxing Eugene Ho, et al., 2012). However, to 
date, there has not been a study that has employed metabolomics to study asthma 
using BALF samples. On the other hand, metabolomics study of BALF collected from 
patients suffering from cystic fibrosis, another chronic respiratory disease, has been 
successful in identifying key disease-related metabolic biomarkers and has also 
provided novel insights of the disease (Wolak, Esther, & O'Connell, 2009). 
Metabolomics analyses using BALF have also been useful in identifying lung toxicity 
in animals exposed to silica dust (Hu, et al., 2008) or 1-nitronaphthalene (Azmi, et al., 
2005). Development of metabolomics investigations of the BALF to understand the 
pathogenesis of asthma will provide invaluable in vivo molecular information on the 
disease mechanisms. 
 
In this PhD project, we have lately uncovered for the first time novel disease-relevant 
metabolic changes in the BALF from an experimental model of allergic asthma, 
which involved substantial losses of sugars, corresponding increases in energy 
metabolites and reductions of sterols. Notably, this application of metabolomics to 
study therapeutics in asthma revealed that dexamethasone is capable of reversing 
most metabolic alterations in allergic airway inflammation, but also induced 
considerable changes in other metabolites. Currently, metabolomics has only been 
used to study metabolic effects of dexamethasone and has not been applied to study 
the metabolic effects of other non-steroidal therapeutic agents in asthma. Therefore, 
we adopted a systems pharmacology approach to investigate if non-steroidal anti-
inflammatory agents, such as artesunate, can induce similar positive metabolic 
changes in experimental allergic asthma.  
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Figure 1.31: Overview of current metabolomics investigations of asthma.   






NMR-derived Urine Metabolomic Profile of 
Human Asthmatics Versus Controls
 
Figure 1.32: Metabolomics Exploration of Asthmatic Urine Reveals Distinctive 
Metabolite Profile Differences in Clinical Asthma. Figure adapted from (Saude, et 
al., 2011) 
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1.12 Main Objectives of this PhD Project 
This PhD project seeks to expand current understanding of the molecular mechanisms 
and therapeutic effects of anti-malarial drug, artesunate, in allergic asthma. Based on 
our preliminary research of investigating artesunate in an OVA-model of allergic 
asthma (Cheng, et al., 2011), we were able to identify a safe and effective regime of 
artesunate treatment of 30 mg/kg via intra-peritoneal administration. In addition, our 
previous study identified that artesunate was effective against major hallmarks of 
allergic asthma, namely airway inflammation, mucus hypersecretion and AHR.  
 
Here, we seek to compare the broad anti-inflammatory actions of artesunate to a broad 
and potent anti-inflammatory corticosteroid, dexamethasone. As oxidative stress and 
subsequent molecular damage to the airways are also major features of the disease, we 
studied the potential protective effects of artesunate and dexamethasone against 
oxidative stress and redox damages in the allergic inflamed airways. Correspondingly, 
the effects of artesunate on major molecular mediators which contribute to oxidative 
stress (antioxidants, pro-oxidants and related transcription factors) were also 
investigated to provide mechanistic understanding of artesunate in asthma.  
Metabolomics is an upcoming discipline of systems biology, which promises to 
advance current molecular understanding of allergic asthma and fuel the current 
demand for novel molecular diagnostic biomarkers. As metabolomics has not been 
widely applied to study allergic asthma, especially for metabolic changes within 
allergic inflamed airways, this PhD study seek to provide a comprehensive 
understanding of potential metabolic alterations which are involved during allergic 
airway inflammation. Additionally the potential protective metabolic effects of 
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artesunate and dexamethasone were also correspondingly compared in the same 
disease model.  
 
With the above objectives, this PhD project aims to expand the current molecular 
understanding of artesunate in allergic asthma, via investigating the effects of the drug 
on oxidative and redox profile, as well as on the pulmonary metabolic profile.  The 
findings obtained will become vital validating and supportive experimental evidences 
to support the development of artesunate as an alternative therapeutic agent to treat 
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Rationale: Oxidative stress is a critical pathophysiological factor for the development 
of allergic airway inflammation, resulting in oxidative damage to lipids, proteins, and 
DNA. Our recent report revealed potent anti-inflammatory effects of the anti-malarial 
drug artesunate in experimental allergic asthma.  
Hypothesis: We hypothesised artesunate possess comparable anti-inflammatory 
effects to dexamethasone, a potent corticosteroid and is able to suppress oxidative 
stress and lung damage via promotion of nuclear Nrf2. The present study investigated 
potential anti-oxidative effects of artesunate in a murine model of allergic asthma in 
comparison with dexamethasone.  
Measurements and Main Results: Mice were sensitized and challenged with 
ovalbumin, and developed airway inflammation and oxidative lung damage. 
Artesunate markedly suppressed ovalbumin-induced increases in total cell, eosinophil 
and neutrophil counts. In contrast, dexamethasone failed to inhibit neutrophil 
recruitment. Oxidative damage markers 8-isoprostane, 8-hydroxy-2-deoxy-guanosine 
and 3-nitrotyrosine levels were potently repressed by artesunate. However, 
dexamethasone showed weaker inhibitory effects on 3-nitrotyrosine production. 
Ovalbumin-induced increases in the expressions of pro-oxidants, iNOS and NADPH 
oxidase (NOX 1, 2, 3 and 4) were significantly abated by artesunate. Gene 
expressions of regulatory subunits of NOX, p22phox and p67phox, were also reduced 
by artesunate. The expressions and activities of antioxidants superoxide dismutase 
and catalase were substantially reversed with artesunate in ovalbumin-challenged 
mice. Artesunate significantly enhanced nuclear levels of nuclear factor erythroid-2-
related-factor 2 (Nrf2) in lung tissues from ovalbumin-challenged mice and in TNF-
-stimulated human bronchial epithelial cells.  
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Conclusions: Our findings implicate a potential therapeutic value for artesunate in the 
treatment of asthma by ameliorating oxidative damage in allergic airways and it may 
act by suppressing pro-oxidants’ and restoring antioxidants’ activities and expressions 
via activation of Nrf2. Artesunate may be a potential novel anti-asthma drug capable 
of controlling both inflammation and oxidative damage in chronic severe asthma. 
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1 RATIONALE, OBJECTIVES AND HYPOTHESIS 
Reactive oxygen and nitrogen species (RONS) are key signaling molecules involved 
in various biological processes and energy metabolism. Under normal physiological 
conditions, low levels of oxidative stress are well-tolerated under the protection of 
endogenous antioxidants present in the lungs and epithelial cells, including SOD, 
catalase and GPx (Giustarini, Dalle-Donne, Tsikas, & Rossi, 2009; MacNee, 2001). In 
allergic asthma, exposure to allergen and inflammatory signaling leads to the 
increased production of RONS (superoxide anion (O2
·−
), hydrogen peroxide (H2O2), 
hydroxyl radicals (OH
−
) and nitric oxide (NO) by endogenous pro-oxidants (iNOS 
and NADPH oxidases) (Dozor, 2010). Heightened levels of RONS in the lungs 
eventually overwhelm the antioxidant defenses and lead to perpetuation of pro-
inflammatory cytokines, chemokines and adhesion molecules. Recruited 
inflammatory cells into the airway, such as eosinophils and neutrophils, will release 
additional RONS, leading to escalations in pulmonary oxidative stress. These further 
increases in oxidative stress will inflict direct toxic effects, causing cellular apoptosis 
and necrosis, and oxidative lung damage. As such, oxidative stress has been observed 
to be a common phenotype in almost all forms of asthma and is considered to be the 
upcoming hallmark of the disease (Y. S. Cho & Moon, 2010; Sugiura & Ichinose, 
2008a). It has been observed in patients with severe asthma that oxidative stress is a 
major contributing factor towards resistance to steroid therapy (Adcock & Barnes, 
2008; P. J. Barnes, 2012). Drugs which are capable of suppressing oxidative stress 
and/or promote nuclear Nrf2 levels have been highlighted as potential drug candidates 
to better control allergic asthma and related inflammatory disorders.  
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Initial findings from our lab have identified artesunate is a promising anti-
inflammatory drug, able to suppress various hallmarks of asthma, namely airway 
inflammation, mucus hypersecretion and AHR (Cheng, et al., 2011). Correspondingly, 
artesunate also abated increases in allergic cytokines, IL-4, IL-5 and IL-13, and serum 
increases in IgE. These anti-inflammatory effects have been attributed possibly via 
inhibition of PI3K/Akt signaling cascade. However, it is unclear if artesunate is 
effective against oxidative stress and related oxidative lung damage. Secondly, a key 
step in developing artesunate as a clinical drug for treating asthma will require 
rigorous pre-clinical validation and comparisons against standard anti-inflammatory 
therapies, namely corticosteroids. Furthermore, it is unknown if the protective effects 
of artesunate involves the modulation of other major disease-related signaling 
pathways, such as Nrf2.  
 
In this study, we hypothesized that artesunate can ameliorate oxidative stress and 
related oxidative lung damage in allergic asthma, possibly via promotion of nuclear 
Nrf2. We also compared the anti-inflammatory effects of artesunate against a potent 
corticosteroid, dexamethasone to investigate for potential differences in their 
efficacies and mechanisms in modulating protective effects in the disease model. The 
effects of artesunate and dexamethasone on the profile of endogenous pulmonary 
antioxidants and pro-oxidants were also investigated to understand for possible 
benefits of using artesunate over corticosteroids (Figure 2.02). Findings from this 
study will potentially provide additional pre-clinical evidences and understanding of 
drug mechanisms of artesunate to support the therapeutic applications of this anti-
inflammatory drug to treat allergic asthma.  
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2 MATERIALS AND METHODS 
2.1  Materials and Chemicals 
Artesunate, chicken ovalbumin (OVA), dexamethasone, dimethyl sulfoxide (DMSO), 
Harris hematoxylin solution, 10% neutral buffered formalin, aluminium hydroxide 
(Al(OH)3), bovine serum albumin (BSA) and Tween-20 were obtained from Sigma-
Aldrich (St Louis, MO, USA). Ammonium chloride (NH4Cl) (BDH Laboratory 
Supplies, Poole, England); RNA later (Ambion, Austin, Texas); alkaline phosphatase 
(AP) conjugated substrate kit, agarose, blotting paper, polyvinylidene difluoride 
(PVDF) membrane, tetramethylethylenediamine (TEMED), 3,3’,5,5’-
tetramethylbenzidine (TMB) substrate kit, Triton X-100 (Bio-Rad Laboratories, 
Hercules, CA, USA); phosphate buffered saline (PBS), sodium dodecyl sulfate (SDS), 
and tris-acetate-EDTA (TAE) (1
st
 BASE, Singapore); diethylpyrocarbonate (DEPC)-
treated water, penicillin, L-glutamine, Roswell Park Memorial Institute (RPMI) 
medium, Trizol, and trypan blue (Invitrogen, Carlsbad, CA, USA), Fetal bovine 
serum (FBS) (Hyclone Laboratories, South Logan, Utah). Anesthetic mixture (10 l/g 
ketamine: medetomidine:H2O=3:4:33) was obtained from Animal Holding Unit AHU 
(NUS, Singapore). avidin-horseradish peroxidase (HRP), (BD Biosciences 
Pharmingen, San Diego, CA, USA); bicinchonic acid (BCA) protein assay kit, calf 
serum, Restore
TM
PLUS western-blot stripping buffer (Thermo Fisher Scientific Inc, 
Waltham, MA, USA); sodium carbonate (Na2CO3) (Kanto chemical, Tokyo, Japan); 
absolute ethanol, isopropanol (Merck, Darmstadt, Germany); Histoclear, Histomount 
(National Diagnostics, Altalanta, GA, USA); Non-fat milk powder (Nestle, 
Switzerland); avian myeloblastosis virus (AMV) reverse transcriptase, dNTP mix, 
polymerase chain reaction (PCR) master mix, oligo(dT)15 primer and ribonuclease 
inhibitor (RNasin) (Promega, Madison, USA); enhanced chemiluminescent (ECL) 
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western blotting detection reagents (Perkinelmer, Waltham, MA, USA); hyperfilm 
(GE Healthcare, Piscataway, NJ, USA); protease inhibitor cocktail (Roche 
Diagnostics, Indianapolis, IN, USA); HRP-conjugated anti-mouse Ig and anti-rabbit 
Ig, AP- conjugated anti-mouse Ig and anti-rabbit Ig (Dako, Glostrup, Denmark); 
nuclear extract kit, (Cayman Chemical, USA). 
 
2.2    Asthma mouse model 
Female BALB/c mice, 6 to 8 weeks old (Interfauna, East Yorkshire, UK) for this 
study were purchased from center for animal resources and housed in filter cages 
(maximal 5 mice/cage) in Animal Holding Unit (AHU) in the National University of 
Singapore. Animal experiments were performed according to the Institutional 
Guidelines for Animal Care and Use Committee of the National University of 
Singapore. Briefly, animal rooms were regulated by automatic timer to provide cycles 
with 12-14 hours of light and 10-12 hours of dark. The temperature in the animal 
room ranged along 18C-26C, with an average temperature of 22C. Standard meals 
for mice generally contain 4-5% of fat and 14% of protein. A minimal of 3 days of 
acclimatization was given for newly arrived mice to adapt their new environment. 
Mice were sensitized with 20 g OVA and 4 mg Al(OH)3 in 0.1ml saline by i.p on 
day 0 and day 14. For OVA challenge, 0.3 g of OVA was dissolved in 30ml of saline 
to be aerosolized by a DeVlibiss Ultra-Neb Large-Volume Ultrasonic Nebulizer 
(Sunrise Medical Respiratory Products, Somerset, PA) (Figure 2.01). Mice were 
challenged with 1% OVA aerosol for 30 min in a chamber (maximal 12 mice per 
chamber) on days 22, 23 and 24. The average OVA aerosol particle size is less than 
5μM. Saline aerosol was used as a negative control. The re-expose of antigen to the 
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lung was capable of generating an immune response in the airway that models 
pathogenesis of asthma and thus develop an ideal murine asthma model. 
Artesunate (powder) was dissolved in DMSO and stocked at concentration of 
100mg/ml in -20°C. For drug treatment, artesunate was further diluted to 30mg/kg in 
0.1 ml saline from stocks and injected intraperitoneally into the mice 1 hour prior 
each OVA aerosol challenge. Dexamethasone (Dex) was dissolved in saline and 
administered at 1 mg/kg using the same drug administration regime. DMSO (5%) was 
injected as the vehicle control. Mice were sacrificed 24 hours later after the last 
aerosol challenge and various samples such as lung tissues, bronchoalveolar lavage 
fluid (BALF) and serum were collected for consequent studies.  
 
Figure 2.01 The Ultrasonic Nebulization Aerosolization system. The ultrasonic 
nebulizer was delivered 1% of OVA aerosol mist (particle size less than 5µM) into 
the mice holding chamber.  
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Figure 2.02: Schematic flow of experiments to investigate the anti-inflammatory 
effects of artesunate against oxidative lung damage in allergic asthma.  Original 




2.3     BALF collection from mice 
BALF was collected 24 hours after the last saline or OVA challenge from all four 
treatment groups of mice. Mice were anaesthetized by an i.p. injection of 300 µl of 
mice anesthetic mixture. Tracheotomy was carried out and a blunt cannula needle 
(20G) was inserted into the trachea. Lungs were instilled with 0.5ml x 3 ice cold PBS 
and a final volume of 1.40 - 1.45ml of BALF was retrieved from the lungs and kept 
on ice until subsequent processing.  
 
2.4  Total and differential cell count in BALF 
 The BALF was centrifuged at 3000rpm for 5 min at 4°C. Supernatant was collected 
and stored at -80°C for cytokine and oxidative markers analysis. The cell pellet was 
resuspended in 200µl of 0.85% NH4Cl solution for 5min at room temperature to lyses 
red blood cells. Suspension of cell pellet was centrifuged 3000 rpm for another 5 min 
at 4°C and the supernatant was discarded. The cell pellet was resuspended in 200µl of 
RPMI with 1% BSA. A total number of viable cells were enumerated using a 
haemocytometer (10µl cell suspension mixed with equal volume of trypan blue) under 
a light microscope (magnification X 100). Following the total cell count, 10
5
 cells in 
150 RPMI were subjected to cytospin onto a glass side in a Shandon Cytospin 3 
(Thermo Electron Corporation, Pittsburgh, PA, USA) at 600rpm for 10 min at RT. 
The cells smear was dried and stained using Liu staining (modified Wright staining). 
Briefly, cell smear was stained with 800 µl of LiuA for 30 sec and followed by 1600 
µl of LiuB for 90 sec. Differential cell counts was performed under oil immersion lens 
(magnification x1000) and counted up to 500 cells. Four types of inflammatory cells, 
namely macrophages, eosinophils, neutrophils and lymphocytes were identified and 
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enumerated, based on standard morphological criteria and staining (Figure 2.2). The 
count was performed in a single blinded manner to eliminate bias. 
 
2.5   Histological Preprocessing 
Lung samples from the mice were extracted from the thoracic cavity by careful 
dissection 24 hours after the last OVA or saline challenge and stored in 10% neutral 
buffered formalin solution for at least 24 hours and processed in a tissue processor 
(Leica Microsysterms, Wetzler, Germany). Briefly, lung samples were dehydrated by 
immersing them in a series concentration of ethanol (70%  80%  90%  100%) 
for 30 minutes each and two hours for 100%. The samples were then placed in a 
clearing agent, xylene, for 3.5 x 3 hours. Samples were infiltrated in hot molten 
paraffin wax for another 3 hours. Tissues were then further embedded in paraffin wax, 
fixed and sectioned into 5 µm pieces using a microtome (Leica Microsysterms, 
Wetzler, Germany). The sectioned tissues were then placed and dried on glass slides 
to undergo staining. 
 
2.51 Immunohistochemical (IHC) and Immunocytochemical (ICC) Staining of 
Oxidative Damage Markers  
Lungs were fixed in 10% neutral formalin, paraffinized and cut into 5-μm sections. 
Antigen retrieval was performed by heating the slides in 10 mM sodium citrate in 
0.05% Tween 20 at pH 6.0 before immunoreactivity staining. BAL fluid cell slides 
and lung section slides were incubated in Universal Blocking Solution (Dako 
Corporation, Carpinteria, CA) and then in Peroxidase Block (Dako). Slides were 
probed with primary antibodies targeted at 3-NT or 8-OHdG followed by biotinylated 
secondary antibodies (HRP or AP), and visualized using Fuschin for 3-NT and 
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diaminobenzidine (DAB) for 8-OHdG. Counterstaining was performed with 
hematoxylin. BAL fluid slides were counted blind for at least 500 cells and 3-NT-
positive cells were expressed as a percentage of total cells.  
 
2.6 Measurement of  Oxidative Lung Damage Markers  
Aliquots of BALF, previously stored in -80°C, were thawed and assayed for oxidative 
lung damage markers, 8-OHdG and 8-IsoP (Cayman Chemical), according to the 
manufacturer’s instructions.  Briefly, the assay was performed to quantitatively 
measure the levels of 8-Isoprostane and 8-OH-dG in the BALF (Figure 2.03), with a 
detection limit of 2.7 ρg/ml and 33 ρg/ml respectively. The competitive binding 
between 8-Isoprostane/8-OH-dG and its tracer (8-Isoprostane-acetlycholinesterase/8-
OH-dG-acetylcholinesterase) is the basis of this assay. A known concentration of 
tracer and specific antiserum to 8-Isoprostane/8-OH-dG were added into the pre-
coated 96-well plate (mouse anti-rabbit IgG), along with the standards and samples 
into respective wells for 18 hours at 4
o
C. The pre-coated antibody binds to the 
antiserum, which binds to 8-Isoprostane/8-OH-dG and the tracer competitively. After 
incubation, the plate was washed five times before Ellman’s Reagent (substrate to 
acetylcholinesterase) was added to each well. The product of this enzymatic reaction 
was yellow in color and the intensity was measured spectrophotometrically at 412 nm 
after 60 min. The resulting intensity was inversely proportional to the amount of 8-
Isoprostane/8-OHdG in the BAL fluid, where standard curves were plotted to 




Figure 2.03: Overview of Key Steps in 8-IsoP Assay (Caymen Chemicals).  Figure 
adapted from Cayman Chemicals Manual. Similar steps are used for the quantification 
of 8-OHdG. 
Unlike 8-isoP or 8-OHdG, 3-NT is found abundantly on the inflamed lung tissues 
(tyrosine residues on proteins) and can be better quantified using lung homogenates. 
Lung levels of 3-NT were measured using an enzyme immunoassay (Millipore, 
Billerica, MA, USA) according to the manufacturer’s instructions. Briefly, lung 
tissues were snap-frozen in liquid nitrogen and lyophilized using a freeze-dryer 
(Labconco Corp., Kansas City, MO, USA) at -85°C. Lyophilized lung tissues were 
were normalized by dry weight and homogenized at 4°C in phosphate-buffered saline 
using a glass bead-based homogenizer (TissuelyserLT; Qiagen, Valencia, CA, USA). 
The supernatants were assayed for 3-NT levels. Costar 3922 high-binding 96-well 
plate (Millipore, USA) was coated with nitrated BSA for 2 hours and blocked with 
blocking buffer for 1 hour at 37
o
C. Samples and standards were then added 
accordingly along with primary antibody (Rabbit anti-Nitrotyrosine IgG) for 1 hour. 
Plates were washed and incubated with secondary antibody (HRP-conjugated Goat 
71 
anti-Rabbit IgG) for 1 hour, before LumiGLO
®
 chemiluminescent substrate (HRP 
substrate) was added for 10 min. The luminescence was recorded as counts per second 
and standard curves were plotted to calculate the amount of 3-NT. 
 
2.7   Antioxidant Activities Enzymatic Assays 
Enzymatic activities of respective major antioxidants in lung homogenates were 
measured using enzymatic assays. Assay kits and reagents were obtained from 
Cayman Chemical (USA), where the protocols of each assay were adapted from the 
manufacturer’s manual provided. 
 
2.71   Superoxide Dismutase (SOD) Activity Assay 
The SOD activity assay measures the activity of SOD with detection limits of 1.25 
units/g of lungs, where one unit is the amount of SOD required to dismutate 50% of 
the superoxide anion. Tetrazolium salt solution (radicals detector) was added to 
separate wells containing samples and standards in the 96-well plate. Xanthine 
oxidase which catalyzes the formation of superoxide anions from oxygen was then 
added to start the reaction and timed for 20 min, before readings were computed in the 
spectrophotometer at 450 nm. The readings were directly proportional to SOD activity 
and standard curves were plotted to obtain the precise units of activity. 
 
2.72   Catalase (CAT) Activity Assay 
The CAT activity assay quantified CAT activity in samples, with a detection limit of 
20 nmol/min/g of lungs. Methanol and hydrogen peroxide can be converted to 
formaldehyde by CAT, which is the key mechanism in this assay. The chromogen 
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Purpald (4-amino-3-hydrazino-5-mercapto-1,2,4-triazole) is oxidized after interaction 
with form-aldehyde, resulting in the change in color from colorless to purple. Known 
concentrations of methanol and sample were added to the wells, with various 
concentrations of formaldehyde as the standard. Addition of hydrogen peroxide 
started the reaction, where potassium hydroxide was added 20 min later to stop the 
reaction. Purpald was added for 10 min before the addition of potassium periodate for 
5 min. The intensity is directly proportional to the activity of CAT and was measured 
spectrophotometrically at 540 nm. Standard curves were plotted to calculate the 
activity of CAT in nmol/min/g of lung. 
 
2.73   Glutathione Peroxidase (GPx) Activity Assay 
The GPx activity assay was employed to quantify the activity of GPx, with a detection 
limit of 5.0 nmol/min/g of lungs. Through the reduction of hydrogen peroxide, GSH is 
converted to oxidized glutathione (GSSG), where GSSG is recycled back to GSH by 
glutathione reductase (GR) and NADPH. The oxidation of NADPH to NADP
+
 results 
in a decrease in absorbance at 340 nm, which is directly proportional to the activity of 
GPx. Assay buffer and co-substrate mixture (containing NADPH, GSH and GR) were 
added to standards or samples wells. The reaction was initiated when cumene 
hydroperoxide was added to the wells and absorbance was read at 340 nm every 
minute, for 7 min. Standard curves and change in absorbance graphs were plotted to 
determine the activity of GPx. 
 
2.8   Reverse Transcriptase - Polymerase Chain Reaction (RT-PCR) 
Lung samples from the mice were extracted from the thoracic cavity on the sacrificing 
day and stored in RNAlater, an aqueous tissue storage reagent that rapidly permeated 
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the lung tissues to stabilize and protect the RNA. The samples were first incubated at 
4°C overnight for the RNAlater to permeate the tissues and then were stored at -80°C. 
 
2.8.1  RNA isolation 
Lung tissues were removed from RNAlater with clean forceps and immersed in 1 ml 
of Trizol reagent (Invitrogen, USA). A homogenizer was used to disrupt the cells and 
the lung tissues were placed in an ice bath during homogenization to help reduce 
degradation of RNA. The homogenate was then centrifuged at high speed 12,000g for 
10 min at 4°C to spin down the unwanted membranes and cell components. The 
cleared supernatant was transferred to another 1.5ml tube for the next step. The RNA 
was isolated from this clear supernatant according to the manufacturer’s instructions 
from Invitrogen. The RNA pellet was dissolved in DEPC water and quantified by 
using a nanodrop ND-1000 spectrophotometer (Thermo Fisher Scientific Inc, 
Waltham, MA, USA).  Both A260/A280 (DNA/Protein) and A260/A230 
(DNA/organic contaminants) ratios were recorded as an indication of the purity of the 
RNA extracted. Ratios around of 1.9 to 2.0 meant an acceptable level of purity of the 
RNA extracted.  
 
2.8.2 Reverse Transcription 
1 g of total RNA together with an oligo dT primer amd AMV reverse transcriptase 
was used to reverse transcribe into cDNA by a multiwell thermal cycler (GeneAmp 





2.8.3 Polymerase Chain Reaction 
Synthesized cDNAs could be used as templates for PCR amplification. PCR 
amplification were performed on 1µl cDNA template in a 25 µl reaction volume 
containing 12.5 µl 2× PCR master mix (50 units/ml TaqDNA polymerase, 400µM 
dATP, 400µM dGTP, 400µM dCTP, 400µM dTTP and 3mM MgCl2), 9.5 µl 
nuclease-free water, 1 µl forward primer (10 µM) and 1 µl reverse primer (10 µM). 
The primers were obtained from 1
st
 base and the respective sequences are shown in 
Table 2.1.  
 
2.8.4 Real-time PCR Relative Quantification 
The 20 µl real time PCR mixture contained 10 µl of 2x QuantiFast SYBR Green PCR 
Master Mix (Applied Biosystems, USA), 2 µl of 10x QuantiTect Primer Assay 
(Qiagen, USA), 1 µl template cDNA, and RNase-free water. Each sample was run in 
triplicate. Amplification and detection was performed using the ABI 7500 Real-Time 
PCR System (Applied Biosystems, USA) using the following settings: 2 min at 95
o
C, 
40 cycles of 10 sec at 95
o
C and 30 sec at 60
o
C. 18s was used as an endogenous 
control to normalize each target sample. All data were analyzed using the Sequence 
Detection System SDS software package, version 1.4.0.25 (Applied Biosystems, 
USA). A relative Quantification plate document was created for analysis. 
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Table 2A Targets and sequences for primer sets of RT-PCR 


























































2.9  Immunoblotting (Western blotting) 
Lung samples were harvested from various treatment groups of mice on 25
th
 day and 
stored at -80°C until study. Lung lobes were cut into small pieces and homogenized in 
protein lysis buffer in an ice bath with a beads-based homogenizer (TissuelyserLT; 
Qiagen, Valencia, CA, USA). Nuclear (NE) and cytosolic extracts (CE) were 
collected from the lung lysates using a nuclear extraction kit (Cayman Chemicals, 
USA) according to manufacturer’s instructions. Protein concentrations in both 
extracts were determined using BCA protein assay kit (Thermo Fisher Scientific Inc, 
Waltham, MA, USA). The same amount of protein (30g) were subjected to 10% 
SDS-PAGE in a Trans-Blot tank (Bio-Rad Laboratories, Hercules, CA, USA) and 
transferred to PVDF membrane. Membrane was blocked in 5% milk for 2 hours and 
probed with various primary antibodies (Nrf-2, MnSOD, Catalase, NOX2 and NOX4) 
in 1% milk for overnight at 4C. The next day, membrane was washed with TTBS 
buffer and probed with corresponding secondary antibody for 1 to 2 hours and 
developed on hyperfilms using ECL reagents (HRP) or AP reagents. TATA- Binding 
Protein (TBP) was used as control to normalize for NE protein amount and loading, 
while β-actin was used as the loading control to normalize for CE proteins.  Relative 
densitometry quantifications were performed using professional imaging software 
(ImageJ) to quantitate relative density of respective immune-blots.  
 
2.10 Human bronchial epithelial cell culture 
Transformed human bronchial epithelial cells (Beas-2B) (ATCC, USA) were cultured 
in RPMI 1640 medium with 10% fetal bovine serum (FBS) supplements. Cells of 
passage numbers 3-12 were seeded into 100 mm petri dishes at 1 x 10
6
 respectively. 
Cells were pretreated with 30 M of artesunate, 1 µM of dexamethasone or vehicle 
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(0.01% DMSO) for 2 hours before 30 minutes stimulation with 10 ng/ml TNF-α. 
Nuclear protein was extracted from cells using commercially available nuclear 
extraction kits (Cayman chemicals, USA). 
 
2.11 2,2-diphenyl-1-picrylhydrazyl (DPPH) – Antioxidant Power Assay 
A routine chemical assay, the DPPH˙ radical scavenging activity assay, was employed 
to investigate if artesunate possesses any potential radical scavenging activities. 2,2-
Diphenyl-1-picrylhydrazyl (DPPH) (Sigma Aldrich) was dissolved in methanol to 
obtain a concentration of 0.1mM working solution. 100 μL of scaled doses of DMSO, 
Arts, Dex, Resveratrol (Res) and Trolox (soluble Vitamin E), are incubated with 100 
μL of 0.1 mM DPPH in 96 well format and radical scavenging activity was measured 
at 517 nm at 30 mins post incubation at 37°C. The reaction mixture was subsequently 
measured at 1, 2, 4 and 24 hours later to measure for potential delayed radical 
scavenging activities.  
 
2.12 Statistical analysis 
Data are presented as means ± SEM. One-way ANOVA followed by Dunnett’s test 
was used to determine significant differences between treatment groups. Significant 









3.1 Artesunate Suppresses OVA-induced BAL Inflammatory Cell   Counts.  
BAL fluid was collected 24 h after the last OVA or saline aerosol challenge. OVA 
inhalation markedly increased total cell and eosinophil counts, with moderate 
elevation in macrophage, lymphocyte and neutrophil counts, as compared with saline 
aerosol control (Figure 2.04). This indicates successful establishment of the OVA-
induced asthma model. No significant differences were noted between OO and 
OO/DMSO indicating the regime of 5% DMSO (drug vehicle) did not induce any 
significant effects on the various inflammatory cell populations. Treatment with 
artesunate (30 mg/kg) significantly suppressed the total inflammatory cell, eosinophil 
and neutrophil counts in BAL fluid as compared with the DMSO vehicle control. 
Artesunate was found to produce similar magnitudes of anti-inflammatory action on 
pulmonary cell infiltration as dexamethasone. Notably, dexamethasone failed to 
inhibit neutrophil lung recruitment. The same regime of artesunate was also noted to 
















Figure 2.04. Effects of artesunate on OVA-induced inflammatory cell pulmonary 
recruitment in comparison with dexamethasone. Inflammatory cell counts were 
performed in BAL fluid obtained from sensitized mice 24 h after the last saline 
aerosol (OS) or OVA aerosol (OO) without and with DMSO vehicle control, 30 
mg/kg artesunate (Arts) or 1 mg/kg dexamethasone (Dex). Differential cell counts 
were performed on a minimum of 500 cells to identify macrophages, eosinophils, 
lymphocytes and neutrophils. N represents naïve un-treated mice without and with 
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treatment of artesunate (N/Arts) for baseline drug effect. Values are means ± SEM for 
6-7 mice per group. * Significant difference (p < 0.05) from DMSO control. 
 
3.2 Artesunate Reduces Nitrosative Stress in Inflammatory Cells 
3-nitrotyrosine (3-NT) is a product of protein nitration and protein damage due to 
nitrosative stress induced by nitric oxide (NO) and peroxynitrite (ONOO·) on tyrosine 
peptides (Andreadis, Hazen, Comhair, & Erzurum, 2003; Duguet, Iijima, Eum, Hamid, 
& Eidelman, 2001b). Immunocytochemical staining of 3-NT was employed to 
investigate if the infiltrated inflammatory cells obtained in the BAL fluid contributed 
towards nitrosative lung damage, OVA inhalation dramatically increased the 
proportion of 3-NT-positive cells (stained red) as compared to saline aerosol control. 
Among the various infiltrated cells, majority of the 3-NT-positive cells were observed 
to be eosinophils and neutrophils (Figure 2.05A).  Artesunate strongly reduced the 
level of 3-NT-positive cells. In sharp contrast, although both artesunate and 
dexamethasone were able to reduce inflammatory cell infiltration to the same extent, 






Figure 2.05. Immunocytochemical staining of BALF cells for 3-NT. (A) 
Representative photomicrographs (1000X magnification) of BALF cells probed with 
an anti-3NT antibody visualized with Fuchsin and counterstained with hematoxylin 
(3-NT-positive cells appear in red color). Mac, macrophages; Lym, lymphocytes; Eos, 
eosinophils and Neu, neutrophils. (B) 3-NT-positive (3-NT+) cells were enumerated 
and expressed as a percentage of total inflammatory cell counts. N represents naïve 
un-treated mice without and with treatment of artesunate (N/Arts) for baseline drug 
effect. OS represents OVA-sensitized and saline aerosol challenged mice. OO 
represents OVA-sensitized and OVA aerosol-challenged mice without and with 
DMSO vehicle control, 30 mg/kg artesunate (OO/Arts) or 1 mg/kg dexamethasone 
(OO/Dex). Values are percentage means ± SEM for 6-7 mice per group.  * Significant 
difference (p < 0.05) from DMSO control. 
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3.3  Artesunate Inhibits Oxidative and Nitrosative Lung Damage in       
Allergic Airways and Epithelium  
Lung homogenates were assayed for 3-NT levels, whereas BAL fluid was used to 
assay for 8-OHdG, a marker for oxidative DNA damage (Giustarini, et al., 2009); and 
8-isoprostane, an indicator for lipid peroxidation (Wood, Gibson, & Garg, 2003), 
using ELISA. These biomarkers aid our understanding of the complex inflammatory 
processes and redox imbalance in asthmatic airways. OVA challenge significantly 
increased pulmonary levels of 3-NT as compared to the saline aerosol control. 
Artesunate markedly suppressed the levels of 3-NT, ameliorating nitrosative damage 
to the lungs, as compared to the vehicle control. In line with the findings in infiltrated 
inflammatory cells, dexamethasone also failed to suppress 3-NT formation in the 
lungs (Figure 2.06A) OVA aerosol exposure greatly enhanced oxidative DNA 
damage, indicated by the 3-folds increase in 8-OHdG levels in the BAL fluid, in 
comparison to saline aerosol control (Figure 2.06B). Both artesunate and 
dexamethasone effectively blocked oxidative DNA damage by suppression of 8-
OHdG levels to the same extent. We also observed a substantial increase in BAL fluid 
8-isoprostane level upon OVA challenge (Figure 2.06C). Both artesunate and 
dexamethasone significantly reduced oxidative damage to lipids by abating 8-
isoprostane formation as compared to vehicle control.  
 
Immunohistochemical staining of the lung sections similarly show that OVA 
inhalation promoted 3-NT and 8-OHdG formation in the lungs, especially the 
bronchial epithelium. Significant bronchial epithelium hypertrophy was also observed 
in OVA-challenged lungs (Figure 2.07). Artesunate dramatically reduced 3-NT and 8-
OHdG staining in lung epithelium, together with noticeable reduction of bronchial 
84 
epithelium hypertrophy. Consistent with a weaker inhibitory effect on 3-NT level in 
infiltrated inflammatory cells and lung tissue lysates, dexamethasone elicited a milder 
reduction in 3-NT staining in lung sections than artesunate. In contrast, both 
artesunate and dexamethasone were equally effective in suppressing 8-OHdG in the 
lung sections. Collectively, these results suggest that artesunate is capable of 
suppressing both oxidative and nitrosative stress-induced damage to pulmonary 




Figure 2.06: Levels of oxidative damage markers measured in BALF or lung 
tissues obtained 24 h after the last aerosol challenge. (A) 3-NT levels in lung 
homogenate, (B) 8-OHdG levels in BAL fluid and (C) 8-Isoprostane levels in BAL 
fluid, measured by ELISA. N represents naïve un-treated mice without and with 
treatment of artesunate (N/Arts) for baseline drug effect. OS represents OVA-
sensitized and saline aerosol challenged mice. OO represents OVA-sensitized and 
OVA aersol-challenged mice without and with DMSO vehicle control, 30 mg/kg 
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artesunate (OO/Arts) or 1 mg/kg dexamethasone (OO/Dex). Values are means ± SEM 






Figure 2.07. Immunohistochemical staining of lung sections for oxidative lung damage 
markers. Representative photomicrographs (400X magnification) of lung sections probed 
with anti-3-NT antibody visualized by Fuchsin (appear in red color) and counterstained with 
hematoxylin (A) or probed with anti-8-OHdG antibody visualized by DAB (appear in brown 
color) and counterstained with hematoxylin (B). OS represents OVA-sensitized and saline 
aerosol challenged mice. OO represents OVA-sensitized and OVA aerosol-challenged mice 
without and with DMSO vehicle control, 30 mg/kg artesunate (OO/Arts) or 1 mg/kg 
dexamethasone (OO/Dex). BE, bronchial epithelium; ASM, airway smooth muscles; and AS, 
alveolar space. 
 
3.4  Artesunate Does Not Possess Direct Radical Scavenging Activity 
To investigate the anti-oxidative mechanisms of action of artesunate, we first examined if 
artesunate possesses free radical scavenging activity using the 1,1-diphenyl-2-picrylhydrazyl 
(DPPH˙) assay. The DPPH˙ radical scavenging activity assay is a routinely used assay to 
measure for direct scavenging activities in drugs, antioxidants and natural compounds (Moon 
& Shibamoto, 2009). Incubation of artesunate (Arts), dexamethasone (Dex), resveratrol (Res), 
a known antioxidant extracted from grapes and soluble vitamin E, Trolox with DPPH˙ for 30 
mins indicate that both artesunate and dexamethasone did not possess significant radical 
scavenging capabilities as compared to the methanol solvent in controls (Con) and the 
positive drug controls, Res and Trolox (Figure 2.08). Similar results were obtained with 
repeated readings measured after 1, 6, 12 and 24 hours incubation. Consistently, our results 
indicate that artesunate do not directly scavenge free radicals and it is postulated that the anti-
oxidative effects observed are probably mediated via modulation of endogenous antioxidants 
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Figure 2.08: Investigation of Direct ROS scavenging Activity of Artesunate by 2,2-
diphenyl-1-picrylhydrazyl DPPH˙ Radical Scavenging Activity Assay. Increasing 
concentrations of artesunate (Arts), dexamethasone (Dex), resveratrol (Res) and soluble 
vitamin E (Trolox) were incubated with 0.1 mM DPPH for 30 min and free radical 
scavenging activity was measured at 517 nm. Each experiment was performed at least three 
times and data are expressed as average DPPH percent changes. * Significant difference (p < 




3.5  Artesunate Modulates Pulmonary Pro-oxidants’ and Antioxidants’ Activities 
and Expressions in Allergic Asthma 
Pro-oxidants such as NADPH Oxidase (NOX) and inducible nitric oxide synthase (iNOS) are 
major contributors of oxidants in the lungs and are often the cause of oxidative damage in the 
lungs (Abdala-Valencia, et al., 2007; van der Vliet, 2008). We hypothesized that artesunate 
may suppress the expression of pulmonary pro-oxidants such as NOXs and iNOS to limit the 
generation of ROS and RNS in allergic airway inflammation. Using quantitative real-time 
PCR, we observed that gene expression of NOX1, 2, 3 and 4, were markedly raised by 6-8 
folds upon OVA exposure, as compared to saline control (Figure 2.09). Artesunate 
effectively suppressed gene expressions of all 4 isoforms, whereas dexamethasone was only 
able to abate NOX3 expression (Figure 2.09C). Unexpectedly, dexamethasone strikingly 
increased NOX2 (Figure 2.09B) and NOX4 (Figure 2.09D) expressions. NOX has several 
regulatory subunits such as p22phox and p67phox, which are essential for its optimum 
enzymatic activity (van der Vliet, 2008). Gene expressions of p22phox and p67phox were 
observed to be elevated with OVA exposure (Figures 2.09E and 2.09F). Both artesunate and 
dexamethasone were equally effective in diminishing p22phox and p67phox gene expressions. 
Gene expression of iNOS was strongly up-regulated by 10 folds with OVA exposure (Figure 
2.09G). Both artesunate and dexamethasone were able to subdue OVA-induced iNOS 
expression to basal level.  
 
Apart from suppressing pro-oxidant expression in the lungs, artesunate was found to 
modulate the enzymatic activity of superoxide dismutase (SOD) and catalase, a protective 
mechanism against oxidative lung damage (Nadeem, et al., 2003a; Nadeem, et al., 2008). 
Acute OVA challenge resulted in an increase in total SOD enzymatic activity but a decrease 
in catalase activity in the lungs, as compared to aerosol saline control (Figure 2.10). Both 
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artesunate and dexamethasone were equally effective in blocking the SOD activity and in 
restoring catalase activity in OVA-challenged lungs. Gluthathione peroxidase (GPx) activity 
was unaltered in all the treatment groups, suggesting that the short-term exposure to allergen 
does not affect GPx activity in the lungs (Figure 2.10C).  
 
Gene expressions of all three isoforms of SOD: CuZnSOD (SOD1), MnSOD (SOD2) and 
ECSOD (SOD3) were elevated by OVA exposure, and MnSOD was noted to be the most 
induced isoform. Artesunate effectively suppressed gene expression of CuZnSOD and 
MnSOD but was ineffective against EC-SOD expression (Figure 2.11A-C). In contrast, 
dexamethasone selectively suppressed MnSOD and ECSOD expression but did not affect 
CuZnSOD expression.  The gene expression of catalase was drastically subsided in OVA-
exposed mice as compared to saline aerosol. Both artesunate and dexamethasone halted the 
drop in catalase expression (Figure 2.11D), which correlates well with catalase activity data 
(Figure 2.10B). In line with the enzyme activities, GPx-1 expression was unaltered in all 
treatment groups (Figure 2.11E)). Heme oxygenase-1 (HO-1) is an inducible antioxidant in 
response to inflammation such as asthma (Carter, Garat, & Imamura, 2004). Both artesunate 
and dexamethasone showed comparable inhibition of HO-1 expression in OVA-challenged 
lungs (Figure 2.11F).   
 
To validate the gene expression data, we probed the protein levels of several key antioxidants 
and pro-oxidants in lung homogenates using immunoblot analysis. For antioxidants, catalase 
protein levels were markedly reduced in OVA-challenged lungs but were largely restored by 
either artesunate or dexamethasone treatment. In contrast, MnSOD protein levels were 
enhanced in OVA-exposed mice and were effectively suppressed by either drug treatment 
(Figure 2.12A). For pro-oxidants, NOX2 and NOX4 proteins were increased in the lungs of 
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OVA-challenged mice and were effectively repressed by artesunate, but not by 
dexamethasone (Figure 2.12B). The effects of artesunate on various antioxidants and pro-
oxidants are generally consistent at both mRNA and protein levels. Our collective results 
indicate that artesunate can ameliorate oxidative and nitrosative lung damage in airway 
inflammation by modulating the expressions of major pro-oxidants and antioxidants in the 




Figure 2.09:  Real-time PCR analyses of pro-oxidant gene expressions in lung tissues.  
mRNA expressions of 4 isoforms of NADPH oxidase: NOX1 (A), NOX2 (B), NOX3 (C), 
NOX4 (D), regulatory subunits of NOX: p22phox (E) and p67phox (F), and iNOS were 
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performed. OS represents OVA-sensitized and saline aerosol challenged mice. OO represents 
OVA-sensitized and OVA aersol-challenged mice without and with DMSO vehicle control, 
30 mg/kg artesunate (OO/Arts) or 1 mg/kg dexamethasone (OO/Dex). Values are means ± 
SEM for 6-7 mice per group. * Significant difference (p < 0.05) from DMSO control. 
 
Figure 2.10: Investigation of major antioxidants enzymatic activities in lung tissues. 
Enzymatic activities of (A) Total SOD, (B) catalase and (C) GPx in lung tissues obtained 24 
h after the last aerosol challenge were measured using ELISA. N represents naïve un-treated 
mice without and with treatment of artesunate (N/Arts) for baseline drug effect. OS 
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represents OVA-sensitized and saline aerosol challenged mice. OO represents OVA-
sensitized and OVA aersol-challenged mice without and with DMSO vehicle control, 30 
mg/kg artesunate (OO/Arts) or 1 mg/kg dexamethasone (OO/Dex). Values are means ± SEM 
for 6-7 mice per group. * Significant difference (p < 0.05) from DMSO control. 
 
Figure 2.11: Real-time PCR analyses of antioxidant gene expressions in lung tissues. 
mRNA expressions of 3 isoforms of SOD: CuZnSOD (A), MnSOD (B) and ECSOD (C), 
catalase (D), GPx-1(E), and HO-1 (F) were performed. OS represents OVA-sensitized and 
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saline aerosol challenged mice. OO represents OVA-sensitized and OVA aersol-challenged 
mice without and with DMSO vehicle control, 30 mg/kg artesunate (OO/Arts) or 1 mg/kg 
dexamethasone (OO/Dex). Values are means ± SEM for 6-7 mice per group. * Significant 






Figure 2.12. Immunoblots of antioxidant and pro-oxidant protein expressions in lung 
tissues. Total protein extracts of lung tissues isolated from mice 24 h after the last saline 
aerosol (OS) or OVA aerosol (OO) challenge with and without DMSO, 30 mg/kg artesunate 
(OO/Arts) or 1 mg/kg dexamethasone (OO/Dex) were separated in 10% SDS-PAGE. 
Immunoblots were probed for antioxidants catalase and MnSOD (A), and for pro-oxidants 
NOX2 and NOX4 (B). β-actin was used as the internal control. The experiments were 
repeated three times (n = 3 mice) with similar pattern of results. Protein band intensities were 
analyzed using ImageJ software and were normalized to β-actin controls. Values shown are 
the mean ± SEM of three separate experiments. * Significant difference from DMSO control, 
p < 0.05. 
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3.6 Artesunate Promotes Nuclear Nrf2 Levels in Human Epithelial Cells and         
 Inflamed Murine Lung Tissues 
 
Nrf2 is a redox-sensitive transcription factor involved in the transcriptional regulation of 
many antioxidant and pro-oxidants genes (N. Li & Nel, 2006; Williams, et al., 2008). We 
hypothesized that artesunate may promote nuclear levels of Nrf2 to modulate expressions of 
the various antioxidants and pro-oxidants in the allergic airways. In BEAS-2B human 
bronchial epithelial cells stimulated with TNF-, artesunate markedly elevated nuclear level 
of transcription factor Nrf2 as compared to vehicle control (Figure 2.13A). Artesunate 
promoted a greater increase in nuclear Nrf2 than dexamethasone. In un-stimulated epithelial 
cells, artesunate alone did not raise nuclear Nrf2 level, suggesting that artesunate does not 
promote nonspecific activation of Nrf2 under resting conditions. Likewise, artesunate 
significantly promoted nuclear Nrf2 level in lung tissues from experimental asthma as 
compared to vehicle control mice (Figure 2.13B). However, dexamethasone failed to elevate 
nuclear Nrf2 level in OVA-challenged lungs.  Consistently, our results reveal that artesunate 
in capable of promoting nuclear Nrf2 levels in human epithelial cells and murine lung tissues 




Figure 2.13. Immunoblotting of nuclear levels of Nrf2 in human bronchial epithelial 
cells and mouse lungs. Nuclear extracts obtained from (A) BEAS-2B cells stimulated with 
TNF- for 30 min with and without 2 h pre-incubation with 0.01% DMSO, 30 µM artesunate 
(Arts) or 1 µM dexamethasone (Dex), or (B) lung tissues isolated from mice 24 h after the 
last saline aerosol (OS) or OVA aerosol (OO) challenge with and without DMSO, 30 mg/kg 
artesunate (OO/Arts) or 1 mg/kg dexamethasone (OO/Dex), were separated in 10% SDS-
PAGE. Immunoblots were probed for Nrf2. TBP nuclear protein was used as an internal 
control. The experiments were repeated three times with similar pattern of results. Protein 
band intensities were analyzed using ImageJ software and normalized to TBP controls. 
Values shown are the mean ± SEM of three separate experiments. * Significant difference 







4   DISCUSSION 
Oxidative stress is associated with airway inflammation, mucus secretion, airway 
hyperresponsiveness and even insensitivity to steroids in asthma (Baraldi, Carraro, et al., 
2003; Chung & Marwick, 2010; Hanta, Kuleci, Canacankatan, & Kocabas, 2003). Normally, 
low levels of oxidative stress are well-tolerated under the protection of antioxidants present in 
the lungs including SOD, catalase and GPx (Giustarini, et al., 2009; MacNee, 2001). In 
asthma, exposure to allergen up-regulates production of ROS and RNS including superoxide 
anion (O2
−
), hydrogen peroxide (H2O2), hydroxyl radicals (OH
−
) and nitric oxide (NO) 
(Dozor, 2010). Higher levels of oxidative stress eventually overwhelm the antioxidant 
defenses in the lungs and lead to induction of pro-inflammatory cytokines, chemokines and 
adhesion molecules. Further increases in oxidative stress inflict direct toxic effects, causing 
cellular apoptosis and necrosis, and oxidative lung damage. It has been observed in patients 
with severe asthma that oxidative stress is a major contributing factor towards resistance to 
steroid therapy (P. J. Barnes, 2004, 2010). There is an urgent need to discover drug 
compounds with both anti-inflammatory and anti-oxidative damage properties for the 
treatment of chronic severe asthma. 
 
In the present study, aerosolized OVA not only promoted pulmonary inflammatory cell 
infiltration, but also increased oxidative lung damage to proteins, DNA and lipids as 
indicated by the increased levels of 3-NT, 8-OHdG and 8-isoprostane in the lungs. These 
results are consistent with increased oxidative lung damage detected in asthmatic patients 
(Nadeem, Chhabra, Masood, & Raj, 2003b; Nadeem, Raj, & Chhabra, 2005; Wood, et al., 
2005). Immunohistochemical staining for 8-OHdG and 3-NT further revealed that oxidative 




In line with our recent study (Cheng, et al., 2011), artesunate (30 mg/kg) demonstrated strong 
anti-inflammatory effects on pulmonary cell infiltration in OVA-challenged mice, especially 
eosinophil and neutrophil recruitment. The overall effects are comparable to those produced 
by 1 mg/kg dexamethasone, a very potent corticosteroid drug. Nevertheless, dexamethasone 
failed to inhibit neutrophil recruitment, which is consistent with clinical findings that steroid 
treatment failed to resolve neutrophilic inflammation in chronic asthma (P. J. Barnes, et al., 
2007; Ito, et al., 2008).    
 
3-NT, a major nitrosative damage product, is produced by the attack on tyrosine residues in 
the lungs by peroxynitrite (ONOO-) which is formed by the combination of NO with O2
-
 
(Dedon & Tannenbaum, 2004). Eosinophils and neutrophils are active contributors to protein 
nitration, via the release of eosinophil peroxidase and myeloperoxidase respectively 
(Andreadis, et al., 2003; Duguet, et al., 2001b). Increased levels of 3-NT in exhaled breath 
condensate have been consistently detected in asthmatic patients (Hanazawa, et al., 2000; 
Sugiura & Ichinose, 2008b). Studies revealed that nitration of tyrosine residues can lead to 
loss or gain of function in lung antioxidants (Radi, 2004), suggesting the pathophysiological 
role of 3-NT. In this study, we found that artesunate could potently suppress the formation of 
3-NT in both inflammatory cells as well as in lung tissues, whereas dexamethasone failed to 
significantly inhibit 3-NT formation. This could be attributed to the inability of 
dexamethasone to suppress neutrophils recruitment. These results suggest an additional 
therapeutic benefit in using artesunate for asthma as opposed to corticosteroid.  
 
8-Isoprostane, also known as 8-iso prostaglandin F2, is one of the best-characterized F2-
isoprostanes and has been shown to be a representative biomarker for lipid oxidative damage 
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(Wood, Fitzgerald, Gibson, Cooper, & Garg, 2000). It is also reactive and can propagate 
further damage by modifying important biomolecules (Roberts, et al., 2004). Clinical studies 
have shown a positive correlation of 8-isoprostane levels in exhaled breath condensates from 
asthmatics to the severity of asthma (Baraldi, Carraro, et al., 2003; Van Hoydonck, et al., 
2004). On the other hand, 8-OHdG is an indicator for oxidative DNA damage and is formed 
when reactive OH
- 
attacks deoxyguanosine nucleotides in DNA (Giustarini, et al., 2009). 
Increased 8-OHdG levels have similarly been observed in severe asthmatics (Fitzpatrick, et 
al., 2011). In the present study, we observed a consistent and robust suppression of these 
oxidative damage biomarkers by artesunate in the inflamed lungs, suggesting that artesunate 
could markedly reduce reactive oxygen and nitrogen species in the lungs, and prevent 
oxidants-induced lung damage.  
 
We found that gene expressions of NOX 1, 2, 3 and 4, a major class of pro-oxidants 
responsible for O2
-
 production, were consistently up-regulated in OVA-challenged lungs, 
which were significantly (P<0.05) suppressed by artesunate. Besides, gene expressions of the 
regulatory subunits of NOX, p22phox and p67phox, essential for NOX enzymatic activities, 
were similarly up-regulated in the inflamed lungs and repressed with artesunate. The major 
drop in eosinophil pulmonary recruitment in artesunate-treated mice may be attributable to 
the reduction in various NOX isoforms (Abdala-Valencia, et al., 2007). iNOS is another pro-
oxidant which is induced in asthma to release NO, contributing to nitrosative stress. NO can 
combine with O2
-
 to form ONOO
-
 which attacks tyrosine residues, resulting in 3-NT 
formation (Ghosh, et al., 2006). We found that gene expression of iNOS was greatly elevated 
in OVA-challenged lungs but suppressed to basal levels by artesunate. In contrast, among the 
4 NOX isoforms, dexamethasone was only effective in suppressing NOX3. These results 
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suggest that artesunate may possess broader inhibitory effects on pro-oxidant production than 
corticosteroids, accounting for extensive suppression of oxidative lung damage.  
 
Artesunate also produced major alterations in the activities and expressions of various 
antioxidants in this experimental asthma model. SOD is responsible for the dismutation of 
reactive O2
-
 into less potent H2O2, and has been shown to be induced in airway inflammation 
(Nadeem, et al., 2003a). In this study, total SOD activity was noticeably enhanced in OVA-
challenged lungs. Our mRNA investigations of various pulmonary SOD isoforms have 
supported that the increase in SOD activity could be jointly contributed by the consistent 
elevation in CuZnSOD, MnSOD and ECSOD expressions. While both artesunate and 
dexamethasone strongly suppressed total SOD activity to the same extent, they showed clear 
differences in SOD isoform inhibition. Artesunate selectively down-regulated the expression 
of CuZnSOD and MnSOD, but dexamethasone blocked the expression of MnSOD and 
ECSOD. These results suggest that both anti-inflammatory drugs may modulate the 
expressions of pulmonary antioxidants via distinct signaling pathways differently.  
 
In OVA-challenged lungs, loss of catalase activity is likely due to a substantial reduction in 
catalase expression and protein levels. Both artesunate and dexamethasone were equally 
effective in rescuing the expression of catalase, resulting in the restoration of lung catalase 
activity and protein levels. Catalase is an important antioxidant in the lungs, responsible for 
the neutralization of reactive H2O2 into H2O and O2 (Rahman, et al., 2006). Our findings 
suggest that artesunate may be able to promote and restore neutralization of harmful H2O2 
species and thus prevent oxidative lung damage. HO-1 is an inducible form of heme 
oxygenase, in response to oxidative stress, redox imbalance and inflammation in asthma 
(Carter, et al., 2004). HO-1 expression was strongly increased in OVA-challenged lungs but 
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significantly repressed with treatment with either artesunate or dexamethasone. Our results 
suggest that artesunate could reinstate redox balance in the lungs and reduce oxidative lung 
damage.  
 
Nuclear erythroid 2 p45-related factor 2 (Nrf2) is a redox-sensitive basic leucine zipper 
transcription factor that is involved in the transcriptional regulation of many major 
antioxidant genes. Bronchial epithelial cells are the first layer of cells in the lungs and have 
been known to possess robust antioxidant defences against environmental insults modulated 
via activation of Nrf2 (Boutten, Goven, Boczkowski, & Bonay, 2010; H. Y. Cho, Reddy, 
Debiase, Yamamoto, & Kleeberger, 2005). We have observed substantial increases in nuclear 
Nrf2 levels by artesunate in Beas-2B cells, a transformed human bronchial epithelial cell line, 
stimulated with TNF- α; similar promotion of nuclear Nrf2 levels were similarly observed in 
the lungs tissues of artesunate-treated mice. Indeed, artesunate have also been recently shown 
to modulate anti-inflammatory properties via promotion of nuclear Nrf2 levels in microglia 
cells (I.-S. Lee, et al., 2012). We report here that this is first time that artesunate is found to 
promote nuclear Nrf2 levels in an in vivo study and our findings also concurred with this 
recent in vitro study that has reported artesunate could promote Nrf2 levels attenuating LPS-
induced inflammation (I.-S. Lee, et al., 2012).   
 
Disruption or loss of Nrf2 can lead to increased susceptibility to asthma, with potent 
increases in airway inflammation, especially augmented recruitment of eosinophils and 
neutrophils (Rangasamy, et al., 2005; Williams, et al., 2008). In our study, we observed that 
the promotion of nuclear Nrf2 levels in artesunate-treated mice was accompanied with a 
substantial inhibition in eosinophil and neutrophil recruitment. Restoration in expression 
levels and protein levels of catalase in artesunate-treated mice may also be attributed to the 
105 
promotion of nuclear Nrf2 levels, as Nrf2 functions to modulate expression of endogenous 
antioxidants in the lungs, especially catalase (H. Y. Cho, et al., 2005; N. Li, et al., 2004). 
Nrf2 has also shown to negatively regulate iNOS expressions (J. Kim, Y.-N. Cha, & Y.-J. 
Surh, 2010) and is consistent with the robust suppression of iNOS expression by artesunate 
observed in our study and in a recent study (Cheng, et al., 2011). We have affirmed that 
artesunate do not possess direct antioxidant properties, as artesunate failed to exert any 
substantial radical scavenging activities in the DPPH˙ radical scavenging assay. Collectively, 
these results suggest that artesunate do not directly scavenge for free radicals in the lungs and 
may prevent oxidative lung damage in asthma by exerting a direct upstream effect in 




In summary, we have shown that artesunate, a clinically effective anti-malarial drug, 
possesses comparable anti-inflammatory effects and broader anti-oxidative effects as 
compared to dexamethasone in experimental mouse asthma. It acts by the suppression of 
NADPH oxidases and iNOS, and by modulation of antioxidants, such as catalase and SODs, 
in the lungs (Figure 2.14), possibly via promotion of nuclear Nrf2 levels. The present study 
together with our recent report (Cheng, et al., 2011) suggest a potential therapeutic value of 
artesunate in treating allergic asthma, by suppressing airway inflammation, oxidative stress 
and subsequently preventing oxidative lung damage. Inhibition of oxidative stress, 
neutrophilia and PI3K/Akt signaling and promotion of Nrf2 have been highlighted as useful 
therapeutic strategies to reverse corticosteroid-resistance in severe asthmatics (P. J. Barnes, 
2012; P. J. Barnes, et al., 2007; Ito, et al., 2008). Our collective results also suggest that 
artesunate may be a potentially useful alternative anti-inflammatory agent, complementary to 
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Figure 2.14. Overview of proposed therapeutic mechanisms of action of artesunate on 


















METABOLOMICS REVEALS NOVEL METABOLIC 














Rationale: Metabolomics refers to the comprehensive analysis of metabolites in biological 
systems and has been employed to study asthmatic patients based on their urinary and 
exhaled breath condensate metabolite profile.  
Hypothesis: We hypothesize that airway allergic asthma would affect metabolism in the 
lungs, and could be detected in the BALF using a combined liquid chromatography (LC)- and 
gas chromatography (GC)- mass spectrometry (MS) platform. We aim to investigate lung 
metabolism changes in allergic asthma by metabolomic analysis of BALF.  
Methods: BALB/c mice were sensitized and challenged with ovalbumin to develop 
experimental asthma. Dexamethasone was administered to study the effects of corticosteroids 
on lung metabolism. Metabolites in BALF were measured using LC-MS and GC-MS, and 
multivariate statistical analysis was performed by orthogonal projections to latent structures 
discriminant analysis. 
Measurements and Main Results: Metabolomic analysis of BALF from ovalbumin-
challenged mice revealed novel changes in metabolic pathways in the lungs as compared to 
control animals. These metabolite changes suggest alterations of energy metabolism in 
asthmatic lungs, with increases of lactate, malate and creatinine and reductions in 
carbohydrates such as mannose, galactose and arabinose. Lipid and sterol metabolism were 
affected with significant decreases in phosphatidylcholines, diglycerides, triglycerides, 
cholesterol, cortol and cholic acid. Dexamethasone treatment effectively reversed many key 
metabolite changes, but was ineffective in repressing lactate, malate and creatinine and 
induced additional metabolite changes.  
Conclusions: Metabolomic analysis of BALF offered a promising approach to investigate 
allergic asthma. Our overall findings revealed considerable pathway changes in lung 
metabolism in asthmatic lungs, including energy, amino acids and lipid metabolism.  
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1 RATIONAL , OBJECTIVES AND HYPOTHESIS 
Metabolomics is an emerging systems biology tool which possesses potential to uncover 
unique molecular mechanisms and metabolic perturbations in biological systems. In 
respiratory research, specifically asthma, there have been initiatives to utilize metabolomics 
to discover novel non-invasive metabolic biomarkers in asthma, such as in exhaled breath 
condensate (Carraro, et al., 2007; Effros, 2008) and urine (Mattarucchi, Baraldi, & Guillou, 
2012; Saude, et al., 2009b; Saude, et al., 2011).  These metabolomics studies have revealed 
promising aeroallergen-induced metabolic profile shifts in the breath condensate and urine, 
which can be further explored as novel biomarkers to diagnose the disease status and 
conditions of asthmatic patients. Despite these encouraging discoveries of metabolic 
perturbations in asthmatic urine and breath condensate, it is presently unknown if there are 
relevant metabolic alterations in the allergic-inflamed airways.  
 
With the eventual goal to identify possible beneficial metabolic effects induced by artesunate 
in allergic asthma, we first investigated for potential disease-associated metabolic changes in 
the allergic airways. Findings from this study will potentially identify metabolic markers 
which are relevant to asthma and will become an important research milestone in the 
respiratory field to utilize metabolomics for understanding of the disease pathogenesis. In this 
study, we hypothesized that metabolism is altered in allergic airway inflammation and can be 
detected via an integrated liquid-chromatography-(LC-) and gas-chromatography-(GC-) mass 
spectrometry (MS) metabolomics platform. Complementary to our investigations of 
metabolic profile shifts in the inflamed airways, we also investigated for potential metabolic 
effects of dexamethasone in allergic asthma to better understand if disease-related metabolic 
modifications that we have observed were reversible by corticosteroid therapy.  
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2 METHODS AND MATERIALS 
2.1 Materials and Reagents 
Dexamethasone, N-(9-fluorenylmethoxycarbonyl)-glycine (FMOC-glycine) and N-methyl-N-
trimethylsilyl-trifluoroacetamide (MSTFA) were purchased from Sigma-Aldrich (St. Louis, 
MO, USA). Formic acid, pyridine, HPLC grade methanol and ethanol were purchased from 
Merck (Darmstadt, Germany).  
2.2 Animals 
Female BALB/c mice, 6 to 8 weeks old (Canning Vale, Western Australia, Australia), were 
sensitized and challenged with ovalbumin (OVA) to develop allergic airway inflammation 
(OO) as previously described (Cheng, et al., 2011; Wanxing Eugene Ho, et al., 2012). 
Dexamethasone (1 mg/kg) was dissolved in saline and administered intraperitoneally to the 
mice 1 hour before each aerosol challenge (OO/Dex). Saline aerosol was used as a negative 
control (OS), while naïve mice were used as baseline controls (N). Animal experiments were 
performed according to the Institutional guidelines for Animal Care and Use Committee of 
the National University of Singapore. 
 
2.3 BALF Collection and Analysis 
Mice were anesthetized 24 hours after the last aerosol challenge and bronchoalveolar lavage 
(BAL) was performed. In essence, tracheotomy was performed for each animal, using a 
cannula inserted into the trachea. Ice-cold PBS (3 X 500 µL) was instilled into the lungs, and 
a consistent volume of BALF, ranging between 1400 – 1450 µL, was recovered from each 
animal. Total and differential cell counts were determined from BALF collected as described 




2.4 Sample Pretreatment 
400 µL of BALF were concentrated for 3 hours using a freeze-dryer (Labconco Corporation, 
Kansas City, USA) at -85°C and reconstituted using 200 µL ice-cold methanol spiked with 10 
µg/mL FMOC-glycine as internal standard. The solution was vortexed (3 min) and ultrasonic 
extracted (15 min, 4°C). After two centrifugations (16000 rcf × 10 min, 4°C), the supernatant 
were divided into two portions: 70 µl for LC-MS analysis directly and the other 70 µl for 









2.5 GC/MS Analysis 
GC-MS derivatization was based on our earlier method (Ng, et al., 2012). In essence, 70 µL 
supernatant were dried under nitrogen and derivatized by 70 µL methoxyamine (50 µg/mL in 
pyridine, 37 °C×2 h) and followed by 70 µL MSTFA (37°C×16 h). After centrifugation 
(6000 rcf × 1 min, 4
o
C), 1 µl of derivatized supernatant was injected splitlessly by an Agilent 
7683 Series autosampler into an Agilent 6890 GC system equipped with a HP-5MSI column. 
The inlet temperature was set at 250°C. Helium was used as the carrier gas at a constant flow 
rate of 1.0 ml/min. The column temperature was initially maintained at 70°C for 1 min, and 
then increased to 250°C at a rate of 10°C /min and further increased at 25°C/min to 300°C 
Figure 3.01: Labconco freeze-dryer used for 
BALF concentration. 400 µL BALF samples are 
lyophilized at -85°C for 3 hours into powder form 
and reconstituted with 200 µL of ice-cold 
methanol with 10 µg/mL FMOC-glycine (IS). 
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where it remained for 5 min. The column effluent was introduced into the ion source of an 
Agilent Mass selective detector. The transfer line temperature was set at 280°C and the ion 
source temperature at 230°C. The mass spectrometer was operated in electron impact (EI) 
mode (70 eV). Data acquisition was performed in full scan mode from m/z 50-550 with a 
scan time of 0.5s. Compounds were identified by comparison of mass spectra and retention 
time with those of reference standards, and those available in libraries (NIST 0.5). 
 
2.6 LC/MS Analysis  
LC-MS analysis was performed on an Agilent 1200 HPLC system equipped with 6410 QQQ 
mass detector. 5 µl of the pre-treated BALF supernatant was injected into an Agilent 1200 
HPLC system (Waldbronn, Germany) equipped with 6410 QQQ mass detector and managed 
by a MassHunter workstation. The column used for the separation was an Agilent rapid 
resolution HT zorbax SB-C18 (2.1 × 50 mm, 1.8µm) (Agilent Technologies, Santa Clara, 
CA). The oven temperature was set at 50°C. The gradient elution involved a mobile phase 
consisting of (A) 0.1% formic acid in water and (B) 0.1% formic acid in methanol. The initial 
condition was set at 5% of B. The following solvent gradient was applied: from 95% A and 
5% B to 10% A and 90% B within 10 min, hold for 10 min and then to 100% B within 5 min 
and hold for 10 min. Flow rate was set at 0.2 ml/min and 5µl of samples were injected.  The 
ESI-MS were acquired in positive and negative ion mode, respectively. The ion spray voltage 
was set at 3,000 V. The heated capillary temperature was maintained at 350°C.  The drying 
gas and nebulizer nitrogen gas flow rates were 10 L/min and 30 psi, respectively. For full 
scan mode analysis spectra were stored from m/z 100 to 1000. Compounds showing 
significant differences between groups were searched in the Human Metabolome Database 
(HMDB, www.hmdb.ca) using mass-to-charge ratio (m/z) and identified by either MS/MS 
fragmentation patterns or reference standards. 
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2.7 Data Preprocessing 
Each chromatogram obtained from GC/MS and LC/MS analysis was processed for baseline 
correction and area calculation using MZmine 2.0 software package (Pluskal, Castillo, Villar-
Briones, & Oresic, 2010). Data were combined into a single matrix by aligning peaks with 
the same mass and retention time for GC/MS and LC/MS data, respectively. Area of each 
peak was normalized to that of internal standard (FMOC-glycine) in each data set. The 
missing values were replaced with a half of the minimum value found in the data set (Ng, et 
al., 2012). 
 
2.8 Statistical Analysis 
Cell counts data are presented as means±SEM. One-way ANOVA followed by Dunnett’s test 
was used to determine significant differences between groups, with significant levels at p < 
0.05.  Correlations between metabolites and inflammatory cells were calculated using 
Pearson correlation analysis. Multivariate statistical analysis was performed using SIMCA-P 
software version 11.0 (Umetrics AB, Umea, Sweden). Orthogonal projections to latent 
structures discriminant analysis (OPLS-DA) was used to model the discrimination between 
treatment and control subjects by visualization of score plots. Prior to OPLS-DA, data were 
mean-centered and unit variance scaled. Metabolites heatmap and nonparametric test 
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3.1 Development of OVA-induced Airway Inflammation and Reversal with 
Dexamethasone 
BALF was collected 24 hours after the last OVA or saline aerosol challenge, and total and 
differential cell counts were performed. OVA sensitization, followed by saline inhalation, did 
not promote significant increases in inflammatory cell recruitment as compared to naïve mice 
(Figure 3.03). OVA inhalation markedly increased total cell and eosinophil counts, with 
moderate increases in macrophage, lymphocyte and neutrophil counts, as compared with 
saline aerosol control (p < 0.05). Dexamethasone treatment (1 mg/kg) suppressed eosinophils, 
macrophages and lymphocytes recruitment (p < 0.05), but was ineffective in repressing 
neutrophil counts.  
 
3.2 Multivariate Analysis of Metabolic Fingerprint by GC/MS and LC/MS 
We investigated BALF samples from four groups of mice (N, naïve, n=12; OS, sensitized, 
n=12; OO, asthma model, n=12; OO/Dex, asthma treated with dexamethasone, n=8) using 
GC/MS and LC/MS. Over eighty peaks in GC/MS were consistently detected in at least 90% 
of the BALF samples. Similarly, more than three hundred peaks were collected in both 
positive and negative modes of LC-MS after 90% filter threshold. In OPLS-DA analysis, the 
value of R
2
Y describes how well the data in the training set are mathematically reproduced, 
ranging between 0 and 1, where 1 indicates a model with a perfect fit. Models with a Q
2
 value 
greater than or equal to 0.5 are generally considered to have good predictive capability. 
Statistical analysis of lung metabolite profiles showed clear separation of OO from OS and N 
groups (Figures 3.04A and 3.04B), with strong modeling fit R
2
Yvalues of 0.866 (GC/MS) 
and 0.863 (LC/MS), as well as good prediction Q
2
 values of 0.495 (GC/MS) and 0.694 
(LC/MS). Experimental asthma lung metabolite profiles with dexamethasone treatment, 
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OO/Dex, also showed distinct separation from OO (Figures 3.04C and 3.04D), with robust 
modeling fit R
2
Y values of 0.881 (GC/MS) and 0.941 (LC/MS), and high prediction Q
2
 
values of 0.725 (GC/MS) and 0.859 (LC/MS). 
 
3.3 Altered Lung Metabolism in Experimental Asthma and Effects with 
Dexamethasone Treatment  
BALF metabolites were significantly altered in OO, as compared to OS. Fold changes are 
depicted in the heatmap for each treatment group (Figure 3.05A). Detailed fold changes in 
various phosphatidylcholines, diglycerides, triglycerides as well as other metabolites are 
available in the heatmap below (Figure 3.05A) Altered energy metabolism was noted in 
allergic airway inflammation with significant increases in pulmonary levels of lactate, malate 
and creatinine (Figure 3.05B).  On the other hand, concentrations of carbohydrates, including 
mannose, galactose and arabinose, were significantly reduced in experimental asthma, as 
compared to saline-challenged controls (Figure 3.05B). Alterations in lipids and sterols 
metabolism were also observed with substantial decreases in phosphatidylcholines (PC), 
diglycerides (DG), triglycerides (TG), cholesterol, cholic acid and cortol and increase in 
choline and hexadecenoylcholines levels only (Figure 3.05C). Dexamethasone showed 
reversed changes of most altered metabolites, except for some metabolites, such as lactate, 
malate and creatinine.  
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Figure 3.03. OVA-induced inflammatory cell pulmonary recruitment and treatment 
using dexamethasone. Inflammatory cell counts were performed in BALF obtained from 
naïve untreated mice (N), sensitized mice 24 h after the last saline aerosol (OS) or OVA 
aerosol (OO) or treated with 1 mg/kg dexamethasone (OO/Dex). Differential cell counts were 
performed on a minimum of 500 cells to identify macrophages (Mac), eosinophils (Eos), 
lymphocytes (Lym) and neutrophils (Neu). Values are expressed as means ± SEM for 8-12 
mice per group. # denotes significant difference from OS; p < 0.05. * denotes significant 




Figure 3.04: Statistical Discrimination of OVA-induced Lung Inflammation and 
Treatment with Dexamethasone. (A) OPLS-DA score plot obtained from GC/MS data 
comparing naïve controls (N), sensitized (OS) and OVA-challenged mice (OO). (B) OPLS-
DA score plot obtained from LC/MS comparing naïve controls (N), sensitized (OS) and 
OVA-challenged mice (OO). (C) OPLS-DA score plot obtained from GC/MS data comparing 
OVA-challenged mice (OO) and OVA-challenged mice treated with Dex (OO/Dex). (D) 
OPLS-DA score plot obtained from LC/MS data comparing OVA-challenged mice (OO) and 
OVA-challenged mice treated with Dex (OO/Dex). Black unfilled circles, naïve untreated 
mice (N) (n=12); blue unfilled diamonds, sensitized mice 24 h after the last saline aerosol 
(OS) (n=12); red filled circles, sensitized mice 24 h after the last OVA aerosol (OO) (n=12); 
green filled diamonds, sensitized mice 24 h after the last OVA aerosol with Dex treatment 
(OO/Dex) (n=8). The X-axis, t[1] and Y-axis, t[2] indicate the first principle component and 










Figure 3.05: Key Metabolite Changes Induced by Airway Inflammation and Reversal 
with Dexamethasone Treatment. (A) Significant fold level changes in BALF metabolites 
are expressed as a heatmap showing metabolite changes in all treatment groups, detected by 
either LC/MS or GC/MS. Detailed fold changes in various phosphatidylcholines, diglycerides, 
triglycerides and other metabolites can be found in the heatmap below. Fold changes are 
derived from the fold difference over normalized means for each metabolite. Green squares 
indicate a reduction of up to 2 folds; Black squares indicate no significant fold changes; Red 
square indicates an increase of up to 2 folds. + denotes no significant change in OO/Dex as 
compared to OO, p > 0.05. (B) Mass abundance of key metabolites involved in the alteration 
of energy metabolism in asthma, detected by GC/MS or LC/MS. # denotes significant change 
in OO compared to OS or N; p < 0.05. * denotes significant change in OO/Dex compared to 
OO; p < 0.05. (C) Mass abundance of key metabolites involved in lipid metabolism in 
asthmatic lungs, detected by GC/MS or LC/MS. # denotes significant change in OO 
compared to OS or N; p < 0.05. * denotes significant change in OO/Dex compared to OO; p 
< 0.05. 
 
3.4 Correlations between Specific Metabolites and Various Inflammatory Cells 
Amongst the list of metabolites found to be significantly altered in the BALF of experimental 
asthma (Figure 3A), 13 specific metabolites were noted to possess significant linear 
correlations to inflammatory cell counts (Table 3A) and to various inflammatory cell 
percentages (Table 3B).  Energy metabolites (lactate and malate) and lipid metabolites 
(choline and hexadecenoylcholine) showed moderate-strong correlations to recruited 
inflammatory cells, especially to percentage of macrophage (negative correlations) and 
eosinophils (positive correlations) (Pearson coefficient, r > 0.5, p < 0.01). On the other hand, 
carbohydrates (galactose and mannose), sterols (cholesterol, cortol and cholic acid) and other 
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lipid metabolites (phosphatidylcholines, diglycerides and triglycerides) had substantial 
negative relationships to total cells, eosinophils and neutrophils percentages (Pearson 
coefficient, r < -0.5, p < 0.01) and also positively correlated to macrophage percentages 
(Pearson coefficient, r > 0.5, p < 0.01). In most cases, lymphocyte counts (Table 1A), but not 
percentages (Table 1B), were shown to be moderately associated with most of these 
metabolites (r in the range of ± 0.3 to ± 0.5, p < 0.05). 
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Table 3A: Pearson Correlation Coefficients (r) of BALF Metabolite Levels versus 
Various Inflammatory Cells Recruitment 
 
Total Mac Eos Lym Neu 
Energy Metabolites      
Lactate 0.662** 0.691** 0.632** 0.366* 0.371* 
Malate 0.485** 0.441** 0.482** N.S. N.S. 
Carbohydrates      
Galactose -0.562** -0.450** -0.573** -0.350* -0.569** 
Mannose -0.549** -0.444** -0.559** -0.339* -0.548** 
Sterols Metabolites      
Cholesterol -0.498** -0.346* -0.509** -0.487** -0.532** 
Cortol -0.619** -0.505** -0.618** -0.486** -0.587** 
Cholic acid -0.648** -0.526** -0.655** -0.502** -0.522** 
Lipid Metabolites      
Phosphatidylcholines -0.541* -0.398* -0.544** -0.508** -0.594** 
Diglycerides -0.454** -0.341* -0.445** -0.494** -0.536** 
Triglycerides -0.612** -0.522** -0.597** -0.529** -0.603** 
Choline 0.747** 0.721** 0.731** 0.410* 0.527** 
Hexadecenoylcholine 0.567** 0.473** 0.591** 0.374* N.S. 
Total – Total inflammatory cell numbers; Mac –Macrophages; Eos – Eosinophils;  
Lym – Lymphocytes; Neu –Neutrophils 
Moderate correlations: values of -0.5 to -0.3 (negative correlations) or 0.3 to 0.5  
Strong correlations: values of -1.0 to -0.5 (negative correlations) or 0.5 to 1.0  
** denotes significant correlation, p < 0.01; * denotes significant correlation, p < 0.05 
N.S. denotes no significant correlations, p > 0.05 
Correlation analysis was derived using all data obtained from N, OS and OO groups. 
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Table 3B: Pearson Correlation Coefficients (r) of BALF Metabolite Levels versus 
Various Inflammatory Cells Percentages 
 
Mac% Eos% Lym% Neu% 
Energy Metabolites     
Lactate -0.448** 0.506** N.S. N.S. 
Malate -0.421* 0.465** N.S. N.S. 
Carbohydrates     
Galactose 0.588** -0.621** N.S. -0.493** 
Mannose 0.569** -0.602** N.S. -0.474** 
Arabinose N.S. -0.362* N.S. N.S. 
Sterols Metabolites     
Cholesterol 0.624** -0.575** N.S. -0.467** 
Cortol 0.650** -0.667** N.S. N.S. 
Cholic acid 0.649** -0.643** N.S. -0.426** 
Lipid Metabolites     
Phosphatidylcholines 0.650** -0.615** N.S. -0.466** 
Diglycerides 0.579** -0.525** N.S. -0.419* 
Triglycerides 0.630** -0.620** N.S. -0.473** 
Choline -0.622** 0.683** N.S. 0.477** 
Hexadecenoylcholine -0.449** 0.489** N.S. N.S. 
Mac% – percentage of Macrophages over total cells; Eos% – percentage of Eosinophils over 
total cells; Lym% – percentage of Lymphocytes over total cells; Neu% – percentage of 
Neutrophils over total cells;   
Moderate correlations: values of -0.5 to -0.3 (negative correlations) or 0.3 to 0.5 Strong 
correlations: values of -1.0 to -0.5 (negative correlations) or 0.5 to 1.0  
** denotes significant correlation, p < 0.01; * denotes significant correlation, p < 0.05 
N.S. denotes no significant correlations, p > 0.05 
Correlation analysis was derived using all data obtained from N, OS and OO groups. 
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3.5 Dexamethasone Alters Lung Metabolite Profile in Experimental Asthma 
Apart from reversing metabolites alterations in inflamed lungs, we observed that 
dexamethasone could also induce additional metabolite changes in experimental asthma. 
Noticeably, dexamethasone caused substantial induction of fatty acids, including steridonic 
acid, eicosapentaenoic acid and petroselinic acid, as well as various monoglycerides, 
diglycerides and triglycerides (Figure 3.06). Other lipid-based metabolites, such as 
monostearin, 2-palmitoylglycerol, sphingomyelin (SM) and lysophosphatidylcholine (LPCs) 
were also found to be up-regulated with dexamethasone. Besides, amino acids, such as N,N-
dimethyl-tyramine and N-acetyl-tyrosine were also found to be increased with corticosteroid 
treatment. Interestingly, 2-oxoarginine, a metabolite of arginine catabolism, suggestive of 
impaired arginase activity, was noted to be reduced by dexamethasone. Although the 
biological relevance of these metabolites cannot be comprehensively investigated in this 
study, these results do suggest the broad and potentially non-specific effects of 
corticosteroids on altering metabolism in asthmatic lungs.  
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Figure 3.06: Additional Changes in Metabolism Induced by Dexamethasone Treatment. 
Heatmap summarizing fold levels changes of significantly changed metabolites induced by 
dexamethasone treatment, but was unchanged in naïve, control and asthmatic animals, 
detected by either LC/MS or GC/MS. Fold changes are derived from the fold difference over 
normalized means for each metabolite. Green squares indicate a decrease of up to 2 folds; 
Black squares indicate no significant fold changes; Red squares indicate an increase of up to 









4.    DISCUSSION 
Metabolomics, especially mass spectrometry-based metabolomics, is an emerging analytical 
tool in  human disease research, due to its high sensitivity and capability to simultaneously 
measure many metabolic biomarkers in a single biological sample (Adamko, et al., 2012).  
Recent studies have used metabolomics to analyze asthmatic patients’ urine or breath 
condensate and demonstrated that this approach could offer opportunities for disease-related 
biomarker discovery (Mattarucchi, et al., 2012; Saude, et al., 2009b; Saude, et al., 2011). To 
date, there are still no metabolomics studies that have investigated these metabolic changes 
directly in asthmatic lungs, which will provide novel insights of changes in lung metabolism 
during asthmatic conditions. In this study, BALF derived from OVA-induced asthma, was 
analyzed using an integrated LC/MS- and GC/MS-based metabolomics approach. We 
hypothesized that asthmatic conditions would lead to alterations in lung metabolism, which 
can be reflected in the BALF. Dexamethasone, a potent corticosteroid, was administered to 
investigate the effects of corticosteroids in lung metabolism resulting from asthma.  
 
Our results indicate that BALF, obtained from OVA-induced asthmatic animals, encompass 
unique disease-relevant metabolic signatures, detected by a combination of GC/MS and 
LC/MS analysis. The measurements of multiple metabolites, known as a metabolic signature, 
versus using a single metabolite, as demonstrated here, enabled discrimination of diseased 
animals from healthy controls. These metabolic signatures, coupled with good predictive 
values of the mathematical modeling, revealed major alterations in lung metabolism in 
experimental murine model of asthma, which were substantially reversed by dexamethasone, 
suggesting that they are disease-relevant metabolic changes. These alterations of the BALF 
metabolome in experimental asthma and reversal effects by a corticosteroid are illustrated in 
Figure 5, adapted from a recent study (Zheng, et al., 2011).  
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In this study, a prominent metabolic feature observed in asthmatic animals was an alteration 
to cellular energy metabolism in the lungs, possibly related to an increased respiratory burden 
in supplying energy to recruited inflammatory cells. Increases in lactate, malate and 
creatinine levels (Figure 3.05B), suggests a stronger demand for energy in allergic airway 
inflammation. Lactate and malate are products of altered energy metabolism, produced 
during abnormal lung respiration, especially during hypoxic or inflamed conditions (Wolak, 
et al., 2009). Correlation analysis performed in this study has revealed strong positive 
correlations between lactate and malate versus macrophages and eosinophils, suggesting 
these energy metabolites may be contributed more significantly from these two cell types 
(Table 3A and 3B). Elevated levels of lactate has been reported in BALF from cystic fibrosis 
patients (Wolak, et al., 2009), urine of asthmatic children (Saude, et al., 2009b) and inflamed 
lungs exposed to silica dust (Hu, et al., 2008) or 1-nitronaphthalene (Azmi, et al., 2005), 
indicating consistent impairment of energy metabolism in these respiratory diseases.  
 
Malate is a metabolic product from carbohydrates breakdown via the tri-carboxylic (TCA) 
cycle to provide additional energy. Although increased levels of malate have not been 
previously reported in asthma, it has been shown that fumarate and succinate, two upstream 
metabolites of malate in the TCA cycle, were correspondingly depleted in experimental 
asthma (Saude, et al., 2009b), supporting the involvement of the TCA cycle with increased 
formation of malate in experimental asthma. Increases in pulmonary levels of creatinine, a 
downstream metabolite of creatine, suggests promotion of energy metabolism via the urea 
cycle. Creatine is involved in muscular protein turnover and energy supply to muscles, such 
as the airway smooth muscles (Bolton, 1996). Substantial increases in creatine have been 
observed in inflamed lungs due to sepsis (Izquierdo-Garcia, et al., 2011) or silica exposure 
(Hu, et al., 2008). Metabolomic analysis of urine from asthmatic children, especially children 
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having an asthma exacerbation, has shown similar increases in creatine, which were 
attributable to the increased respiratory burden (Saude, et al., 2011).  
 
Carbohydrates, such as glucose, are sources of energy in pulmonary cells and have been 
observed to be reduced in urine of experimental asthma (Saude et al., 2009). In our study, the 
levels of carbohydrate related metabolites, such as mannose, galactose and arabinose, were 
substantially lower in the experimental model of asthma as compared to healthy controls 
(Figure 3.05B), as these sugars might have been broken down into lactate and malate to 
provide additional energy. Significant inverse correlations have been observed between 
galactose and mannose with eosinophils and neutrophil levels, suggesting that these 
inflammatory cells may be associated with the reduction of the galactose and mannose (Table 
3A). Mannose has been shown to exert anti-inflammatory and protective effects in the lungs 
against lipopolysaccharide-induced injury (X. L. Xu, et al., 2008). Arabinogalactan, a down-
stream product formed from arabinose and galactose, has also been shown to have protective 
effects in allergic asthma (M. Peters, et al., 2010). Depletion of these saccharides in asthmatic 
lungs of mice may contribute to the development of airway inflammation and increase in 
severity of the disease. To our knowledge, this is the first time that reduced mannose, 
arabinose and galactose levels have reported in experimental asthmatic lungs. 
 
Lipid and sterol metabolism were also affected, with various lipid and sterol metabolites 
markedly lowered in the experimental asthmatic lungs (Figure 3.05C). Various 
phosphatidylcholines, diglycerides and triglycerides were significantly reduced in the BALF, 
with a corresponding increase in downstream choline and hexadecenoylcholine levels. 
Notably, substantial negative correlations have been found between phosphatidylcholines, 
diglycerides and triglycerides with eosinophils, lymphocytes and neutrophil levels, 
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suggesting significant inverse associations of these lipid metabolites with inflammatory cells. 
Phosphatidylcholines are associated with surfactant levels in the lungs, where decline of 
phosphatidylcholines can lead to reduced lung functions in asthma (Wright, et al., 2000). 
Triglycerides have been shown to protect the lungs, by acting as antioxidants and conferring 
cytoprotective effects on epithelial, endothelial and fibroblasts cells against oxygen free 
radical injury (Torday, Torday, Gutnick, Qin, & Rehan, 2001). Choline has been reported to 
possess protective effects in asthma (Mehta, Arora, Gaur, & Singh, 2009; Mehta, Singh, 
Arora, & Gaur, 2010), capable of suppressing inflammation and oxidative stress when given 
in substantial amounts. In a similar fashion, increases in choline levels have been observed in 
lungs exposed to silica dust (Hu, et al., 2008) and in sepsis-induced lung injury (Stringer, et 
al., 2011). Increases in choline and hexadecenoylcholine, may possibly be an adaptive 
response in experimental asthmatic lungs to control the severity of inflammation, as a 
consequence of depleting other beneficial lipid metabolites. Supporting this hypothesis, 
strong positive correlations have been observed between choline and hexadecenoylcholine 
levels with increasing macrophages and eosinophils levels. 
 
Besides, considerable reduction in sterols, including cholic acid, cholesterol and cortol, were 
also noted in asthmatic lungs of the mouse model (Figure 3.05C). In this study, these three 
sterol metabolites have been found to correlate inversely, especially to increasing eosinophils 
and neutrophils, and moderately to lymphocytes levels, implicating considerable relationships 
between sterols and these inflammatory cells. Cholesterol has multiple interactions with 
inflammation and has been similarly reported to be reduced in serum of asthmatic patients 
(Fessler, et al., 2009). Cortol is a metabolite of endogenous cortisol, which is produced from 
cholesterol and cholic acid (Shamim, Yousufuddin, Bakhai, Coats, & Honour, 2000). Cortisol 
is known to modulate immune responses in the lungs and exert broad anti-inflammatory 
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activities to inhibit development of asthma (Peebles, et al., 2000; Zhang, Shen, Hu, Liu, & 
Zhang, 2009). Significant reduction in upstream metabolites, cholic acid and cholesterol, with 
corresponding decline in downstream metabolite, cortol, suggests a possible dampening 
effect on cortisol metabolism, which may be an important feature in the development of 
asthma. So far, this is the first study that features comprehensive changes in lipid and sterol 
metabolism and specific correlations to inflammatory cells in experimental asthmatic lungs. 
 
Dexamethasone (1 mg/kg), a potent corticosteroid, was shown in our recent study to exert 
protective effects in experimental asthma by modulating antioxidants and suppressing pro-
oxidants, as shown in the first project. In this study, the same dose of dexamethasone was 
similarly effective in suppressing airway inflammation and reversed many carbohydrates, 
lipids and sterols changes in experimental asthmatic lungs. Dexamethasone restored levels of 
all three sugars, which possess protective effects in the lungs, suggesting that leverage of 
these sugars could be a beneficial effect induced by corticosteroids to attenuate lung 
inflammation. Another effect of dexamethasone was to reverse the alterations in lipid 
metabolism, possibly by inducing increases in fatty acids, such as stearidonic acid, 
eicosapentaenoic acid and petroselinic acid, as well as promoting other monoglycerides, 
diglycerides and triglycerides. Lastly, dexamethasone was effective in reversing sterol 
metabolism, suggesting that reversal of sterol metabolism may also be a favorable effect 
induced by corticosteroids.  Similar increases in fatty acids, phosphatidylcholines and sterols 
have been observed in an experimental study of lungs treated with dexamethasone (Bruder, 
Lee, & Raff, 2005), as this corticosteroid has been found to induce expression of the fatty 
acid synthase gene (Beneke & Rooney, 2001).   
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In this study, dexamethasone was noted to be ineffective in halting the increase in lactate and 
malate levels and even lead to further increases in creatinine levels. Dexamethasone also 
substantially induced many additional metabolites increases, which were unaffected in naïve, 
sensitized and asthmatic animals. It is beyond the scope of this study to investigate if these 
metabolic changes are beneficial or adverse effects of corticosteroids, but our study suggest 
possible considerations with the use of potent corticosteroids in asthma. A study involving 
rats in hypoxic conditions have also raised similar concerns of pulmonary hyperlipidemia 
with the use of dexamethasone (Bruder, et al., 2005). Future studies may be specifically 
designed to investigate if these additional metabolic changes exert protective or harmful 
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Figure 3.07: Altered Metabolic Pathways in Experimental Asthma and Effects of 
Dexamethasone Treatment. Black arrows indicate a direct relationship between two 
metabolites; Dotted arrows indicate indirect relationships between two metabolites; Red 
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block arrows indicate metabolome changes in lungs of OVA-challenged mice; Green block 
arrows indicates metabolome changes in OVA-challenged mice with Dex treatment.  
 
It is necessary to acknowledge that our findings of metabolic changes in asthmatic lungs are 
derived from an experimental model of allergic asthma due to difficulties in collecting BALF 
or lung tissues in human asthmatics. Use of human samples is further compounded with the 
need to recruit asthmatic patients and control subjects of similar ages, disease states and 
environmental exposures to elucidate meaningful metabolic changes. Our present study aims 
to establish a comprehensive cross-sectional feature in asthmatic lungs and provide a 
reference for future human asthma studies. In view of that, we have observed consistent 
alterations in metabolism in our model of experimental asthma, validating earlier findings 
using urine or exhaled breath condensate from both human and experimental asthma (Carraro, 
et al., 2007; Mattarucchi, et al., 2012; Saude, et al., 2009b; Saude, et al., 2011). Substantial 
associations between specific metabolic changes and respective inflammatory cells have been 
observed in this study, offering possible interactions or contributions of these specific 
metabolites from inflammatory cells. It is important to highlight that more specialized studies 
would be required to define these causative relationships. Indeed, it has been noted that not 
all metabolic changes were completely attributed or associated with inflammatory cell 
recruitment and may be related to native resident cells in the lungs, such as epithelial cells, 
fibroblasts or smooth muscle cells, as suggested in several metabolomics studies of 
respiratory diseases (Saude, et al., 2009b; Wolak, et al., 2009). 
 
The use of an integrated approach of combining LC-MS and GC-MS techniques in this study 
provides the opportunity to investigate a more comprehensive repertoire of metabolites in the 
lungs and further enabled the elucidation of novel metabolic pathway changes in 
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experimental asthma. As demonstrated, this present study has uncovered several unique and 
critical metabolic pathway changes in asthmatic lungs, such as changes in energy metabolism, 
carbohydrate, lipids and sterol depletion, which can be further investigated for potential 
disease-relevant biomarkers (Figure 3.05 and 3.07). Lastly, this study also provided new 
insights of the extensive metabolic effects of a potent corticosteroid, dexamethasone, in 
experimental asthmatic lungs. It is interesting to note that this corticosteroid exerts some 
beneficial metabolic effects in experimental asthma, but is limited in certain metabolic 
pathways and may even exert further metabolism changes.  
 
In short, these findings offer an overview of metabolic profile of an experimental asthma 
model. The data obtained also provide new understanding of metabolic pathway changes in 










METABOLOMICS REVEALS RESTORATIVE ACTIONS BY 




Rationale: Anti-malarial agent, artesunate possess promising anti-inflammatory actions in 
experimental models of allergic asthma. Metabolomics is shown to be capable of revealing 
comprehensive metabolic effect profile of anti-inflammatory drugs in experimental asthma.  
Hypothesis: We hypothesised artesunate can modulate disease-associated metabolic 
alterations in experimental asthma.  
Objectives and Methods: To reveal the metabolic molecular mechanisms induced by 
artesunate in allergic airway inflammation, we analysed the BALF and serum after artesunate 
was administered to naïve and diseased mice, and challenged with aerosolised ovalbumin, 
using a combination of pharmacokinetic investigation, multiplex cytokine assay and gas and 
liquid chromatography-mass spectrometry.  
Measurements and Main Results: Artesunate effectively suppressed airway inflammation 
and repressed increases in inflammatory cytokines, IL-4, IL-5, IL-13, IL-17, IL-12(p40), 
MCP-1 and G-CSF. While inducing no observable metabolic changes in naïve animals, 
specific restorative metabolic effects were observed in the BALF and serum of OVA-
challenged mice treated with artesunate. This anti-inflammatory compound promoted 
restoration of BALF sterols (cholesterol, cholic acid and cortol), phosphatidylcholines and 
carbohydrates (arabinose, mannose and galactose) and abated increases in inflammatory-
related metabolites from arginine-proline metabolism (urea, proline, valine and homoserine). 
Metabolic comparisons of artesunate against dexamethasone further suggest that artesunate 
exerts a differential and favourable metabolic profile than corticosteroids.  
Conclusions: Our study demonstrates that artesunate was able to restore specific metabolic 
and cytokine perturbations in allergic airway inflammation. Metabolomics can effectively 
differentiate metabolic mechanisms between different anti-inflammatory agents.  
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1  RATIONALE, OBJECTIVES AND HYPOTHESIS  
From our earlier study of investigating for novel disease-associated metabolic changes in 
allergic asthma, we have successfully identified several key aeroallergen-induced metabolites 
and associated metabolic pathway changes (W. E. Ho, et al., 2013). Importantly, we have 
also linked these metabolic changes to key inflammatory cells in the inflamed airways, 
especially eosinophils and neutrophils which are known major cell effectors that promote the 
disease progression and outcome. Alongside our metabolomics investigation of the BALF for 
metabolic perturbations in experimental allergic asthma, we have included naïve and diseased 
animals treated with artesunate to identify if artesunate can reverse some of the metabolic 
changes. This will potentially reveal possible favorable artesunate-induced metabolic effects 
and drug mechanisms. To our knowledge, this will also be the first study that utilizes 
metabolomics to study the drug effects of non-steroidal anti-inflammatory drugs in allergic 
asthma. Cytokine profile analysis was also performed to investigate for potential novel 
correlations between metabolite changes to inflammatory cytokine changes in allergic asthma. 
In addition, we aim to study for potential aero-allergen induced metabolic alterations in the 
serum and provide novel comparisons of the prospective favorable metabolic effects induced 
by artesunate to dexamethasone. We hypothesized that artesunate can reverse disease-
associated metabolic changes in allergic asthma and can be detected in the BALF and serum 
using an integrated LC-MS and GC-MS metabolomics investigation.  
 
2   METHODS AND MATERIALS 
2.1 Animals 
Cell count data and BALF metabolomic data of positive controls (OO), saline controls (OS) 
and naïve mice (N) were presented in an earlier study with the publisher’s consent for usage 
of raw data for further analysis (W. E. Ho, et al., 2013). Female BALB/c mice, 6 to 8 weeks 
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old (Canning Vale, Western Australia, Australia), were sensitized and challenged with 
ovalbumin (OVA) to develop allergic airway nflammation as described (Cheng, et al., 2011). 
Mice were sensitized with 20g OVA and 4 mg Al(OH)3 in 0.1ml saline by i.p on day 0 and 
day 14. For OVA challenge, mice were challenged with 1% OVA aerosol for 30 min in a 
chamber (maximal 12 mice per chamber) on days 22, 23 and 24, by a DeVlibiss Ultra-Neb 
Large-Volume Ultrasonic Nebulizer (Sunrise Medical Respiratory Products, Somerset, PA). 
The average OVA aerosol particle size is less than 5μM. Artesunate (30 mg/kg/d) was 
dissolved in 5% dimethyl sulfoxide (DMSO), given intra-peritoneally (i.p.) to naïve (N/Arts) 
and OVA-challenged mice (OO/Arts) an hour prior each aerosol challenge. Vehicle controls 
(OO/DMSO) received the same regime of 5% DMSO (i.p.). Animal experiments were 
performed according to the Institutional guidelines for Animal Care and Use Committee of 
the National University of Singapore. 
 
2.2 Chemicals 
Artesunate, DHA, DMSO, Dexamethasone, N-(9-fluorenylmethoxycarbonyl)-glycine 
(FMOC-glycine) and N-methyl-N-trimethylsilyl-trifluoroacetamide (MSTFA) were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). Formic acid, pyridine, HPLC grade 
methanol and ethanol were purchased from Merck (Darmstadt, Germany).  
 
2.3   BALF and Serum Collection 
Mice were anesthetized 24 hours after the last aerosol challenge and cardiac puncture and 
bronchoalveolar lavage (BAL) were performed (Cheng, et al., 2011). Blood was collected 5 
mins post-anaesthesia and incubated at room temperature for 1 hr prior centrifugation for 
serum collection. Bronchoalveolar lavage was performed immediately following cardiac 
puncture. Tracheotomy was performed for each animal, using a cannula surgically inserted 
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into the trachea. Ice-cold PBS (3 X 500 µL) was instilled into the lungs, and a consistent 
volume of BALF, ranging between 1400 – 1450 µL, was recovered from each animal. Total 
and differential cell counts were determined from BALF collected as described previously 
(12, 13). BALF and serum supernatants were frozen at -80°C prior further analysis.  
 
2.4  Pharmacokinetic investigation of Artesunate  
Artesunate (30 mg/kg) was administered to naïve mice (n=6 per time point) and anesthetized 
prior collection of blood and lung tissues at various time points. 200 µL of methanol, 
containing the internal standard, 5 µg/mL of FMOC-glycine, was added to 50 µL of serum or 
2 mg of lypholized lung tissue. LC/MS was employed to measure artesunate and DHA 
concentrations in serum and lung tissues. LC/MS analysis was performed using an Agilent 
1100 HPLC system connected to Thermo Scientific LCQ FLEET Ion-Trap Mass detector 
with Atmospheric Pressure Chemical Ionization (APCI+).  The column used was Inertsil 
ODS-3 (3um, 3.0×150mm) at room temperature, with a mobile phase of HPLC grade 
methanol and 0.1% formic acid (80:20) at a flow rate of 0.4 ml/min.  Artesunate and DHA 
concentrations were calculated based on seven-point dilution range of spiked pure artesunate 
and DHA standards (10 - 1000 ng/ml) in pooled naïve mice serum or lung tissues. FMOC-
glycine was spiked into the samples for internal control.  
 
2.5 BALF Cytokines Analysis 
Cytokines in the BALF were assayed using a murine Luminex bead-based suspension array 
system (Bio-rad Laboratories, Inc., CA, USA) and analysed using a Bio-Plex Array Reader 




2.6 GC/MS Analysis   
GC-MS derivatization was based on our earlier method (14). Briefly, 1.0 µL derivatized 
supernatant was injected splitlessly with an Agilent 7683 Series autosampler into an Agilent 
6890 GC system equipped with a HP-5MSI column. Compounds were identified by 
comparison of mass spectra and retention time with those of reference standards, and those 
available in libraries (NIST 0.5).  
 
2.7 LC/MS Analysis 
LC-MS analysis was performed on an Agilent 1200 HPLC system equipped with 6410 QQQ 
mass detector. Compounds showing significant differences between groups were searched in 
the Human Metabolome Database (HMDB, www.hmdb.ca) using mass-to-charge ratio (m/z) 
and identified by either MS/MS fragmentation patterns from HMDB, METLIN or reference 
standards. 5 µl of the pre-treated BALF supernatant was injected into an Agilent 1200 HPLC 
system (Waldbronn, Germany) equipped with 6410 QQQ mass detector and managed by a 
MassHunter workstation.  
 
2.8  Data Pre-processing 
Each chromatogram obtained from GC/MS and LC/MS analysis was processed for baseline 
correction and area calculation using MZmine 2.0 software package (Pluskal, et al., 2010). 
Data were combined into a single matrix by aligning peaks with the same mass and retention 
time for GC/MS and LC/MS data, respectively. Area of each peak was normalized to that of 
internal standard (FMOC-glycine) in each data set. The missing values were replaced with a 
half of the minimum value found in the data set (Ng, et al., 2012). 90% filtering was applied 
to the raw data to include only metabolites that were detectable in 90% of the subjects in at 
least one of the treatment groups to ensure selection of relevant metabolites.  
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2.9  Statistical Analysis                                                                                                                  
Cell counts and cytokine data are presented as means±SEM. One-way ANOVA followed by 
Dunnett’s test was used to determine significant differences in cell counts and cytokines 
between groups, with significant levels at p < 0.05.  Correlations between metabolites and 
inflammatory cells were calculated using Pearson’s correlation analysis. Multivariate 
statistical analysis was performed using SIMCA-P software version 11.0 (Umetrics AB, 
Umea, Sweden). Orthogonal projections to latent structures discriminant analysis (OPLS-DA) 
was used to model the discrimination between treatment and control subjects by visualization 
of score plots. Prior to OPLS-DA, data were mean-centered and unit variance scaled. 
Metabolites heatmap and nonparametric test (Wilcoxon, Mann-Whitney test) were conducted 













3.1 Artesunate Metabolizes to Form Active Metabolite, Dihydroartemisinin 
To understand the metabolism of artesunate in the murine circulatory system, 
pharmacokinetics investigation of artesunate uptake in mice was performed. 30 mg/kg of 
artesunate was injected intra-peritoneally into naïve mice (n=6 per time point). Upon 
administration, we observed the rapid metabolism of artesunate into its major active 
metabolite, Dihydroartemisinin (DHA), as early as 5 mins post-administration. Maximum 
serum concentration of artesunate was achieved in 5 mins (Arts Tmax), while maximum serum 
concentration of DHA was observed at 15 mins (DHA Tmax) (Figure 1A). Notably, artesunate 
was completely metabolized within 1 hr, while serum levels of DHA persisted till 6 hrs post-
adminstration. Investigations of artesunate and DHA profiles in the lung tissues yielded no 
detectable levels of artesunate while lung concentrations of DHA peaked at 10 mins and 

















































DHA Cmax – 1376 ng/ml  
DHA Tmax – 15 mins
DHA AUC0-360 – 150446 ng/ml
Arts Cmax – 462 ng/ml  
Arts Tmax – 5 mins






DHA Cmax – 4.27 ng/mg
DHA Tmax – 10 mins
DHA AUC0-360 – 252.18 ng/mg
 
Figure 4.01: Pharmacokinetic Profiles of Artesunate and Active Metabolite, DHA. 
Pharmacokinetic investigations of serum and lungs tissues were performed after a single 
intra-peritoneal dose of artesunate (30 mg/kg) was administered to naïve mice. (A) Serum 
concentrations of artesunate (Arts) and metabolite, DHA (ng/ml) were measured  using 
Liquid-Chromatography–Mass Spectrometry (LC/MS), collected at various time points post 
administration. (B) Concentration of DHA in the lung tissues (ng/ml) collected at various 
time points post administration. Each data point represents the mean drug concentration ± 
SEM in serum or lung tissues (n=6 mice per time point). 
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3.2  Artesunate Does Not Alter Local or Systemic Metabolic Profiles in Naïve 
Animals 
To investigate if the three days regime of intra-peritoneal artesunate (30 mg/kg/d) could 
induce any considerable metabolic effects in naïve animals, we investigated the metabolic 
profiles of naïve animals treated with and without artesunate. In OPLS-DA analysis, the 
value of R
2
Y describes how well the data in the training set are mathematically reproduced, 
ranging between 0 and 1, where 1 indicates a model with a perfect fit. Models with a Q
2
 value 
greater than or equal to 0.5 are generally considered to have good predictive capability. From 
the OPLS-DA plots, we did not observe any distinct separation of BALF metabolic profiles 
in naïve mice (N) versus naïve mice treated with artesunate (N/Arts), detected by either 
analytical metabolomics platforms, using GC/MS (Figure 4.02A) and LC/MS (Figure 4.02B). 
Metabolomics investigation of the serum profiles provided similar consistent observations 
that artesunate did not modify serum metabolome in naïve animals (Figures 4.02C and 





values indicate poor separation and predictability of naive animals treated with 
artesunate from those untreated. Pulmonary inflammatory cell counts between N and N/Arts 
also indicate that artesunate do not significantly alter inflammatory cell profiles in the lungs 
of naïve animals (Figure 4.05A). Additional toxicological tests, WST-1 and peripheral blood 
cells counts, on artesunate in human bronchial epithelial cells and naïve mice similarly reflect 
that artesunate does not induce any observable toxicity (Figure 4.03A to 4.03F). These 
collective results suggest that artesunate does not induce observable non-specific effects in 
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Figure 4.02: Artesunate does not Alter BALF and Serum Metabolic Profiles in Naïve 
Animals. OPLS-DA of global lung metabolite profiles in the BALF of Naïve mice treated 
with (N/Arts) or without artesunate (N), detected by (A) GC-MS analysis or (B) LC-MS 
analysis.   OPLS-DA of global metabolite profiles in the serum of naïve animals treated with 
(N/Arts) or without artesunate (N), detected by (C) GC/MS or (D) LC-MS analysis. In OPLS-
DA analysis, the value of R2Y describes how well the data in the training set are 
mathematically reproduced, ranging between 0 and 1, where 1 indicates a model with a 
perfect fit. Models with a Q2 value greater than or equal to 0.5 are generally considered to 
have good predictive capability. Black unfilled circles, N (n=12); brown asterisks, N/Arts 
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Figure 4.03: Effects of artesunate on human epithelial cells and murine peripheral 
blood mononuclear cell (PBMC). Beas-2B cells were incubated with 0.018% DMSO, 
artesunate (10 – 100 µM) or 10 mM H2O2 (positive control) for 3 hrs (n = 6 per treatment 
group). WST-1 was added 21 hours later and measured 30 mins later at 440 nm. Murine 
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plasma was collected 24 hour after three consecutive days of artesunate (30mg/kg) or vehicle 
(DMSO) injections. Experiments of (B) CD3, (C) CD4, (D) CD8, (E) NK1.1, (F) B220 on 
PBMC were analyzed by FACS (n=4 mice per group). Values shown are the mean ± SEM. 
*Significant difference from DMSO control, p<0.05. 
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3.3 Drug Vehicle Does Not Affect BALF or Serum Metabolite Profiles in 
Experimental Asthma 
In this study, 5% DMSO was used to dissolve artesunate and a corresponding vehicle group, 
OO/DMSO was included in this study. Using OPLS-DA, statistical comparisons of BALF 
and serum metabolite profiles were performed between OVA-sensitized and challenged mice 
treated with (OO/DMSO) and without DMSO (OO). From the OPLS-DA plots, it can be 
observed that there were little differences in BALF metabolite profiles between OO and 
OO/DMSO, indicated by weak modeling scores R
2
Y (0.56 and 0.79) and predictive Q
2
 values 
(0.0126 and 0.00477), detected by both GC/MS (Figure 4.04A) and LC/MS (Figure 4.04B) 
respectively. OPLS-DA of serum metabolic profiles demonstrated similar observations of 
poor separations between OO and OO/DMSO, indicated by weak modeling R
2
Y (0.424 and 
0.638) and predictive Q
2
 scores (-0.111 and -0.126), detected by both GC/MS (Figure 4.04C) 
and LC/MS (Figure 4.04D) respectively. From the inflammatory cell counts, DMSO 
administration also exhibited no significant effects on the inflammatory cell counts in 
inflamed lungs as compared to OO (Figure 4.05A). Toxicological tests performed on DMSO 
in human bronchial epithelial cells and naïve mice also affirmed these observations (Figure 
4.03A to 4.03F). These results demonstrate that the drug vehicle, DMSO, did not affect 
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Figure 4.04: Drug Vehicle Does Not Significantly Modify BALF and Serum Metabolic 
Profiles in Diseased Animals. OPLS-DA of global lung metabolite profiles in the BALF of 
OVA-sensitized and -challenged mice treated with (OO/DMSO) or without DMSO (OO), 
detected by (A) GC-MS analysis or (B) LC-MS analysis.   OPLS-DA of global serum 
metabolite profiles in the serum of OVA-sensitized and -challenged mice treated with 
(OO/DMSO) or without DMSO (OO), detected by (C) GC-MS analysis or (D) LC-MS 
analysis. R2Y describes the goodness of mathematical modelling of the data; while Q2 values 
of 0.5 or more are considered to have good predictive capability. Red filled circles, OO 
(n=12); Blue filled triangles, OO/DMSO (n=10). The x axis, t[1], and y axis, t[2], indicate the 




3.4 Artesunate Suppresses Airway Inflammation, Inflammatory Cytokines and 
Induces Restorative Metabolic Effects in Allergic Airways 
We re-analysed published cell count and BALF metabolomics data of N, OS and OO with 
publisher consent (W. E. Ho, et al., 2013) after incorporation of additional data collected 
together as a batch (N/Arts, OO/DMSO and OO/Arts). Treatment with artesunate (30 
mg/kg/d, i.p.) effectively suppressed airway inflammation, especially eosinophilia, as well as 
moderate inhibition on lymphocytes and neutrophils. Investigation of cytokine profiles in the 
BALF further reveal that artesunate could consistently subdue OVA-induced elevation of 
allergic cytokines (IL-4, IL-5 and IL-13) and inflammatory cytokines (IL-17, IL-12 p(40), 
MCP-1 and G-CSF) (Figures 4.05B to 4.05F). Significant alteration of BALF metabolite 
profiles by artesunate treatment, detected by both GC/MS (Figure 4.06A) and LC/MS (Figure 
4.06B), suggest artesunate could alter local metabolism in inflamed lungs. The R
2
Y (0.993 
and 0.893) and predictive Q
2
 values (0.747 and 0.738) indicate that there were distinctive 
good separation of BALF metabolite profiles between N, OO and OO/Arts mice. 
Metabolomics, using either GC/MS or LC/MS, can effectively differentiate and predict 
diseased animals treated with and without artesunate.  Statistical analysis indicated a total of 
24 metabolites were altered in the BALF by artesunate and are shown in two heatmaps 
(Figure 4.06C and 4.06D). Artesunate could restore OVA-induced changes in 17 metabolites 
(Figure 4.06C and 4.07). Artesunate effectively reversed reductions in carbohydrates, 
galactose, mannose and arabinose. Reductions in sterols and related bile acid, cholesterol, 
cortol and cholic acid, were similarly increased in OO/Arts.  Artesunate also replenished 
losses in 5 phosphatidycholines (PC), PC 32:0, PC 34:1, PC 34:2, PC 34:3, PC 35:5. 
Increases in energy metabolites and amino acids, lactate, creatinine, choline, urea, alanine 
and acetamide, were also suppressed by artesunate treatment. In addition, five BALF 
metabolites, perillic acid, retinyl-glucuronide, eicosadienoic acid, petroselinic and 1-
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pyrroline-5-carboxylic acid, were noted to be independently promoted by artesunate while 2-
oxoarginine levels were reduced (Figure 4.06D and 4.07C). Detailed mass abundance levels 
of altered key metabolites are provided in Figure 4.07. 
 
3.5 Altered BALF Metabolites are Associated with Inflammatory Cytokine 
Elevations in Experimental Allergic Asthma 
Pearson correlation analysis was used to uncover potential associations between the 
metabolite alterations to inflammatory cytokine changes in the BALF.  Ten specific BALF 
metabolites and the collection of five phosphatidylcholines possessed moderate to strong 
correlations to the various inflammatory cytokines (Table 1).  Particularly, IL-4, IL-5, IL-17, 
IL-12 p(40) and G-CSF, significantly correlated with BALF metabolites, such as urea, 
choline, lactate, carbohydrates (arabinose, galactose, mannose), sterols (cholesterol, cholic 
acid and cortol) and phosphatidylcholines (p < 0.05 to 0.01). These results suggest multiple 
potential links between the alteration of specific metabolites and various allergic and 
inflammatory cytokines in the allergic airways, although causative relationships cannot be 


































































































































































































































































Figure 4.05: Artesunate Suppresses Airway Inflammation and Inflammatory Cytokines 
Levels in Experimental Asthma. (A) Inflammatory cell numbers in the BALF were 
enumerated by total and differential cell counts. Total – Total number of inflammatory cells; 
Mac - Macrophages; Eos – Eosinophils; Lym – Lymphocytes and Neu – Neutrophils. Cell 
numbers are expressed as mean ± SEM (n = 8-12 per treatment group). # indicates statistical 
significance as compared to OS, p < 0.05, while * denotes statistical significance as compare 
to OO/DMSO, p < 0.05. (B) BALF levels of allergic cytokines, IL-4, IL-5 and IL-13. (C) pro-
inflammatory cytokine, IL-17. (D) cytokine IL-12 (p40), (E) inflammatory chemokine, MCP-
1 and (E) neutrophil chemotactic glycoprotein, G-CSF. Cytokine levels are expressed as 
mean ± SEM (n = 6 per treatment group). # indicates statistical significance as compared to 
































Figure 4.06: Artesunate Modulates Lung Metabolic Profile. OPLS-DA of global lung 
metabolite profiles in the BALF of naïve mice (N), OVA-sensitized and -challenged mice 
treated with (OO/Arts) or without artesunate (OO), detected by (A) GC-MS analysis or (B) 
LC-MS analysis. R2Y describes the goodness of mathematical modelling of the data; while 
Q2 values of 0.5 or more are considered to have good predictive capability. Black unfilled 
circles, N (n=12); Red filled circles, OO (n=12); Green filled diamonds, OO/Arts (n=12). The 
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x axis, t[1], and y axis, t[2], indicate the first and second principle components, respectively. 
(C) Significant fold level changes in BALF metabolites are expressed as a heatmap showing 
metabolite changes in naïve mice (N), diseased mice (OO) and artesunate treatment 
(OO/Arts), detected by either LC/MS or GC/MS. (D) Additional BALF metabolite changes 
by artesunate are expressed as a heatmap showing metabolite changes in naïve mice (N), 
diseased mice (OO) and artesunate treatment (OO/Arts), detected by either LC/MS or 
GC/MS. Fold changes are derived from the fold difference over normalized, mean-centered 
values for each metabolite. Green squares indicate a reduction of up to 2 folds; Black squares 





























































































































































































































































































































Figure 4.07: Key Local Metabolite Changes Induced by Artesunate in the BALF. Mass 
abundance of key BALF metabolites changes by artesunate, detected by GC/MS or LC/MS. # 
denotes significant change in OO compared to OS or N; p < 0.05. * denotes significant 
change in OO/Dex compared to OO; p < 0.05. 
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3.6 Associations Between Serum Metabolites with BALF Metabolites 
Pearson correlation analysis was employed to investigate for potential associations between 
the serum metabolites altered in the disease model versus BALF metabolites (Table 2).  Our 
results implicate multiple significant correlations between serum metabolites from the 
arginine-proline metabolic pathway to various BALF metabolites. Notably, serum urea, 
homoserine, aminoadipic acid and 18-oxocortisol were strongly associated to various key 
BALF metabolites, urea, cholic acid, cholesterol, cortol, lactate and sugars, such as arabinose, 
galactose and mannose. These results uncover for the first time potential associations 
between lung and systemic metabolism in allergic airway inflammation.  
 
3.7 Artesunate Reverses Metabolic Changes in the Serum 
OPLS-DA was used to examine global serum metabolite profile changes in N, OS and OO 
animals. From both GC/MS and LC/MS (Figure 5A and 5B), characteristic serum profile 
shifts in the diseased animals can be observed with respectable R2Y values (0.811 and 0.962 
respectively), as well as Q2 values (0.708 and 0.632 respectively). When comparing 
metabolic profile changes between OO, OO/Arts and OO/Dex, detected using GC/MS or 
LC/MS (Figure 5C and 5D), distinctive serum metabolic profiles can be observed between 
the diseased mice from those treated with artesunate or dexamethasone, with robust R2Y 
values (0.959 and 0.977 respectively) and Q2 values (0.658 and 0.589). Data suggest that 
artesunate was effective in reversing alterations in ten specific sera metabolites in OVA-
sensitized, OVA-challenged mice. An overview of these metabolite changes in the serum are 
represented in a heatmap (Figure 6A). Increases in related metabolites from the urea-proline 
metabolic pathways, urea, proline, valine, homoserine and aminoadipic acid, were 
substantially reversed by artesunate (Figure 6B). Losses in carbohydrates, galactose, glucose 
and galacturonic acid, were significantly recovered when treated with artesunate. Similarly, 
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artesunate was also effective in recovering losses in serum sterols, 18-oxocortisol and 24-
methylenecholesterol. Interestingly, dexamethasone demonstrated differential metabolic 
effects on certain disease-affected metabolites, with further suppression of 18-oxocortisol and 
insignificant effects on serum urea and 24-methylenecholesterol levels.  
 
3.8 Differential Metabolic Effects between Artesunate and Dexamethasone in 
Allergic Asthma 
Apart from the metabolites that were altered in diseased animals and reinstated by either drug, 
an assembly of twenty serum metabolites were found to be modulated by dexamethasone, 
which were unaltered in N, OS, OO or OO/Arts (Figure 7). Amongst them, 19 of these 
metabolites were significantly up-regulated by 2 folds or more (p < 0.05). Interestingly, only 
aspartic acid was suppressed by dexamethasone. Unlike dexamethasone, artesunate did not 
induce any significant additional metabolite effects in the serum. This result further reveals 
the differential metabolic effects between these two anti-inflammatory drugs in the diseased 
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Figure 4.08: Overview of Serum Metabolite Profile Changes in Experimental Asthma 
by Artesunate and Dexamethasone. OPLS-DA of global metabolite changes in the sera 
collected from N, OS and OO mice, detected by (A) GC/MS or (B) LC/MS are shown. 
OPLS-DA of global serum metabolite changes of OO, OO/Arts and OO/Dex, detected by (C) 
GC/MS and (D) LC/MS are shown. R2Y describes the goodness of mathematical modelling 
of the data; while Q2 values of 0.5 or more are considered to have good predictive capability. 
Black unfilled circles, N (n=10); Blue unfilled circles, OS (n=10); Red filled circles, OO 
(n=10); Green filled diamonds, OO/Arts (n=10); Blue inverted triangles, OO/Dex (n=10). 
The x axis, t[1], and y axis, t[2], indicate the first and second principle components, 
respectively. 
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Figure 4.09: Serum Metabolite Changes in Experimental Asthma by Artesunate and 
Dexamethasone. (A) Significant fold level changes in serum metabolites are expressed as a 
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heatmap showing metabolite changes in naïve mice (N), diseased mice (OO), with artesunate 
treatment (OO/Arts) or dexamethasone treatment (OO/Dex), detected by either LC/MS or 
GC/MS. Fold changes are derived from the fold difference over normalized, mean-centered 
values for each metabolite. Green squares indicate a reduction of up to 2 folds; Black squares 
indicate no significant fold changes over normalized, mean-centered values. Red square 
indicates an increase of up to 2 folds. (B) Mass abundance of key serum metabolites changes 
by artesunate or dexamethasone, detected by GC/MS or LC/MS. # denotes significant change 
in OO compared to OS or N; p < 0.05. * denotes significant change in OO/Arts or OO/Dex 
compared to OO; p < 0.05. n = 12 per treatment group.  
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Table 4A: Pearson Correlation Coefficients (r) of Key Metabolites Changes Versus 
Inflammatory Cytokines levels in BALF 





† N.S. 0.356† N.S. N.S. N.S. 
Urea 0.599* 0.656* 0.359
† 0.611* 0.613* 0.433+ 0.619* 
Choline 0.551* 0.508* N.S. 0.436
† 0.662* 0.434+ 0.617* 
Lactate 0.628* 0.635* N.S. 0.662* 0.662* 0.397
+ 0.652* 
Arabinose N.S. -0.449
† N.S. -0.476* -0.377† N.S. -0.460* 
Galactose N.S. -0.594* N.S. -0.399
† -0.461* N.S. -0.530* 
Mannose N.S. -0.575* N.S. -0.382
† -0.458* N.S. -0.517* 
Cholesterol N.S. -0.614* -0.388
† N.S. -0.448† N.S. -0.589* 
Cholic acid -0.385
† -0.662* -0.450* -0.399† -0.539* -0.401+ -0.598* 
Cortol -0.368
† -0.594* N.S. -0.511* -0.452* N.S. -0.546* 
Phosphatidylcholines N.S. -0.583* N.S. -0.616* N.S. N.S. -0.561* 
Moderate correlations: values of -0.5 to -0.3 (negative correlation) or 0.3 to 0.5  
Strong correlations: values of -1.0 to -0.5 (negative correlation) or 0.5 to 1.0  
Only metabolites with significant correlations are shown. 
* denotes significant correlation, p < 0.01, n = 32 
†
 denotes significant correlation, p < 0.05, n = 32 




Table 4B: Pearson Correlation Coefficients (r) of Serum Metabolites Versus BALF 
Metabolites 
  Serum Metabolites 
  18-oxo 
cortisol 













Cholic Acid 0.604* 0.728* -0.593* N.S. N.S. 
Cholesterol 0.826* 0.599* -0.449
+
 N.S. N.S. 
Cortol 0.636* 0.651* -0.573* -0.407
+
 N.S. 
Urea N.S. 0.800* 0.573* 0.403
+
 0.572* 
Lactate N.S. 0.486* 0.471
+
 N.S. N.S. 
Malate N.S. 0.607* 0.410
+
 N.S. N.S. 
Creatinine N.S. 0.477* N.S. N.S. N.S. 
        Moderate correlations: values of -0.5 to -0.3 (negative correlation) or 0.3 to 0.5  
        Strong correlations: values of -1.0 to -0.5 (negative correlation) or 0.5 to 1.0  
        * denotes significant correlation, p < 0.01  
            + 
 denotes significant correlation, p < 0.05 
        N.S. denotes no significant correlations, p > 0.05 
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Figure 4.10: Unlike Dexamethasone, Artesunate Does Not Induce Any Significant 
Additional Metabolic Effects in the Serum. Additional serum metabolite changes by 
dexamethasone are expressed as a heatmap showing metabolite changes in naïve mice (N), 
saline controls (OS), diseased mice (OO), with artesunate treatment (OO/Arts) or 
dexamethasone treatment (OO/Dex) detected by either LC/MS or GC/MS. Fold changes are 
derived from the fold difference over normalized, mean-centered values for each metabolite. 
Green squares indicate a reduction of up to 2 folds; Black squares indicate no significant fold 





The pathophysiological relevance and effects of various metabolites changes in asthma are 
poorly understood. Rapid development of metabolomics has recently provided invaluable 
molecular insights of the differential alteration of metabolism in asthma. (W. E. Ho, et al., 
2013; Jung, et al., 2013; Mattarucchi, et al., 2011; Saude, et al., 2011). The potential 
biological impact of metabolites in inflammatory respiratory diseases has been lately 
demonstrated. Exogenous supplement of mannose was revealed to attenuate pulmonary 
edema and suppress LPS-induced lung inflammation (X. L. Xu, et al., 2008). Choline 
supplement in human asthmatics was equally effective at suppressing airway inflammation 
and related oxidative stress (Mehta, et al., 2009; Mehta, et al., 2010). These examples 
highlight the profound impact of certain metabolites in inflammatory respiratory diseases and 
implicate the prospects of investigating metabolite alterations in allergic asthma.  
In this study, we hypothesized that artesunate can exert restorative metabolic changes in the 
BALF and serum of experimental asthma. Using a combined LC/MS and GC/MS 
metabolomics platform, we investigated the BALF and serum metabolic profiles of 
artesunate-treated animals. Despite the abundance of pharmacokinetic information of 
artesunate in humans and rats (Benakis, Paris, Loutan, Plessas, & Plessas, 1997; Morris, et al., 
2011; Teja-Isavadharm, et al., 2001), there is so far no available pharmacokinetic data of 
artesunate in mice. Pharmacokinetic information of artesunate demonstrated that artesunate is 
rapidly transformed into its major metabolite, DHA within an hour following administration 
(Figure 1). Detectable levels of DHA in both the serum and lung tissues validated our timing 
of administering artesunate prior OVA aerosol challenge.  This information also suggests for 
the first time that DHA may be the key molecule mediating the protective effects observed in 
previous mice studies and in the first project (Cheng, et al., 2011).  
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Investigation of the cytokine profile of artesunate-treated mice has yielded validating and 
fresh understanding of artesunate effects on cytokines. Our results affirmed previous 
observations (Cheng, et al., 2011) that artesunate can lower BALF levels of allergic cytokines 
(IL-4, IL-5 and IL-13) which contribute broadly to the pathogenesis of lung inflammation 
(Kuperman, et al., 2002; Ying, Durham, Corrigan, Hamid, & Kay, 1995). Suppression of pro-
inflammatory cytokines (IL-17 and MCP-1) by artesunate implicates the drug is capable of 
exhibiting broad anti-inflammatory actions in the allergic airways. Artesunate showed an 
interesting positive action of suppressing IL-12 p(40), as elevation of this cytokine can 
contribute to the full-blown asthma phenotype (Meyts, et al., 2006). Suppression of G-CSF 
by artesunate corroborated with the subdual of neutrophil counts, as G-CSF is a major 
survival factor of neutrophils (Dai, et al., 2012). 
Our metabolomics investigations suggest that artesunate does not induce non-specific effects 
in naïve animals and specifically functions under inflammatory conditions to restore disease-
associated metabolic modifications. Validating our previous studies (Cheng, et al., 2011; W. 
E. Ho, et al., 2012), artesunate (30 mg/kg/d) was effective in suppressing airway 
inflammation, especially eosinophilia, in the OVA-challenged mice (Figure 2A). OPLS-DA 
plots have presented distinctive metabolite profile shifts in the BALF and serum of diseased 
mice treated with artesunate versus those untreated, proven by robust modeling R2Y and 
predictive Q2 values (Figure 3A and 3B, 5C and 5D). Interestingly, metabolomics could 
distinguish serum metabolic profiles of asthmatic mice treated with artesunate or 
dexamethasone, implicating the distinctive molecular profile differences between the two 
drugs in modulating metabolism during inflammatory conditions.  
In asthma, depletion of sterols, such as cholesterol, cholic acid and cortol, are strongly 
associated with inflammation in diseased airways (Fessler, et al., 2009; W. E. Ho, et al., 
2013). Cholesterol and cortol are respective upstream and downstream metabolites of cortisol, 
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an endogenous anti-inflammatory sterol. Cortisol can exert robust and broad anti-
inflammatory effects in experimental asthma (Peebles, et al., 2000; Zhang, et al., 2009). In 
this study, artesunate promoted recoveries in pulmonary sterols, cholesterol, cholic acid and 
cortol. Correspondingly, in the serum of the diseased mice, artesunate also restored levels of 
a cortisol metabolite, 18-oxocortisol. Promotion of cortisol-associated metabolites may be 
linked to the various anti-inflammatory effects induced by artesunate.   
There appears to be a causative link between PC and lung surfactants levels, where 
reductions in PC levels can lead to loss of lung functions in asthma (Wright, et al., 2000). 
Deregulation of PCs with strong associations to asthma risk alleles, have also been recently 
uncovered in asthmatic patients (Ried, et al., 2013). Consistent adaptive increases in a down-
stream PC metabolite, choline, was noted in our previous study. Choline can exert beneficial 
effects in asthma (Mehta, et al., 2009; Mehta, et al., 2010), where excessive supplements of 
choline are shown to reduce oxidative stress and inflammation in asthma. Artesunate 
promoted recoveries in five PCs, PC 32:0, PC 34:1, PC 34:2, PC 34:3, PC 35:5, and also 
brought down corresponding adaptive increases of choline in the allergic airways. Indeed, 
restoration of lung functions and reduction of AHR by artesunate were noted in our previous 
investigation (Cheng, et al., 2011). Taken together, we believe the elevation of PC could be a 
mechanism which artesunate restores lung functions in the diseased airways. 
In inflamed lungs, consistent increases in energy-related metabolites have been observed, 
suggesting the involvement of an energy burden during asthma-related inflammation (W. E. 
Ho, et al., 2013).  Amongst them, lactate is the most prominent energy metabolite, shown to 
be elevated in multiple inflamed airway conditions, such as in allergic airways (shown in this 
project), urine of childhood asthma (Saude, et al., 2011) and in the BALF from inflamed 
lungs exposed to silica dust (Hu, et al., 2008) and 1-nitronaphthalene (Azmi, et al., 2005). In 
this study, artesunate demonstrated a beneficial advantage in lowering increases in lactate 
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which dexamethasone was incapable of suppressing. Interestingly, artesunate induced further 
increases in creatinine, similar to the actions of dexamethasone. It is unclear at present why 
both of these anti-inflammatory drugs led to increase in serum creatinine despite substantial 
amelioration of the disease.  
Aminoadipic acid is an uncommon small metabolic marker of protein carbonyl oxidation, 
linked to tissue proteolysis and oxidative stress in sepsis, diabetes and renal failure (Sell, 
Strauch, Shen, & Monnier, 2007). In this study, OVA-induced increase in serum aminoadipic 
acid was suppressed by both artesunate and dexamethasone, which may be related to potent 
anti-oxidative effects of these drugs in asthma. Increases in BALF and serum urea, as well as 
other downstream serum metabolites from the arginine-proline metabolism, proline, valine, 
homoserine, were reversed by artesunate, and partially suppressed by dexamethasone (Figure 
8). Arginine-proline metabolism has been implicated as a major disease-relevant metabolic 
pathway for asthma (Lara, et al., 2008), where increases in arginase activity in asthmatics 
(Meurs, et al., 2002), can lead to augmented conversion of L-arginine to urea and ornithine. 
Ornithine will be transformed to proline and subsequently to valine, via proline oxidation to 
pyruvate (Weeda, de Kort, & Beenakkers, 1980). Proline is a key disease-contributing 
metabolite leading to increased collagen formation (Barbul, 2008; Lara, et al., 2008) while 
valine is linked to tissue repair (Smith & Sun, 1995).  Artesunate reversed increases in these 
disease-related metabolites, suggesting artesunate could limit arginine-proline metabolism in 
asthma. Corresponding accumulation in 1-pyrroline-5-carboxylic acid by artesunate (Figure 
5B), an intermediate metabolite formed between conversion of ornithine to proline in the 
arginine-proline metabolism, also suggests the blockage of conversion from ornithine to 
proline.  
Our earlier study has uncovered substantial losses in carbohydrates (mannose, galactose and 
arabinose) in the BALF of allergic airways (W. E. Ho, et al., 2013). Notably, these sugars, 
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galactose and mannose shared strong positive correlations to inflammatory cell counts and 
inflammatory cytokines (Table 4A), implicating extensive associations to the disease. 
Mannose possess broad anti-inflammatory effects against LPS-induced lung injury (X. L. Xu, 
et al., 2008), while the product of arabinose and galactose, arabinogalactan similarly exhibits 
protective potential against allergic asthma (M. Peters, et al., 2010). Glucogenic amino acids 
(proline, valine, aspartic acid, homoserine, alanine, 2-oxoarginine) can be metabolised into 
glucose via gluconeogenesis. Broad suppression of these glucogenic amino acids 
complemented with consistent recoveries of BALF and serum carbohydrates, suggest that 
both artesunate and dexamethasone may promote gluconeogenesis during inflammatory 
conditions. Overall, artesunate could induce consistent recoveries of disease-relevant sugars 
in experimental asthma. 
We observed that artesunate induced changes in six BALF metabolites that were unaltered in 
the disease model (Figure 5B). This action is somewhat similar to dexamethasone which 
induced 20 additional metabolite changes in experimental asthmatic airways independent of 
the disease. In fact, some of the affected metabolites are commonly altered by both of these 
anti-inflammatory agents, such as increases in petroselinic acid and marked reductions in 2-
oxoargnine. Elevations in petroselinic acid can reduce arachidonic acid in tissues (Weber, 
Richter, Schulte, & Mukherjee, 1995), which is a key signaling lipid promoting inflammation 
in asthma (Sally E. Wenzel, 1997). Reduction of 2-oxoarginine by artesunate, an arginine-
related metabolite, may possibly be a beneficial effect. 2-oxoarginine is a specific metabolite 
due to impaired arginase activity and its accumulation has been reported to lead to certain 
toxicity (Marescau, et al., 1990). Elevation of eicosadenoic acid, an anti-inflammatory fatty 
acid, was noted with artesunate treatment. Eicosadenoic acid is a rare but endogenous 
produced n-6 polyunsaturated fatty acid. It can modulate different inflammatory mediators 
and be further converted to sciadonic acid, an anti-inflammatory fatty acid (Huang, Huang, Li, 
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& Chuang, 2011). In contrast, artesunate did not induce any additional metabolite changes in 
the serum while dexamethasone caused alterations to 20 metabolites independent of the 
disease (Figure 7). Although the relevance of some metabolites remains poorly established, 
these results suggest that steroids broadly alter metabolism and act differently than non-
steroidal anti-inflammatory agents, such as artesunate.  
Our collective results revealed for the first time that artesunate possess considerable 
restorative actions on local and systemic metabolism in experimental asthma. Artesunate 
reversed various literature-reported and disease-associated metabolic changes in the BALF 
and serum of diseased animals. These effects extend to the promotion of beneficial 
carbohydrates, sterols and phosphatidylcholines and reduction of lactate and respective pro-
inflammatory metabolites belonging to the arginine-proline metabolic pathway. Although 
artesunate can suppress airway inflammation and induce numerous anti-inflammatory 
metabolic effects similar to that of dexamethasone, differential restorative metabolic effects 
were observed between the two drugs. These metabolic effects induced by artesunate were 
observably specific to the inflamed conditions in diseased animals and were not observed in 
naïve mice treated with artesunate. This study further demonstrates that metabolomics can be 
a potentially useful investigative platform for understanding disease and drug-related 
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Figure 4.11: Overview of Disease-Associated Metabolites Involved in Allergic Airway 
Inflammation and Altered by Artesunate or Dexamethasone Treatment. A summary 
figure illustrating modifications of disease-associated metabolites in allergic airway 
inflammation, with artesunate or dexamethasone treatments is shown. Artesunate 
demonstrated specific differential restorative effects on distinct metabolites, as compared to 














5.1   Limitations and Future Outlook 
Current investigations of artemisinins in various inflammatory diseases have highlighted that 
the extensive and potent anti-inflammatory activities of artemisinins include suppressing Th-
1, Th-2 and Th-17 inflammatory cell and cytokine responses. Furthermore, these collective 
studies have shown that artemisinins can exert rapid and protective pharmacological effects 
in both acute and chronic inflammatory diseases, as well as localised and systemic 
inflammation. These anti-inflammatory effects have been largely attributed to a wide-spread 
inhibition of NF-κB, PI3K/Akt, MAPK and STAT-1, STAT-3 and STAT-5 signaling 
pathways (Cheng, et al., 2011; Hou, et al., 2009; Y. Li, et al., 2013; Mirshafiey, et al., 2006; 
H. Xu, et al., 2007), as well as suppression of upstream signaling molecules, such as TLRs, 
Syk and PLCγ (Fig. 1.25) (Cheng, et al., 2013; B. Li, et al., 2010; B. Li, et al., 2008). 
Activation of protective signaling pathways, such as Nrf2/ARE, by artemisinins in 
inflammatory diseases were also discovered in these studies (Fig. 1.25) (W. E. Ho, et al., 
2012; I. S. Lee, et al., 2012). Up till now, the exact signaling molecules which artemisinins 
directly interact with remains unclear; however, it is likely to involve several key upstream 
signaling molecules, considering that artemisinins can mediate potent and wide-spread effects 
on several different major inflammatory pathways.  
 
It has been demonstrated that artemisinins, especially artesunate, are potent anti-
inflammatory agents, capable of suppressing inflammation in autoimmune and allergic 
diseases, as well as bacterial infections. Nonetheless, there still exists plentiful of research 
opportunities for investigating artemisinins in many other inflammatory conditions. Firstly, 
artemisinins have not been comprehensively investigated in several of the inflammatory 
disorders discussed in this review, such as IBD, uveitis and endometriosis. A recent review 
has hypothesized potential immunosuppressive applications of artemisinins in transplant-
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rejections, however no related investigations or clinical attempts have been investigated since 
then (Shakir, Hussain, Javeed, Ashraf, & Riaz, 2011). Up till now, there are also little or no 
evidences if artemisinins are effective against viral-induced inflammatory conditions or 
inflammation in cardiovascular and neurological disorders. Furthermore, the anti-
inflammatory potential of artemisinins can also be explored in many other autoimmune and 
allergic diseases, such as reactive arthritis, primary biliary cirrhosis, allergic rhinitis and 
conjunctivitis.  
 
Most findings of artemisinins in various inflammatory diseases are derived from preclinical 
animal studies which primarily seek to investigate biological effects and have utilised an 
exceptionally wide range of drug dosages (1 - 300 mg/kg/d), as well as different 
administration routes. There exist several important steps to develop artemisinins for 
validation and clinical use in humans for each inflammatory disease, which involves 
optimizing drug dosages and administration routes for consistent and optimum biological 
activities in different diseases. This PhD project and other studies have demonstrated that 
artemisinins possess comparable anti-inflammatory and protective effects to standard 
immunosuppressants, especially glucocorticoids (X. Q. Wang, et al., 2011). Interestingly, 
these anti-inflammatory activities are often complementary with standard therapeutics, such 
as antibiotics or glucocorticoids, and can produce potent synergistic protective effects in 
several severe inflammatory disorders (Jiang, et al., 2011; J. Wang, et al., 2006; Wu, et al., 
2011).  These novel drug combinations may be particularly useful for a substantial number of 




Validating pharmacological actions in additional clinically-relevant experimental models of 
asthma will be an important area to focus on for future studies of artemisinins. Prospective 
studies should also emphasize upon the optimization of drug dosages, selection of appropriate 
derivatives and administration routes so as to achieve optimal pharmacological responses in 
allergic asthma. Demonstrated in the studies here, the comparisons of artemisinins against 
recommended doses of standard therapies are exceptionally useful for identifying various 
strengths and weaknesses of artemisinins in asthma. As discussed, artemisinins still remain 
unexplored in many diseases, which are triggered by common disease signaling mechanisms, 
such as elevation of NF-κB, PI3K/Akt and MAPK. Although their effects on major signaling 
pathways have been substantially explored, current investigations of artemisinins’ 
pharmacological mechanisms are not comprehensive and the exact molecular signaling 
targets which artemisinins interact with are also presently unknown. Elucidation of these 
molecules will enable better understanding of key chemical functional groups on artemisinins 
and facilitate the development of specialised derivatives with safer and improved efficacies.  
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5.2 Conclusions 
Respiratory inflammatory diseases, such as asthma, constitute to the most common causes of 
chronic illness worldwide. The rising prevalence, mortality and high economic burden 
require a better understand the pathophysiology of allergic diseases and the need to explore 
for more potentially effective therapies to treat allergic airway diseases. Artesunate, a semi-
synthetic derivative of artemisinin, is a widely-used drug for the treatment of complicated and 
uncomplicated malaria. Previous studies from our laboratory has shown that artesunate 
possess a broad spectrum of anti-inflammatory effects and can dose-dependently suppress 
various hallmarks of airway inflammation, mucus hyper-secretion and airway 
hyperresponsiveness in an OVA-induced murine model of allergic asthma.  Despite so, there 
exist manifolds of stages of pre-clinical drug development which included repeated 
validations of therapeutic effects, continued exploration of drug mechanisms and 
comparisons to standard therapies prior clinical testing in human patients.  
The aim of this PhD project seeks to expand current understanding of the broad therapeutic 
effects of artesunate in allergic asthma. Anti-inflammatory effects of artesunate were 
examined and compared against a potent anti-inflammatory corticosteroid, dexamethasone, in 
the OVA-induced asthma mouse model (key findings summarized in Table 5A). Our findings 
reveal that complementary to dexamethasone, artesunate could equally suppress airway 
inflammation in the inflamed airways, especially eosinophilia. Artesunate also demonstrated 
significant inhibition on neutrophil recruitment in the diseased airways, whereas 
dexamethasone was ineffective against. In this asthma model, artesunate was equally or more 
effective as dexamethasone in preventing the formation of various oxidative lung damage 
products, namely 3-nitrotyrosine (protein nitration), 8-hydroxy-2-deoxy-guanine (oxidative 
DNA damage) and 8-isoprostane (lipid peroxidation).  
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Although both drugs produced comparable inhibitory effects on airway inflammation, our 
investigations of the lung antioxidants’ and pro-oxidants’ profiles reveal that artesunate and 
dexamethasone exert dissimilar effects on various pulmonary antioxidants and pro-oxidants. 
While both agents can reverse catalase and total superoxide dismutase (SOD) activities and 
expressions in the airways, artesunate modulates CuZnSOD (SOD1) and MnSOD (SOD2) 
while dexamethasone modulates MnSOD (SOD2) and EcSOD (SOD3). Artesunate was also 
effective at inhibiting expressions of various pro-oxidants, such as inducible nitric oxide 
synthase (iNOS), NADPH oxidases (NOX1, NOX2, NOX3 and NOX4) and NOX subunits 
(p22phox and p67phox), while dexamethasone was only effective against iNOS, NOX3, 
p22phox and p67phox. Investigation using DPPH
 
assay reveal that both artesunate and 
dexamethasone do not possess any direct anti-radical properties and their anti-inflammatory 
effects are probably mediated via the alteration of endogenous pulmonary antioxidants and 
pro-oxidants. Consistent in the inflamed murine lung tissues and in TNF-α stimulated human 
bronchial epithelial cells, we observed that the anti-inflammatory effects of artesunate may be 
largely attributed to the promotion of nuclear Nrf2 levels, which is a major transcription 
factor that modulates the gene expressions of many vital antioxidants and pro-oxidants in the 
airways. Overall, this study has demonstrated that artesunate possess novel and promising 
anti-inflammatory properties in preventing oxidative lung damage by modulating major 
antioxidants’ and pro-oxidants’ expressions in allergic asthma, mediated via promotion of 
nuclear Nrf2 levels.  
Apart from investigating the beneficial effects of artesunate on the oxidative lung damage 
profile, metabolomics was also utilized to better understand the therapeutic effects of the drug 
in the disease model. Metabolomics is the investigation of metabolite profiles in biological 
systems and is capable of detecting changes in multiple classes of metabolic molecules, 
ranging from lipids, fatty acids, sterols, carbohydrates and amino acids. Metabolomics has 
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been featured recently in studies investigating for metabolic changes in urine and exhaled 
breath condensate of experimental and clinical asthma. Notably in this PhD project, we report 
for the first time, comprehensive metabolic profile changes in the bronchoalveolar lavage 
fluid and serum of experimental allergic asthma (key findings summarized in Table 5B). 
These metabolic changes involved alterations to energy metabolites, sterols, lipids and 
carbohydrates. These discoveries have established major research milestones in the 
exploration of altered metabolism during allergic asthmatic inflammation, especially the 
discovery of disease-associated BALF and serum metabolic markers and the novel use of 
metabolomics for asthma-related metabolic marker discovery in BALF and serum samples.  
Metabolomics investigation of artesunate has uncovered restorative and differential metabolic 
changes in the BALF and serum of OVA-challenged mice, as compared to dexamethasone 
(key findings summarized in Table 5B). We further revealed that several specific metabolite 
changes are moderately-strongly associated with inflammatory cells, such as eosinophils and 
neutrophils, and inflammatory cytokines IL-4, IL-5, IL-13, IL-17, IL-12 (p40), MCP-1 and 
G-CSF. Overall, our metabolomics studies have uncovered specific restorative metabolic 
effects induced by artesunate in experimental allergic asthma. Consistent with our 
investigation of antioxidants and pro-oxidants profile, we observed that artesunate mediates 
metabolic changes in allergic asthma effectively and differently than dexamethasone, 
suggesting that these two anti-inflammatory agents may mediate their anti-inflammatory 
effects via different molecular mechanisms. Our compiled findings advocate that artesunate is 
suitable to be further developed as an alternative and complementary therapeutic anti-
inflammatory drug for the treatment of allergic asthma. Complementing our research interests 
of developing artesunate outside of malaria, we have also compiled an extensive review 
article discussing the broad uses of artemisinins beyond malarial therapy (Ho, Peh, Chan, & 
Wong, 2013). This review article has been useful in enhancing our understanding of 
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artemisinins, especially in inflammatory and allergic diseases and will be of substantial 
scientific value to the research field. We sincerely believe the research projects covered in 
this PhD thesis will provide vital preclinical knowledge for the research advancement in 
developing artesunate as an effective therapeutic for asthma, as well as to improve current 
molecular understanding of the disease and corticosteroids mechanisms.  
 
Summary of Key Novel Findings from this PhD Project
ARTESUNATE AMELIORATES OXIDATIVE LUNG DAMAGE ALLERGIC AIRWAY
INFLAMMATON VIA PROMOTION OF NUCLEAR NRF2
Background: Artesunate is shown to be effective against major hallmarks of allergic
asthma, it is unknown if Arts is effective against oxidative stress and related damage.
We demonstrate for the first time in this project that ……
• Artesunate possess comparable and differential anti-inflammatory effects in
asthma, as compared to dexamethasone.
• Artesunate is effective against neutrophilia, whereas dexamethasone is ineffective
against.
• Artesunate can effectively suppress oxidative damage to proteins, lipids and DNA. 
• These protective actions are due to modulation of pulmonary antioxidants (SODs 
and Catalase), alongside broad suppression of pro-oxidants (iNOS and NOXs).
• Gene expressions and modulations of these major molecular mediators are via the 
promotion of nuclear transcription factor, Nrf2 by artesunate in the lungs. 
 
Table 5A: Summary of Key Novel Findings from PhD Project 1. A simple summary is 
tabulated, providing key background information and novel key findings of the project on 
Artesunate and its effects of oxidative stress and related lung damage in allergic asthma.   
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Summary of Key Novel Findings from this PhD Project
METABOLOMICS REVEALS NOVEL METABOLIC PATHWAY CHANGES IN
EXPERIMENTAL ASTHMA
Background: Metabolomics is an upcoming analytical technology, used to study
exhaled breath and urine of asthmatic patients. It is unestablished if relevant metabolic
changes are detectable directly in allergic inflamed airways.
We demonstrate for the first time in this project that ……
• Mass-spectrometry metabolomics, by LC/MS and GC/MS, reveal comprehensive
metabolic profile alterations directly in the BALF from allergic inflamed lungs.
• Alterations of energy metabolism were detected with increases in energy
metabolites, alongside corresponding losses of sugars.
• Lipid and sterol metabolism were also affected with decreases in PCs, DGs, TGs,
cholesterol, cortol and cholic acid.
• Dexamethasone could reverse most metabolite changes but induced many other
metabolic alterations, independent of the disease.
• Metabolomic analysis of BALF is a promising approach to understand pulmonary 
metabolism in allergic asthma. 
METABOLOMICS REVEALS RESTORATIVE ACTIONS BY ANTI-MALARIAL DRUG 
ARTESUNATE IN ALLERGIC AIRWAY INFLAMMATION
Background: Our research has shown comprehensive BALF metabolome changes in
allergic asthma. It is unknown if artesunate can reverse these metabolic alterations in
the BALF and serum.
We demonstrate for the first time in this project that ……
• While Arts did not induced metabolic profile changes in naïve animals, restorative
metabolic effects were observed in the BALF and serum of Arts-treated asthmatic
animals.
• Artesunate further abated increases in the pro-inflammatory arginine-proline
metabolic pathway.
• Metabolic comparisons of artesunate against dexamethasone further suggest that
artesunate exerts a differential and favourable metabolic profile than
corticosteroids.
• Arts induced minimal non-specific metabolic effects in the BALF, as compared to
Dex, and did not induce any non-specific effects in the serum.
• Metabolomics analysis reveals a favourable and differential metabolic effect profile 
induced by Arts in allergic asthma, as compared to corticosteroids.
  
Table 5B: Summary of Key Novel Findings from PhD Project 2 & 3. A simple summary 
is tabulated, providing key background information and novel key findings of the project on 
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